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Description of the Company
Johnson & Johnson has $36.3 billion in sales
and is the world’s most comprehensive and broadly
based manufacturer of health care products,
as well as a provider of related services, for the
consumer, pharmaceutical, and medical devices
and diagnostics markets. Johnson & Johnson
has approximately 108,300 employees and more
than 200 operating companies in 54 countries
around the world, selling products in more than
175 countries.
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At the Malvern, Pennsylvania, facility of Centocor,
Inc., the new monoclonal antibody manufacturing
facility where Joyce Salpan, manufacturing
associate, foreground, and Chaley Larson, senior
supervisor, work will help the company double its
capacity to produce REMICADE® (infliximab) for
rheumatoid arthritis and Crohn’s disease patients.
Three Years in Brief–Worldwide
(Dollars in Millions Except Per Share Figures) 2002 2001 2000 2002 2001
Sales to customers $36,298 $ 32,317 29,172 12.3 10.8 
Net earnings* 6,597 5,668 4,953 16.4 14.4 
Cash dividends paid 2,381 2,047 1,724 16.3 18.7 
Shareholders’ equity 22,697 24,233 20,395 (6.3) 18.8 
Percent return on average
shareholders’ equity 28.1 25.4 26.5 – –
Per Share
Net earnings - basic 2.20 1.87 1.65 17.6 13.3 
- diluted 2.16 1.84 1.61 17.4 14.3 
Cash dividends paid 0.795 0.70 0.62 13.6 12.9 
Shareholders’ equity 7.65 7.95 6.77 (3.8) 17.4 
Market price (year-end close) 53.11 59.86 52.53 (11.3) 14.0 
Average shares outstanding (millions)
- basic 2,998.3 3,033.8 2,993.5 (1.2) 1.3
- diluted 3,054.1 3,099.3 3,099.2 (1.5) 0.0 
Number of employees (thousands) 108.3 101.8 100.9 6.4 0.9 
* Net earnings and earnings per share for 2002 include In-process research and development (IPR&D) charges of $189 million or .07 diluted earnings per share
related to the acquisitions of Tibotec-Virco N.V. and Obtech Medical AG. Excluding the impact of these charges, 2002 net earnings increased 16.8% over 2001.
Net earnings and earnings per share in 2001 and 2000 include $231 million or .07 diluted earnings per share and $45 million or .02 diluted earnings per share,
respectively, related to IPR&D and ALZA merger costs in 2001 and IPR&D net of restructuring gains in 2000. For detailed discussion of these charges, refer to
Note 17 of the Notes to Consolidated Financial Statements. 
1Letter to Shareholders
S trong performance across all segments of ourbroadly based health care business in 2002enabled Johnson & Johnson to achieve excep-tional growth in both sales and earnings.
Record sales of $36.3 billion represented 12.3% growth
from 2001. Operational growth was 12.1%, with curren-
cy exchange rates contributing a favorable effect, .2%,
for the first time in seven years.
Record net earnings of $6.8 billion, an increase of
15.0%, excluding special charges, led to diluted earnings
per share growth of 16.8%, from $1.91 in 2001 to $2.23.
Against this strong performance, the Board of Directors
increased the quarterly dividend in April 2002 for the
40th consecutive year, from $.18 per quarter to $.205 per
quarter, an increase of 13.9%.
Our cash flow from operations continued to be very
strong in 2002, at $8.2 billion. This is net of approximate-
ly $750 million, after tax, that we invested in our various
pension plans during the year to ensure their continued
strength. More relevant is what we monitor as “free cash
flow,” or the portion of operating cash flow that remains
William C. Weldon,
Chairman and Chief Executive Officer
after the Company has made the necessary investments
through capital expenditures to support the growth
of the business. In 2002, strong free cash flow of $6.2
billion provided fuel for a $5 billion share repurchase
program, acquisitions of $.5 billion, and the dividend
increase referred to earlier. We did this while maintaining
the Company’s outstanding “triple A” credit rating.
Setting these results in the context of our historical per-
formance, 2002 was a very good year for our Company,
and was consistent with our long tradition of growth.
In fact, the last time we did not achieve year on year
sales growth was in 1931, during the Great Depression.
Earnings growth, too, has been remarkably consistent,
with double-digit gains, excluding special charges, in
each of the past 18 years.
One of the most important ways we can encourage
long-term consistent performance is through invest-
ments in science and technology. Indeed, the theme
of our report this year, “Delivering on the Promise of
Technology,” is evidence of our belief that these
investments are fundamental to both sustaining and
2James T. Lenehan,
Vice Chairman and President
establishing leadership positions that permit us to deliver
superior returns to our shareholders, and make a mean-
ingful difference in health care for people around the world. 
In each of our business segments, and throughout
our worldwide operations, we face the future with opti-
mism and commitment because we see many opportuni-
ties for continued growth and development. We pursue
this growth by managing against a set of broad princi-
ples: maintaining a broadly based health care business,
stressing a decentralized system of management, and
managing for the long term on a foundation of values as
espoused in Our Credo. 
Our extraordinary record of consistent performance is a
result of our broad base in human health care. Increasingly,
we emphasize collaborations across our technology plat-
forms that will enable proprietary positions. The CYPHER™
Sirolimus-eluting Stent is a promising example of the col-
laborative outcomes we can achieve. At the same time,
we recognize the potential to seize opportunity through
both external licensing arrangements and strategic acqui-
sitions. In the second quarter, we completed the acquisition
of Tibotec-Virco N.V. of Belgium, an organization focused
on developing anti-viral treatments, and early this year
acquired OraPharma, Inc., a specialty pharmaceutical
company. The recently announced agreement to acquire
Scios Inc., a California-based company with a product
to treat congestive heart failure and an important biophar-
maceutical pipeline, is further evidence of this strategy.
We hope to conclude this acquisition in the second quarter
of this year.
Our decentralized management system is also reflected
in our strong performance, as it gives us focus and a
sense of ownership in local markets through dedicated
and empowered management groups. They can quickly
pursue local avenues of opportunity. 
We focus on managing the Company for the long term;
that sustains our performance because it emphasizes
investment for the future and the importance of true inno-
vation. In 2002, we invested $4.0 billion in research and
development, 10.2% more than in the previous year.
Since 1999, in our pharmaceutical companies alone, the
research and development staff has grown more than 50%,
to 6,700. Recently, we announced the pending acquisition
of 3-Dimensional Pharmaceuticals, an outstanding organi-
zation that will be a strategic complement to our pharma-
ceutical discovery and development research capabilities. 
3We are also engaged in a three-year capital invest-
ment program begun in 2001 of more than $500 million
in worldwide research and development across all our
business segments. We are making major enhancements
and additions to our facilities and to our information
technology infrastructure so as to accelerate our ability
to bring new products to market — to deliver on the
promise of technology.
Finally, but no less significantly, we sustain our consis-
tent performance through a culture that is based on a
strong system of values. We expect the highest standards
of ethical behavior throughout our global organization,
achieved when each of us assumes responsibility for lead-
ership and integrity. We are guided in that pursuit by Our
Credo, the embodiment of our values, which has now
been in place for 60 years.
This four-part strategic business model — broadly
based in human health care, decentralized, managed for
the long term, on a foundation of strong values — has
served us well, yielding an enduring record of consistent
growth and performance. It continues to light our way
into the future. 
In terms of business performance, 2002 was a
successful year for Johnson & Johnson, with pharma-
ceuticals once again the largest and fastest growing
of our three business segments. Worldwide pharmaceu-
tical sales grew 15.5%, with operational growth of
14.8%. Importantly, our growth in this area reflects the
performance of a number of key products. PROCRIT®/
EPREX®, for the treatment of anemia, continued to
realize new potential around the world, although the
entry of a key competitor in the U.S. market will man-
date increased focus on clinical and competitive advan-
tages going forward. Other strong performers were
RISPERDAL®, an antipsychotic, for which we have now
filed an application for use as a treatment for bipolar
disorder; REMICADE®, a treatment for rheumatoid
arthritis and Crohn’s disease, which is now being
reviewed for other indications in immune-mediated dis-
eases; DURAGESIC®, a transdermal patch for chronic
pain; ACIPHEX®/PARIET®, a proton pump inhibitor for
gastrointestinal disorders which was approved in 2002
for two additional indications, symptomatic gastroin-
testinal reflux disease and the most common cause of
peptic ulcers; and TOPAMAX®, an antiepileptic, for
which we have now filed for monotherapy treatment
and for the prevention of migraine headaches in adults. 
During the year, the Company also received U.S. Food
and Drug Administration (FDA) approval for LEVAQUIN®
for an additional indication for the treatment of nosocomi-
al pneumonia, the second most common hospital-acquired
infection. And, extending leadership in the contraceptives
market, we launched ORTHO EVRA®, the first contracep-
tive patch, and ORTHO TRI-CYCLEN® LO, a new low-dose
oral contraceptive. 
But 2002 was not without product challenges. In
Europe, in a small subset of the patients taking EPREX
subcutaneously for chronic renal failure, and some tak-
ing other erythropoietins, we saw the rare but serious
occurrence of Pure Red Cell Aplasia, an immune
response. Based on our continuing investigation of the
issues, we implemented a labeling change for EPREX
that provides patients with important information about
the safest method of administration. While we recog-
nize the potential effect on the growth of EPREX as a
result of our actions, our urgent priority is to ensure the
safety of patients who rely on this product.
Our Medical Devices and Diagnostics segment, the
leading medical device business in the world, repre-
sents 34.7% of worldwide sales, and saw operational
growth of 12.9% in 2002. Strong sales growth was
achieved across our major areas of business, including
the Cordis circulatory disease management products;
DePuy orthopaedic joint reconstruction and spinal
products; Ethicon wound care, surgical sports medicine
and women’s health products; LifeScan blood glucose
monitoring products; Ethicon Endo-Surgery minimally
invasive surgery products; Ortho-Clinical Diagnostics
professional diagnostic products, and Vistakon dispos-
able contact lenses.
The CYPHER Sirolimus-eluting Stent from Cordis, a
great example of collaboration between our devices
and pharmaceutical segments, is now available in more
than 50 countries around the world, with FDA approval
in the United States hoped for soon. Although the reim-
bursement system in Europe has constrained growth to
some extent, we are pleased with the level of market
acceptance for this product. This is a breakthrough tech-
nology that will have a significant impact on the health
and well-being of patients.
Other developments included the FDA approval of
VICRYL® Plus suture from Ethicon, the only suture with
an antibacterial coating to reduce the potential for surgi-
cal site infection; the acquisition of Obtech Medical AG,
which markets Europe’s leading treatment for morbid
obesity, and its integration into the Ethicon Endo-Surgery
4business; and a favorable FDA panel recommendation
for the INDEPENDENCE™ iBOT™ Mobility System, which
we hope to bring to market in 2003.
The Vision Care franchise had an outstanding year,
particularly with the broad acceptance of ACUVUE® 2,
further penetration in the Japanese market of 1-DAY
ACUVUE®, and the growing popularity of ACUVUE® 2
COLOURS™ tinted contact lens. 
Our Consumer segment continues to deliver solid per-
formance, representing 18.1% of total sales and achieving
2002 operational growth of 4.6%. The combined skin
care businesses of NEUTROGENA®, AVEENO®, CLEAN &
CLEAR® and RoC® saw strong growth, particularly
through an emphasis on superior science and technology,
as did the nutritionals category, most notably SPLENDA®
no-calorie sweetener, now a market leader in the
table top sweetener category and an ingredient in more
than 2,000 brands sold in more than 30 countries, and
VIACTIV® calcium chews. The new BAND-AID® Brand
Liquid Bandage helped the wound care franchise achieve
strong growth, and is one more example of collaboration
on a proven technology — in this case the prescription
device DERMABOND® Topical Skin Adhesive — and its
adaptation for a new market application. 
Against this backdrop, we are confident that we are
well positioned for the future. Our performance in 2002 is
evidence of our shift in recent years to businesses more
firmly rooted in science and technology — higher margin,
proprietary businesses that offer opportunity for sus-
tained profitable growth. We will continue to seize these
competitive advantages, to capitalize on opportunities
that offer the promise of better health care for people
around the world. 
The strength of our leadership, and the diversity of
experiences and background they bring to our organiza-
tion, are key to our continued success. We thank our ded-
icated Board of Directors for the counsel they provide in
this regard. In April 2002, we welcomed David Satcher,
M.D., Ph.D., to the Company’s Board of Directors.
Dr. Satcher, the former Surgeon General of the United
States, is Director of the National Center for Primary Care
at the Morehouse School of Medicine. With regret, we
accepted the resignation of John Snow, who has been
named to the Cabinet position of Secretary of the Treasury
of the United States. We appreciate the guidance he pro-
vided since 1998 as a member of our Board, and we wish
him well in service to the country.
We acknowledge the outstanding contributions of
William C. Weldon
Chairman of the Board and
Chief Executive Officer
James T. Lenehan
Vice Chairman of the Board and
President
March 12, 2003
two Board members who will retire in April —
Dr. Maxine Singer, a member of the Board since 1991,
and Robert Wilson, who most recently served as
Senior Vice Chairman of the Board. Bob’s contribu-
tions, first to our pharmaceutical businesses and later
to our Corporate management and Board direction,
were instrumental to our growth over the last decade
and will be greatly missed. 
We begin another year with enthusiasm. These are
exciting times. We move ahead with an agenda focused
on key strategic imperatives — the development of
innovative product solutions, collaborations across our
broadly based health care business, flawless execution,
and leadership. We acknowledge the great heritage on
which we stand but see the promise of the future yet to
be fulfilled. As we build on that foundation, we move
from strength to strength, recognizing the enormous
dedication and power of our workforce now more than
108,300 strong. We are grateful for their efforts and for
the continued allegiance of you, our shareholders.
Together, you give us confidence that we can harness,
and indeed deliver on, the promise of technology to
improve health care.
DELIVERING ON THE PROMISE OF TECHNOLOGY
Ours is a company driven by a mission toimprove human health care. In science andtechnology, we see the promise to fulfill
that mission. We deliver on that promise through
collaboration, research, process improvement,
and the dedication of a committed workforce in
common pursuit of better health care for people
around the world.
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YREMICADE® (infliximab), a mono-clonal antibody for the treatment
of rheumatoid arthritis developed
by Centocor, is the only biologic
therapy approved by the U.S. FDA
to induce and maintain clinical
remission in patients with moderate
to severe Crohn’s disease. Tanabe
Seiyaku, Ltd. launched REMICADE in
Japan for Crohn’s disease patients.
The Janssen-Cilag and Ortho Biotech
European sales forces are max-
imizing pharmaceutical sales and
marketing techniques by using new
Customer Relationship Management
technologies to plan sales calls,
share important data with peers,
and better serve customers.
Johnson & Johnson, through
Ortho-McNeil Pharmaceutical and
Janssen Pharmaceutica, is among
the founding members of the
Together Rx™ prescription savings
program that provides savings to
eligible Medicare enrollees on
prescription products.
For more than 10 years, PROCRIT®
(Epoetin alfa) – also marketed as
EPREX® and ERYPO™ outside the U.S.
– has helped millions of patients
overcome the anemia associated
with cancer chemotherapy, pre-
dialysis kidney disease, AZT-treated
HIV, and certain elective surgeries.
EPREX and ERYPO also are indicated
to treat anemia in dialysis patients.
Combining the proprietary OROS® delivery technology
from ALZA with an ascending dose profile, CONCERTA®
(methylphenidate HCl) CII from McNeil Consumer & Specialty
Pharmaceuticals is the first extended-release formulation of
methylphenidate for the treatment of attention deficit hyperactivity
disorder that minimizes the ups and downs in blood levels that a
patient can experience with stimulant medications taken several times
a day. Lasting through 12 hours, CONCERTA demonstrates the power
of OROS to transform the standard pharmaceutical tablet into an
advanced drug delivery system. It uses osmosis, or the natural move-
ment of water through a semi-permeable membrane, to make oral
drug administration more controlled, precise and convenient. It is
incorporated in 13 commercialized products, including CONCERTA. In
2002, the U.S. FDA approved CONCERTA 27 mg extended-release
tablets, offering greater dosing flexibility. CONCERTA is also approved
in many countries in Europe, Latin America and Asia. Shown here,
Katya Alvarez, now a successful college student with ADHD symptom
control from CONCERTA, gets some help heading back to the dormito-
ry from her dad, Julio Alvarez, McNeil district manager. 
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7The acquisition of Tibotec-Virco expands drug discovery
and research and development capabilities, particularly
in the field of anti-infectives. The Belgium-based biopharma-
ceutical company brought to Johnson & Johnson several promising
compounds now in development for the treatment of HIV and a number
of innovative disease management tools. Tibotec applies the latest
techniques in ultra-high throughput screening, anti-viral profiling,
molecular biology and drug design to discovering and developing new
anti-infective drugs. The company has programs focusing on potential
drugs that are active against drug-resistant strains of HIV, including
two products in early clinical development. Additionally, there are
early stage research programs concentrating on treatments for other
infectious diseases, including Hepatitis C. Virco develops and markets
advanced diagnostic tools based on pharmacogenomic principles
for the clinical management of viral infections, including HIV. Featured
here are, left to right, Gery Dams, senior scientist, Koen Van Acker,
research fellow, and Paula McKenna, director, diagnostic lab operations.
We create new options for health care across arange of disciplines in pharmaceutical agents,
medical devices, diagnostics and delivery platforms,
and consumer products.
8The ALZA focus on sophisticated drug
delivery technology-based products
expanded in 2002 with the construction of
a manufacturing facility in Cashel, Ireland.
Products that incorporate drug delivery technologies
from ALZA have been widely commercialized by com-
panies both inside and outside of Johnson & Johnson
to deliver unique patient advantages. The Cashel
plant, a 60,000 square-foot facility with ample room
for future expansion, adds critical capacity for the
manufacture of products growing in the European
marketplace. At the same time, it reduces pressure on
the production and supply chain operations in the
United States, improving efficiency and enhancing
service. The Cashel site represents the shared com-
mitment of ALZA and Johnson & Johnson engineering
and technical resources to create a manufacturing
center of excellence for drug delivery technology,
says Robert Strickland, managing director of the
Cashel facility, shown here. The company expects to
begin shipping product from the facility in the third
quarter of 2003.
A lthough we are broadly based, we focus onhuman health care, from compounds derived
from small molecules and smart technologies that
compensate for the frailties of disease, to patented
formulations to serve growing consumer needs.
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An intricate, state-of-the-art computing research net-
work laboratory which connects major research facilities
throughout the Company was created by Johnson & Johnson
Networking & Computing Services (NCS) to facilitate product design
and creation while alleviating roadblocks such as the geographic and
time zone differences throughout the Company. In rooms at various
Johnson & Johnson locations around the world, global researchers use
such advanced communication tools as “high-definition visualization,”
which can model science in ways not typically visible to the human
eye, and “grid collaboration,” which connects persons at diverse loca-
tions via the “Internet2 research network.” This leading-edge technol-
ogy enables massive amounts of data to be exchanged and, over time,
is expected to help Johnson & Johnson businesses reduce the time it
takes to bring a product to the marketplace. James Regina, vice presi-
dent of technology engineering and development, NCS, left, and Stuart
Kippelman, director of advanced technologies research, are pictured
in front of the prototype collaboration system at NCS.
ACIPHEX® (rabeprazole sodium),
co-promoted by Eisai Inc. and
Janssen Pharmaceutica Inc. and
prescribed for gastroesophageal
reflux disease, was approved by
the U.S. FDA as part of the first
seven-day treatment for H. pylori
infection, the most common cause
of peptic ulcers.
The U.S. FDA approved LEVAQUIN®
(levofloxacin) Tablets/Injection
and LEVAQUIN® (levofloxacin in
5% dextrose) Injection 750 mg
for the treatment of nosocomial
(hospital-acquired) pneumonia.
LEVAQUIN is a fluoroquinolone
anti-infective from Ortho-McNeil
Pharmaceutical, Inc.
A clinical study of the anti-
epilepsy medication TOPAMAX®
(topiramate/topiramate capsules)
Tablets and Sprinkle Capsules,
from Ortho-McNeil Pharmaceutical,
Inc. demonstrated a significant
effect on controlling seizures in
newly-diagnosed patients, even
when used as a stand-alone therapy.
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The regulatory agencies of Germany
and the U.K. were the first to
approve RISPERDAL CONSTA™
(risperidone) from Janssen-Cilag
as the first atypical antipsychotic
available in the form of a long-
acting injection. This form is now
approved in other European coun-
tries and in New Zealand, Mexico,
Israel and Korea.
Johnson & Johnson acquired
OraPharma, Inc., a specialty pharma-
ceutical company focused on the
development and commercialization
of unique, patented therapeutics.
OraPharma will operate as part of
Personal Products Company and
provides an entry into the oral care
professional marketplace with an
initial focus on the treatment and
prevention of periodontal disease.
ORTHO TRI-CYCLEN® LO (norgesti-
mate/ethinyl estradiol) from Ortho-
McNeil Pharmaceutical, Inc. is
the new, low-dose version of the
most prescribed birth control pill
in the U.S., ORTHO TRI-CYCLEN®
(norgestimate/ethinyl estradiol).
With a lower level of estrogen, the
new version is highly effective.
The U.K. regulatory authority
granted Janssen-Cilag Ltd. an exten-
sion of its license for DUROGESIC™
(fentanyl transdermal system)
beyond cancer to include all types
of severe, chronic pain. Also,
Janssen Pharmaceutical K.K. in
Japan launched the product
(called DUROTEP®) for cancer pain.
Process excellence – a major focus at Johnson & Johnson –
has resulted in important solutions to a wide range of formi-
dable challenges. One such solution was successfully implemented
after an increasing number of patients began raising concerns that a
key product marketed by Janssen — DURAGESIC® (fentanyl transder-
mal system), a medicated patch providing up to three days of relief for
patients with chronic pain — was apparently detaching from their skin.
The Process Excellence team at Janssen, which included members
from other Johnson & Johnson companies, was charged with resolving
this problem. The team, led by Director of Process Excellence Chris
Herbine, left, and Director of Marketing Jim Eckhardt, right, followed
a specific analytical improvement methodology and concluded that the
detaching problem was mostly related to patients improperly applying
the patch. They designed a program centered on educational materials
that clearly described the proper way to apply the patch and a plan to
ensure that those patients, caregivers and health care professionals
who use the product had access to this information. The result was a
42 percent reduction in the complaint rate during a two-year period
and an improvement in customer satisfaction, contributing to a sub-
stantial increase in DURAGESIC sales.
10
11
Centocor will double the manufacturing capacity for 
REMICADE® (infliximab) when the new Malvern,
Pennsylvania, facility is fully operational by mid-2003.
REMICADE is a monoclonal antibody used to treat patients with
rheumatoid arthritis and patients with the gastrointestinal disorder,
Crohn’s disease. Hundreds of thousands of patients have been treat-
ed worldwide with REMICADE. Fully capable of meeting current
market demand for REMICADE, Centocor is now poised to maximize
the potential of this product in markets throughout the world. The
facility shown here, where Valerie Ulicny monitors processes, is one
of the largest and most advanced mammalian cell culture and bio-
pharmaceutical bulk production centers in the world. In addition to
the Malvern operation, Centocor produces therapeutic agents using
monoclonal antibody technology in Leiden, the Netherlands.
We employ dedicated people, givethem state-of-the-art facilities
to work in worldwide, and provide
them with the resources they need to
become the workforce of the future.
12
The acquisition of Inverness Medical Limited (IML) has 
strengthened the ability of LifeScan to serve the global 
diabetes market and helped to enhance the company’s commit-
ment to improve the quality of life for people with diabetes. The
Inverness facility manufactures test strips used by diabetes patients
for blood glucose self-testing as part of the LifeScan ONETOUCH®
ULTRA®, INDUO™, ONETOUCH® ULTRASMART™, SMARTSCAN™ and
EUROFLASH® systems. Due to the need to expand research and
development capabilities and production capacity, IML recently initi-
ated new construction as part of a substantial capital investment at
its facilities in Inverness, Scotland, enabling IML to bolster the pro-
duction of test strips and increase new product development. Pictured
checking the quality on a card of strips are Thomas Stevenson, manu-
facturing team leader, left, and Nigel Spiller, manufacturing director.
We focus on those imperatives that will enableus to make a meaningful contribution: on
collaboration across disciplinary lines, a unique
advantage in our broadly based company…
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The LAP DISC™ Hand Access Device,
introduced by Ethicon Endo-Surgery,
is used in hand-assisted laparoscopic
surgery. It is enabling less invasive
and less painful surgical procedures,
and also reduces hospitalization
and recovery time compared to
traditional surgery.
SURGIFOAM™ Absorbable Gelatin
Powder from Johnson & Johnson
Wound Management is the only
hemostatic powder that comes in a
self-contained sterile mixing vessel.
It can be spread or shaped to con-
form to irregular surfaces to stop
bleeding fast.
PROLENE™ 3D Patch Polypropylene
Mesh from Ethicon Products, an
innovative three-dimensional device
for the repair of abdominal wall
hernias, offers a simple, streamlined
insertion technique. It is designed
to prevent migration and recur-
rence, and provides a new dimen-
sion in comfort and healing.
The MONARCH™ Spine System from
DePuy AcroMed is a comprehensive
pedicle screw, rod and hook system
for immobilization and stabilization
of spinal segments for the treat-
ment of acute and chronic instabili-
ties or deformities of the thoracic,
lumbar and sacral spine.
The stringent quality and production standards of
pharmaceutical manufacturer Janssen-Cilag are applied
to the new CYPHER™ Sirolimus-eluting Stent, giving Cordis
a unique advantage. First in the market worldwide, now available in
countries throughout the world and expected to be available this year
in the United States, the CYPHER Stent is reported to reduce the rate of
reblockage of coronary arteries. Bare metal stents, the current treat-
ment for clogged arteries, cannot prevent the reblockage that occurs in
approximately 30 percent of the world’s stent patients. In trial follow-
up at about eight months, binary in-stent restenosis, or reblockage,
occurred in only 3.4 percent of the cases where the CYPHER Stent was
used. In addition to the Latina, Italy, facility of Janssen-Cilag, where
Francesca Finocchiaro, pictured, inspects coated stents, the CYPHER
Stent is manufactured at the Janssen facility in Beerse, Belgium, and at
another plant beginning in 2003. The partnership of device and phar-
maceutical technologies that led to the development of the CYPHER
Stent was made possible by the diversity of interests in human health
care distinct to the Johnson & Johnson companies. 
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for Percutaneous Transluminal Coronary
Angioplasty (PTCA) balloons manufactured
by Cordis. The AQUA T3™ PTCA Balloon Catheter,
now available in markets other than the United States,
was developed in cooperation with cardiologists in
Japan and makes it easier for interventional cardiolo-
gists to cross and treat challenging lesions. Among
the unique attributes of the balloon is its innovative
sealing technology, which makes for a more efficient
delivery. The balloon is designed to navigate more
smoothly through tortuous anatomy, and its tapered
tip aids in crossing of tight lesions. The AQUA T3
Balloon Catheter was first launched in Japan and the
Benelux region of Europe, and will be released in
world markets excluding the United States throughout
the first half of 2003. Here, Cordis associates Donna
Sakaguchi and Shinichi Miyata confer with Dr. Taro
Saito, an interventional cardiologist in Kumamoto.
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Ethicon Endo-Surgery expanded
the MAMMOTOME® Breast Biopsy
System product line by intro-
ducing four new probe sizes, which
increases the number of lesions
that can be biopsied using this
minimally-invasive technique.
WATCHBAND INCISION™, intro-
duced by CardioVations, a division
of Ethicon, Inc., combines multiple
technologies to enable endo-
scopic radial artery harvesting.
This results in a significantly
smaller scar that can be hidden
behind a watchband and offers
the potential for less trauma
than large-incision surgery.
Ethicon Endo-Surgery Company
Group Chairman Karen Licitra, right,
and LPGA Hall of Famer Kathy
Whitworth on the green at the 4th
annual Ethicon Endo-Surgery Pink
Ribbon LPGA Pro-Am benefit in
support of breast cancer research.
Gynecare, a division of Ethicon, Inc.,
introduced a new product to com-
plement its established GYNECARE
TVT™ Tension-free Support for
Incontinence product line. The
GYNECARE TVT with abdominal
guides offers a broader group of
health care professionals options to
treat the growing female stress
urinary incontinence market.
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Normal Pressure Hydrocephalus (NPH) 
afflicts over 350,000 people in the U.S. and 
thousands more all over the world. A form of
hydrocephalus characterized by an abnormal accumu-
lation of cerebrospinal fluid in the ventricles of the
brain, this devastating disease, which can be difficult
to diagnose and often goes untreated, causes such
symptoms as difficulty walking, mild dementia and uri-
nary incontinence. NPH can be treated and, in many
cases, symptoms can be reversed with a CODMAN®
HAKIM™ Programmable Shunt System from Codman,
a world leader in neurosurgical implants and surgical
products. Now, with the introduction of the CODMAN
HAKIM Programmable Valve, a system that uses a
programmer to adjust the pressure of the valve non-
invasively after a cranial shunt is implanted, the need
for surgical adjustment is eliminated. One NPH patient
who received a CODMAN HAKIM Programmable
Valve is Bob Fowler, right, from Dallas, Texas, who
meets up with Michael McIntyre, senior product
director–hydrocephalus, Codman.
…on the research that drives discovery and devel-
opment, and on the investment in facilities and
technologies that make possible the discovery
and development of new health care solutions…
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The acquisition of Swiss-based Obtech Medical AG
provides Ethicon Endo-Surgery the opportunity to offer
surgeons another minimally-invasive alternative, expand
its extensive line of products used in the treatment of morbid obesity
and strengthen its competitive position in advanced technologies. It
exemplifies the way in which Ethicon Endo-Surgery continually seeks
to respond to the diversified needs of surgeons and their patients.
The Swedish Adjustable Gastric Band (SAGB) is an inflatable band
that is fitted around the uppermost part of the stomach during laparo-
scopic surgery, creating a small pouch. Food intake is greatly reduced,
resulting in weight loss. A physician is able to adjust the band’s inner
diameter at any time by injecting or removing fluid through an access
port. Although not yet available in the U.S., the SAGB has been widely
used throughout Europe for the treatment of morbid obesity since
1987 and is also marketed in other countries. Dr. Karl Miller, left,
of Hallein, Austria, and his team, including dietician Monika Zeiner,
seated, work with company representative Franz Buchner, right, to
provide education and support for patients. 
…on honing the processes that put flawless execution
within our grasp, that make our investments as
efficient as possible, and that enable us to fulfill our
mission to improve the quality of life.
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ONETOUCH® ULTRASMART™ Blood
Glucose Monitoring System from
LifeScan, a meter and electronic
logbook in one, automatically
organizes blood glucose results and
other important diabetes informa-
tion into meaningful charts and
graphs to help people better man-
age their diabetes.
The Advanced Diagnostic Systems
(ADS) division of Ortho-Clinical
Diagnostics is focused on high
impact products in human cancer
diagnosis, monitoring, screening and
patient management. David Atkins,
general manager of the molecular
diagnostics group within ADS,
applies genomic tools ordinarily
used for drug discovery to molecular
diagnostic product development.
PROMOGRAN® Matrix Wound
Dressing from Johnson & Johnson
Wound Management was intro-
duced as the only chronic wound
dressing that combines oxidized
regenerated cellulose and collagen.
It is indicated for the treatment of
exuding wounds including, but not
limited to, diabetic, venous and
pressure ulcers.
PRESERVATION™ Minimally
Invasive Uni-compartmental Knee
from DePuy Orthopaedics enables
restoration of soft tissue balance
to assure natural function and
alignment. It is the only system
integrating both fixed and mobile-
bearing components for minimally
invasive knee reconstruction.
From the introduction of the first pre-packaged sterile 
bandage in 1892, to the development of the first-ever 
antibacterial suture, the medical device companies of Johnson
& Johnson have ushered in many new generations of surgical care.
With the year-end 2002 launch of VICRYL® Plus Antibacterial Suture,
Ethicon Products introduced a new era of devices that may help
reduce the risk of complications associated with surgery. In vitro stud-
ies demonstrate that VICRYL Plus is effective against bacteria that
most often cause surgical site infection. In the United States alone,
more than 675,000 surgical site infections occur annually, at a cost
of more than $2 billion to the medical system. More than 60 percent
of surgical site infections occur at the incision site. VICRYL Plus
Antibacterial Suture has all the handling characteristics of VICRYL
Suture, the world’s most widely used absorbable suture. Howard
Scalzo, Jr., staff engineer, and Punam Aggarwal, manager–new
product integration, shown here, examine the “active zone” around
the suture in a laboratory dish.
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commitment of five years ago to bring new freedom
to people with mobility-related disabilities. In late 2002,
the Orthopaedic and Rehabilitation Devices Panel of the U.S. Food
and Drug Administration (FDA) unanimously recommended approval
of the INDEPENDENCE™ iBOT™ Mobility System, for which FDA
approval is now hoped for around the second quarter of 2003. The
INDEPENDENCE iBOT Mobility System can navigate uneven terrain,
climb stairs and ramps, and balance at “standing” height on two
wheels. Also in late 2002, an acquisition led to the recent introduction
of the INDEPENDENCE™ iGLIDE™ Manual Assist Wheelchair, which
uses proprietary technology to continuously monitor the amount of
force needed to propel the chair over different types of terrain. Users
propel the chair over carpet and similarly difficult terrain with much
less effort than with traditional manual wheelchairs, which may
reduce the incidence of common problems such as rotator cuff injury
and carpal tunnel syndrome. In the United States, an estimated 2
million people use wheelchairs. Shown here, Sandy Salerno, an occu-
pational therapist from Independence Technology, acquaints William
Scelza with the INDEPENDENCE iGLIDE Manual Assist Wheelchair.
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VIACTIV® Soft Calcium Chews from
McNeil Nutritionals are now avail-
able in milk chocolate, mochaccino,
caramel and orange cream flavors.
Two chews provide 100 percent of
the daily value of calcium.
SPLENDA® No Calorie Sweetener
from McNeil Nutritionals has
become a leading low calorie
sweetener in the U.S. grocery
market. SPLENDA can now be
found in more than 2,000 prod-
ucts in more than 30 countries.
Vistakon Division of Johnson &
Johnson Vision Care, Inc., introduced
ACUVUE® 2 COLOURS™ Brand Contact
Lenses, which offer natural colors
and superior comfort. Launched glob-
ally in 2002, ACUVUE 2 COLOURS is
already the number two lens in the
U.S. cosmetic tint segment.
A new toothbrush launched by
Personal Products Company, REACH®
MAX™ is clinically proven to reduce
gingivitis. Its rubber bristles
massage gums and multi-level
bristles clean hard-to-reach places
to help prevent gum disease.
NEUTROGENA® Men is a clinically
proven line of skin care products
which respond to men’s specific skin
care needs. The line contains RAZOR
DEFENSE™ and skin clearing prod-
ucts designed to turn problem skin
into healthier looking skin.
Brand expansion and customer development
strategies help the Johnson & Johnson 
worldwide baby products business continue 
to grow. For example, global retail operations in
the dynamic Latin America market focus on five key
franchises. In most, the consumer business in the
region holds the number one or two market position.
Around the world, innovation results from insights into
consumer preferences that serve to expand markets
and grow sales. Recent launches of products such as
JOHNSON’S® Baby Shampoo for Curly Hair — now
available in several Latin America countries and
appropriate for all family members — exemplify the
importance of market expansion through line exten-
sions, brand-building and creative merchandising con-
cepts. Pictured in a retail outlet in Buenos Aires,
Argentina, is Marita Messuti, trade marketing manag-
er, consumer business, Johnson & Johnson de
Argentina S.A. C.e.l. 
We cultivate a leadership – people committedto making a measurable difference – that will
take this corporation into the future as a global
contributor to better health care…
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Company researchers work with the world’s leading 
skin care scientists to bring to the marketplace an array
of technology-driven skin care products to fulfill consumers’ needs
at every age. Johnson & Johnson primarily competes in the traditional
skin care arena, which includes facial, body and hand care. Continu-
ous growth within this franchise has been achieved by the Johnson &
Johnson Consumer Products Company comprehensive adult skin care
franchise, with its CLEAN & CLEAR®, AVEENO®, RoC®, PURPOSE® and
SHOWER TO SHOWER® brands, and the steady stream of beneficial
skin care products from Neutrogena. To ensure that its skin care prod-
ucts meet customer needs, the company conducts extensive market
research and creates innovative marketing programs. For example,
the WB CLEAN & CLEAR Casting Call 2002, sponsored in conjunction
with the WB Television Network and showcasing CLEAN & CLEAR
products, helped make the brand a leading teen skin care line in
the U.S. Marketing staff members, including John Weinstock, group
product director, CLEAN & CLEAR U.S., pictured, worked with beauty
consultants at traveling exhibits. 
…and as a company that has seen and
seized the promise of technology to
improve the quality of life.
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A revolutionary liquid bandage that is changing
the way consumers treat minor cuts and scrapes was
introduced by Johnson & Johnson Consumer Products Company.
BAND-AID® Brand Liquid Bandage provides superior protection and
optimal healing, and stays on hard-to-cover areas like fingers and
knuckles. The bandage creates a clear seal that keeps out water
and germs to help prevent infection and promote quick healing, and
stays on until it naturally sloughs off as the wound heals. BAND-AID®
Brand Liquid Bandage contains 2-octyl cyanoacrylate, the same base
material found in DERMABOND® Topical Skin Adhesive, a prescription
device marketed by Ethicon Products. Both are manufactured by
Closure Medical Corporation. Used by physicians to close wounds and
incisions in place of stitches or staples, DERMABOND adhesive acts
as a barrier that seals out bacteria that can lead to infection. In 2002,
Ethicon Products introduced a thicker formulation of DERMABOND
that provides better control for physicians. Michael E. Haddad, east-
ern division manager, pictured, checks a major retail account’s shelf
facing of the new BAND-AID® Brand Liquid Bandage. 
TYLENOL® Sinus and TYLENOL®
Cold Day/Night Convenience Packs
from McNeil Consumer & Specialty
Pharmaceuticals each contain
one package of a day and night
formula to relieve day and night-
time symptoms of sinus pain or
colds in one convenient box.
Johnson & Johnson Consumer
Products Company signed an agree-
ment to acquire the COMPEED®
products business worldwide from
Coloplast A/S. The acquisition
provides worldwide access to a
comprehensive line of patented
technologies as well as a platform
to develop a strong European
wound care presence.
SIMPLY STUFFY® and SIMPLY
COUGH™ are single ingredient
products for children from McNeil
Consumer & Specialty Pharmaceu-
ticals. Containing only that medicine
needed for a specific condition,
one is a nasal decongestant and
the other a cough suppressant
for coughs due to colds.
AVEENO® POSITIVELY RADIANT™
Daily Moisturizer from Johnson &
Johnson Consumer Products
Company uses patented technology
based on the effect of small proteins
in soy in diminishing the appear-
ance of skin pigmentation. Clinically
proven, it gives skin a more even
tone and a smooth texture.
The “Una Gran Familia” campaign
for TYLENOL® (acetaminophen) fea-
tures employees of McNeil Con-
sumer & Specialty Pharmaceuticals
in Las Piedras, Puerto Rico, in a
television commercial.
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The Johnson & Johnson Pediatric
Institute, L.L.C., is dedicated to the
advancement of maternal and chil-
dren’s health care. In partnerships
with health care professionals, devel-
opmental specialists and interna-
tional organizations, the Institute
undertakes initiatives that help
shape the future of children’s health.
Human health depends on the
health of the planet, and the Com-
pany recognizes the links to conser-
vation of the earth’s biological
diversity. Partnerships with The
Nature Conservancy and the World
Wildlife Fund advance that purpose
and improve the quality of life.
McNeil Canada achieved an imme-
diate 11 percent reduction in CO2
emissions in 2002 with the conver-
sion of all company fleet vehicles
to 10 percent ethanol-based fuels
where available. The company rec-
ommends the use of the same more
efficient fuels to employees.
The Campaign for Nursing’s FutureSM,
sponsored by Johnson & Johnson
to address the critical shortage of
nurses, is a U.S. initiative to recruit
and retain nurses and nursing facul-
ty. It includes national advertising,
fundraising events, recruiting mate-
rials and a website.
Through Surgical Eye Expeditions,
Johnson & Johnson provided funds
for a self-sustaining eye clinic to
serve the poor and uninsured of
Juarez, Mexico. Since opening in
July, the clinic has examined more
than 250 patients, about 40 percent
of whom will return for surgery
upon completion of the clinic.
If we didn’t drive 10.6 million miles, or if we planted 1,200
acres of trees, we would reduce emissions by the same
amount to be saved over 25 years by solar panels at
Neutrogena. The 62,000 square feet of panels, the largest com-
mercial solar rooftop installation in California, generate enough elec-
tricity during the day to power over 550 homes. Developed in close
partnership with the City of Los Angeles, they will reduce operating
costs and monthly energy consumption for the company by 35 per-
cent. Senaka Nanayakkara, Neutrogena director of facilities engineer-
ing, and Angelina Galiteva, director of strategic planning, Los Angeles
Department of Water & Power, discuss the initiative here. This project
at Neutrogena exemplifies the Johnson & Johnson commitment to the
use of renewable energy resources. The burning of fossil fuels is the
largest man-made source of greenhouse gases in our atmosphere that
contribute to climate change. The Johnson & Johnson energy conser-
vation goals have established aggressive targets for reducing green-
house gas emissions. Over the past decade, carbon dioxide emissions
have increased by a modest 10 percent. 
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A bove all, we remember our longstandingcommitments to our customers, our employees,
our shareholders, and the communities in which
we live and work.
The Yale-Johnson & Johnson Physician Scholars in 
International Health program puts physicians in hospi-
tals in countries with limited health and technology
resources. Participants learn about the application of their profes-
sion in developing countries while sharing their medical knowledge
with people there. Johnson & Johnson funding enabled Yale to expand
its offering to physicians in residency training from leading U.S. hospi-
tals and universities and to offer international opportunities to more
experienced career physicians. In the 2001-2002 academic year,
nearly 40 physicians were enrolled in the program. Since the program
began in 1981, more than 215 doctors, including Kimberly Curseen,
M.D., shown here at left, and Tracy-Ann Clarke, M.D., right, have par-
ticipated. According to a Yale study, the program’s alumni exhibit
more caring attitudes toward health care delivery, especially to poor
and under-served communities, than do their non-participant counter-
parts. Research has shown that patients respond more favorably to
treatment when their doctors are compassionate and sensitive. 
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Audit
The Audit Committee, composed
entirely of non-employee Directors,
helps the Board oversee the Company’s
accounting and reporting practices. It
recommends independent public
accountants for appointment by the
Board and reviews their performance;
monitors the adequacy of internal
accounting practices, procedures and
controls; and reviews all significant
changes in accounting policies.
James G. Cullen, Chairman
Arnold G. Langbo
Leo F. Mullin
Henry B. Schacht
Benefits
The Benefits Committee, composed
entirely of non-employee Directors,
reviews the management of the vari-
ous retirement, pension, health and
welfare plans that cover substantial-
ly all employees of the Company’s
domestic operations and employees
of certain international subsidiaries.
The Committee also monitors the
performance of the trusts in which
pension funds are invested.
Maxine F. Singer, Ph.D., Chairman
Compensation
The Compensation Committee,
composed entirely of non-employee
Directors, reviews the compensation
philosophy and policy of the non-Board
Management Compensation Committee
with respect to executive compen-
sation, fringe benefits and other
compensation matters. The Committee
also administers the Company’s stock
option plans and determines the
compensation of the members of the
Executive Committee.
Arnold G. Langbo, Chairman
James G. Cullen
Robert J. Darretta
Executive Vice President,
Finance and Information
Management, and Chief
Financial Officer
William C. Weldon
Chairman, Board
of Directors, and
Chief Executive Officer
Leo F. Mullin
Chairman and Chief
Executive Officer,
Delta Air Lines, Inc.
Henry B. Schacht
Director and Senior Advisor,
Lucent Technologies Inc.
David Satcher, M.D.
Director, National
Center for Primary Care
Board of Directors
Ann D. Jordan
Former Director of
the Social Services
Department, Chicago
Lying-In Hospital
Committees of the Board
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Gerard N. Burrow, M.D.
President and Chief
Executive Officer,
Sea Research Foundation
James G. Cullen
Retired President and
Chief Operating Officer,
Bell Atlantic Corporation
Maxine F. Singer, Ph.D.
President, Carnegie
Institution of Washington
Finance
The Finance Committee exercises the
management authority of the Board
during the intervals between Board
meetings.
William C. Weldon, Chairman
Robert J. Darretta
James T. Lenehan
Nominating and Corporate Governance
The Nominating and Corporate
Governance Committee, composed
entirely of non-employee Directors, is
responsible for overseeing corporate
governance matters, reviewing possible
candidates for Board membership and
recommending nominees for election.
The Committee is also responsible
for evaluating the function and perfor-
mance of the Board and overseeing the
process for performance evaluation
of the Committees of the Board.
Additionally, the Committee reviews
the Company's management succes-
sion plans and executive resources.
Henry B. Schacht, Chairman
Gerard N. Burrow, M.D.
Ann D. Jordan
Leo F. Mullin
Public Policy
The Public Policy Advisory Committee
is composed of Board members and the
Company’s Vice President, Administra-
tion. It reviews the Company’s policies,
programs and practices on public
health issues regarding the environ-
ment and the health and safety of
employees, and advises and makes
recommendations to the Board on
such issues.
Ann D. Jordan, Chairman
Russell C. Deyo
M. Judah Folkman, M.D.
David Satcher, M.D.
Science and Technology
The Science and Technology Advisory
Committee is composed of Board mem-
bers and the Company’s Vice President,
Science and Technology. It advises the
Board on scientific matters that include
major internal projects, interaction with
academic and other outside research
organizations, and the acquisition of
technologies and products.
Gerard N. Burrow, M.D., Chairman
M. Judah Folkman, M.D.
Raymond W. Ruddon, M.D., Ph.D.
David Satcher, M.D.
Maxine F. Singer, Ph.D.
Robert N. Wilson
Senior Vice Chairman,
Board of Directors
M. Judah Folkman, M.D.
Senior Associate in
Surgery and Director at
Children’s Hospital and
Professor of Cell Biology,
Harvard Medical School
Arnold G. Langbo
Retired Chairman of
the Board and Chief
Executive Officer,
Kellogg Company
James T. Lenehan
Vice Chairman,
Board of Directors,
and President
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William C. Weldon
Chairman, Board of Directors,
and Chief Executive Officer
Chairman, Executive Committee
James T. Lenehan
Vice Chairman, Board of Directors,
and President
Executive Committee
Robert N. Wilson
Senior Vice Chairman,
Board of Directors
Vice Chairman, Executive Committee
J. Andrea Alstrup
Vice President, Advertising
Michael J. Carey
Vice President, Human Resources
Stephen J. Cosgrove
Corporate Controller
Robert J. Darretta
Executive Vice President,
Finance and Information Management,
and Chief Financial Officer
Executive Committee
John A. Papa
Treasurer
Brian D. Perkins
Worldwide Chairman,
Consumer Pharmaceuticals &
Nutritionals Group
Executive Committee
Per A. Peterson, M.D., Ph.D.
Chairman, Research & Development
Pharmaceuticals Group
Executive Committee
Larry G. Pickering
Vice President, Corporate Development
Christine A. Poon
Worldwide Chairman,
Pharmaceuticals Group 
Executive Committee
Raymond W. Ruddon, M.D., Ph.D.
Vice President, Science and Technology
Michael H. Ullmann
Secretary,
Associate General Counsel 
Corporate Officers and Company Group Chairmen
Russell C. Deyo
Vice President, Administration
Executive Committee
Michael J. Dormer
Worldwide Chairman,
Medical Devices
Executive Committee
Roger S. Fine
Vice President, General Counsel
Executive Committee
Colleen A. Goggins
Worldwide Chairman,
Consumer & Personal Care Group
Executive Committee
Thomas M. Gorrie, Ph.D.
Vice President,
Government Affairs & Policy
JoAnn Heffernan Heisen
Vice President,
Chief Information Officer
Executive Committee
Willard D. Nielsen
Vice President, Public Affairs
Corporate Officers
Company Group Chairmen
Robert W. Croce
William D. Dearstyne, Jr.
Carlos A. Gottschalk
Walter Hak
Karen A. Licitra
Dennis N. Longstreet
Eric P. Milledge
Patrick D. Mutchler
David Y. Norton
Gerald M. Ostrov
Jose V. Sartarelli, Ph.D.
Joseph C. Scodari
Curt M. Selquist
Pericles P. Stamatiades
Gerard Vaillant
Nicholas J. Valeriani
Carol A. Webb
The Executive Committee of Johnson &
Johnson is the principal management
group responsible for the operations and
allocation of the Company’s resources.
In addition, several Executive Committee
members serve as Chairmen of Group
Operating Committees, which are com-
prised of managers who represent key
operations within the groups, as well as
management expertise in other specialized
functions. These Committees oversee and
coordinate the activities of domestic and
international companies related to each
of the Consumer, Pharmaceutical and
Medical Devices & Diagnostics businesses.
Operating management of each company is
headed by a Chairman, President, General
Manager or Managing Director who
reports directly or through a line executive
to a Group Operating Committee.
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Johnson & Johnson is governed by the values set forth in Our
Credo, created by General Robert Wood Johnson in 1943. These
principles have guided us for many years and will continue to
set the tone of integrity for the entire Company. At all levels, the
employees of Johnson & Johnson are committed to the ethical
principles embodied in Our Credo and these principles have
been woven into the fabric of the Company.
The Credo values extend to our accounting and financial
reporting responsibilities that we have to our shareholders and
investors. We, the management of Johnson & Johnson, are
responsible for the integrity and objectivity of the accompanying
financial statements and related information. We are also
responsible for ensuring that financial data is reported accurately
and in a manner that facilitates the understanding of this data.
As evidence of our commitment to this responsibility, we
maintain a strong system of internal accounting controls,
encourage strong and effective corporate governance from our
Board of Directors, continuously review our business results
and strategic choices and focus on financial stewardship.
Our corporate staff of professionally trained internal audi-
tors, who travel worldwide, monitor our system of internal
accounting controls that is designed to provide reasonable
assurance that assets are safeguarded and that transactions
and events are recorded properly. Our internal controls
include self-assessments and internal and external audit
reviews of our operating companies. We also require the
management teams of our operating companies to certify
their compliance with our Policy on Business Conduct and we
have a systematic program to ensure compliance with these
policies at all employee levels.
PricewaterhouseCoopers LLP, the Company’s independent
auditor, is engaged to audit our financial statements.
PricewaterhouseCoopers LLP maintains an understanding of
our internal controls and conducts such tests and other auditing
procedures considered necessary in the circumstances to express
their opinion in the Independent Auditor’s Report on page 56.
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Corporate Governance and Management’s Responsibility
Our Audit Committee of the Board of Directors is composed
solely of independent directors with the financial knowledge
and experience to provide appropriate oversight. We review
internal control matters and key accounting and financial
reporting issues with the Audit Committee on a regular basis.
In addition, the independent auditors, the General Counsel and
the Vice President, Internal Audit regularly meet in private ses-
sions with our Audit Committee to discuss the results of their
work including observations on the adequacy of internal finan-
cial controls, the quality of financial reporting, confirm that they
are properly discharging their responsibilities and other rele-
vant matters.
We regularly review our business results and strategic prior-
ities. Our Executive Committee is continuously involved in the
review of financial results as well as developing and under-
standing strategies and key initiatives for long term growth. Our
intent is to ensure that we maintain objectivity in our business
assessments, constructively challenge the approach to business
opportunities and issues and monitor our business results and
the related controls.
Our consolidated financial statements and financial data that
follow are the responsibility of management. These statements
have been prepared in conformity with accounting principles
generally accepted in the United States of America and include
amounts that are based on our best judgments. We are commit-
ted to providing timely, accurate and understandable informa-
tion to our shareholders.
William C. Weldon Robert J. Darretta
Chairman, Board of Executive Vice President, 
Directors, and Chief Finance and Information
Executive Officer Management, and Chief 
Financial Officer
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Overview
Record 2002 sales of $36.3 billion exceeded 2001 sales by
$4.0 billion or 12.3% and marked the 70th year of consecutive
positive sales growth. This growth was led by the strong
performances of the Pharmaceutical and Medical Devices
& Diagnostics segments.
The balance sheet remains strong with cash generated from
operations of $8.2 billion in 2002. Cash dividends per share paid
to shareholders in 2002 increased by 13.6% over 2001 and rep-
resented the 40th consecutive year of cash dividend increases.
The Company continues to be one of few companies with a
Triple A credit rating.
Organization
Management’s Objectives
The Company’s objective is to achieve superior levels of capital
efficient profitable growth. To accomplish this, the Company’s
management operates the business consistent with certain
strategic principles that have proven successful over time. To
this end, the Company participates in growth areas in human
health care and is committed to attaining leadership positions
in these growth segments through the development of innova-
tive products and services. In 2002, approximately $4.0 billion
or 10.9% of sales was invested in research and development, rec-
ognizing the importance of on-going development of new and
differentiated products and services.
The Company’s system of management operates on a decen-
tralized basis. With over 200 operating companies located in 54
countries, the Company views this management philosophy as
an asset and fundamental to the success of a broadly based
business. It also fosters an entrepreneurial spirit, combining
the extensive resources of a large organization with the ability
to react quickly to local market changes and challenges.
Businesses are managed for the long term in order to sustain
leadership positions and achieve growth that provides an
enduring source of value to shareholders.
Unifying the management team and the Company’s dedi-
cated employees in achieving these objectives is the Johnson &
Johnson Credo. The Credo provides a common set of values and
serves as a constant reminder of the Company’s responsibilities
to its customers, employees, communities and shareholders.
The Company believes that these basic principles, along with its
overall mission of improving the quality of life for people every-
where, will enable Johnson & Johnson to continue to be among
the leaders in the health care industry.
During 2002 as a result of corporate governance issues at cer-
tain companies, government lawmakers enacted the Sarbanes-
Oxley Act of 2002 to protect investors by improving the accuracy
and reliability of corporate disclosures. In light of this legislation,
the Company has established a more documented, formal
process around its already existing internal controls, like the
annual certification of compliance by management with our
Policy on Business Conduct. The Company continues to evaluate
and enhance its internal control processes. Additionally, the
Company continues to maintain a strong ethical environment,
using the Johnson & Johnson Credo as the overall guide.
Description of Business
The Company has approximately 108,300 employees worldwide
engaged in the manufacture and sale of a broad range of prod-
ucts in the health care field. The Company sells products in
virtually all countries of the world. The Company’s primary
interest, both historically and currently, has been in products
related to human health and well-being.
The Company is organized on the principle of decentralized
management. The Executive Committee of Johnson & Johnson
is the principal management group responsible for the opera-
tions and allocation of the resources of the Company. This
Committee oversees and coordinates the activities of domestic
and international companies which span the Consumer,
Pharmaceutical and Medical Devices & Diagnostics segments.
Each international subsidiary is, with some exceptions,
managed by citizens of the country where it is located.
In all its product lines, the Company competes with compa-
nies both large and small, located in the United States of
America and abroad. Competition is strong in all lines without
regard to the number and size of the competing companies
involved. Competition in research, involving the development
and the improvement of new and existing products and
processes, is particularly significant and results from time to
time in product and process obsolescence. The development of
new and improved products is important to the Company’s suc-
cess in all areas of its business. This competitive environment
requires substantial investments in continuing research and
in multiple sales forces. In addition, the winning and retention
of customer acceptance of the Company’s consumer products
involves heavy expenditures for advertising and promotion.
Description of Segments
Consumer
The Consumer segment’s principal products are personal
care, including nonprescription drugs, adult skin and hair care
products, baby care products, oral care products, first aid prod-
ucts, women’s health products and nutritional products. These
products are marketed principally to the general public and dis-
tributed both to wholesalers and directly to independent and
chain retail outlets throughout the world. Major brands in the
skin and hair care line of products include NEUTROGENA®,
RoC®, AVEENO®, CLEAN & CLEAR®, JOHNSON’S pH5.5®, PIZ
BUIN® and SUNDOWN® sun care products and SHOWER TO
SHOWER® personal care products. Major brands in the over-
the-counter line of products include the broad family of
TYLENOL® acetaminophen products, adult and children’s
MOTRIN® analgesic products, IMODIUM®, MYLANTA® and the
PEPCID® Acid Controller from the Johnson & Johnson • Merck
Consumer Pharmaceuticals Co. Major brands in the women’s
health care line of products include CAREFREE®, STAYFREE®,
o.b.® Tampons and MONISTAT®. Major brands in the baby care
line of products include the JOHNSON’S® Baby line of products
and the PENATEN® and NATUSAN® baby care products. Major
first aid products include BAND-AID® Brand Adhesive
Bandages and COMPEED®. Major oral care products include the
REACH® brand of toothbrushes. Major products in the nutrition-
als product line include SPLENDA®, a non-caloric sugar substi-
tute, VIACTIV® calcium chews and BENECOL® food products.
Management’s Discussion and Analysis of Results
of Operations and Financial Condition
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Pharmaceutical
The Pharmaceutical segment’s principal worldwide franchises
are in the antifungal, anti-infective, cardiovascular, contraceptive,
dermatology, gastrointestinal, hematology, immunology,
neurology, oncology, pain management, psychotropic (central
nervous system) and urology fields. These products are
distributed both directly and through wholesalers and health
care professionals for use by prescription by the general public.
Prescription drugs in the antifungal field include NIZORAL®
(ketoconazole), SPORANOX® (itraconazole), TERAZOL® (ter-
conazole) and DAKTARINTM (miconazole nitrate) antifungal
products. Prescription drugs in the anti-infective field include
FLOXIN® (ofloxacin) and LEVAQUIN® (levofloxacin). Prescrip-
tion drugs in the cardiovascular field include RETAVASE®
(reteplase), a recombinant biologic cardiology care product for
the treatment of acute myocardial infarction to improve blood
flow to the heart and REOPRO® (abciximab) for the treatment of
acute cardiac disease.
Prescription drugs in the contraceptive field include
ORTHO EVRA® (norelgestromin/ethinyl estradiol transdermal
system), ORTHO-NOVUM® (norethindrone/ethinyl estradiol)
and TRICILEST® (norgestimate/ethinyl estradiol, sold in
the U.S. as ORTHO TRI-CYCLEN®) group of oral contraceptives.
Prescription drugs in the dermatology field include RETIN-A
MICRO® (tretinoin), a dermatological cream for acne. Prescrip-
tion drugs in the gastrointestinal field include ACIPHEX®
(rabeprazole sodium), a proton pump inhibitor for treating
erosive gastroesophageal reflux disease (GERD) and duodenal
ulcers from which the Company derives service revenue as
this product is co-promoted in the U.S. with Eisai; IMODIUM®
(loperamide HCl), an antidiarrheal; MOTILIUM® (domperidone),
a gastrointestinal mobilizer; and REMICADE® (infliximab), a
novel monoclonal antibody for treatment of certain Crohn’s
disease patients. REMICADE® is also indicated for the treatment
of rheumatoid arthritis.
Prescription drugs in the hematology field include PROCRIT®
(Epoetin alfa, sold outside the U.S. as EPREX®), a biotechnology
derived version of the human hormone erythropoietin that
stimulates red blood cell production. Prescription drugs in the
immunology field include ORTHOCLONE® OKT3® (muromonab-
CD3), for reversing the rejection of kidney, heart and liver
transplants. Prescription drugs in the neurology field include
TOPAMAX® (topiramate), REMINYL® (galantamine) and
STUGERON® (cinnarizine). Prescription drugs in the oncology
field include DOXIL® (doxorubicin), an anti-cancer treatment,
ERGAMISOL® (levamisole hydrochloride), a colon cancer drug
and LEUSTATIN® (cladribine), for hairy cell leukemia. 
Prescription drugs in the psychotropic (central nervous sys-
tem) field include antipsychotic drugs RISPERDAL® (risperidone)
and HALDOL® (haloperidol) and CONCERTA® (methylphenidate)
for attention deficit/hyperactivity disorder. Prescription drugs in
the pain management field include DURAGESIC® (fentanyl trans-
dermal system, sold abroad as DUROGESIC®), a transdermal
patch for chronic pain; and ULTRACETTM (tramadol hydrochlo-
ride), an analgesic for moderate to moderately severe pain.
Prescription drugs in the urology field include DITROPAN XL®
(oxybutynin) for the treatment of overactive bladder.
Medical Devices & Diagnostics
The Medical Devices & Diagnostics segment includes a broad
range of products used by or under the direction of health care
professionals. These products include Ethicon’s wound care,
surgical sports medicine and women’s health products; Ethicon
Endo-Surgery’s minimally invasive surgical products; Cordis’ cir-
culatory disease management products; LifeScan’s blood glucose
monitoring products; Ortho-Clinical Diagnostics’ professional
diagnostic products; DePuy’s orthopaedic joint reconstruction
and spinal products and Vistakon’s disposable contact lenses.
These products are used principally in the professional fields by
physicians, nurses, therapists, hospitals, diagnostic laboratories
and clinics. Acquisitions in the Medical Devices & Diagnostics
segment during recent years have been an integral part of an
ongoing process to transform a medical supply business to one
serving a range of higher technology medical specialties.
Operating Results
Sales
In 2002, worldwide sales increased 12.3% to $36.3 billion,
compared to increases of 10.8% in 2001 and 6.6% in 2000. In
2002, sales to the three largest distributors, AmerisourceBergen
Corp., McKesson HBOC and Cardinal Distribution, accounted for
10.3%, 9.8% and 9.2%, respectively, of total revenues. Excluding
the impact of foreign currencies, worldwide sales increased
12.1% in 2002, 13.4% in 2001, and 9.9% in 2000. Price increases
accounted for approximately 1.7%, 1.2% and 1.0% of growth in
2002, 2001 and 2000, respectively.
Sales by domestic companies were $22.5 billion in 2002,
$19.8 billion in 2001 and $17.3 billion in 2000, that represents
increases of 13.3% in 2002, 14.5% in 2001 and 11.5% in 2000.
Sales by international companies were $13.8 billion in 2002,
$12.5 billion in 2001 and $11.9 billion in 2000, that represents
increases of 10.8% in 2002, 5.4% in 2001 and 0.3% in 2000.
Excluding the impact of the foreign currency fluctuations over
the past three years, sales by international companies
increased 10.3% in 2002, 11.8% in 2001 and 7.8% in 2000. For the
last five years, the annual compound growth rate for sales was
10.0%. Excluding the impact of foreign currency fluctuations,
the annual compound growth rate for sales for the 5-year
period was 12.1%.
All geographic areas throughout the world posted opera-
tional gains during 2002. Excluding the effect of exchange rate
fluctuations between the U.S. dollar and foreign currencies,
sales increased 8.3% in Europe, 10.9% in the Western
Hemisphere (excluding the U.S.) and 13.6% in the Asia-Pacific,
Africa regions. Including the impact of currency fluctuations,
sales increased 14.2% in Europe and 12.2% in Asia-Pacific,
Africa but decreased 2.5% in the Western Hemisphere (exclud-
ing the U.S.). The Company achieved an annual compound
growth rate of 10.3% for worldwide sales for the 10-year period
since 1992 with domestic sales growing at a rate of 12.5% and
international sales growing at a rate of 7.5%. Excluding the
impact of foreign currency fluctuations, the annual compound
growth rate for the 10-year period was 12.0%.
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During the second quarter of 2002, the Company completed
its acquisition of Tibotec-Virco N.V. for approximately $320 mil-
lion. Tibotec-Virco N.V. is a privately-held biopharmaceutical
company focused on developing anti-viral treatments, with sev-
eral promising compounds in development for the treatment of
infectious diseases including HIV.
During the fourth quarter of 2002, the Company received
U.S. Food and Drug Administration (FDA) approval for
LEVAQUIN® (levofloxacin) for an additional indication for the
treatment of nosocomial pneumonia, the second most common
hospital-acquired infection. The Company also filed several new
drug applications with the FDA. These include TOPAMAX® (top-
iramate) for the prevention of migraine headaches in adults as
well as for use as a monotherapy treatment in epilepsy (it is
currently approved as adjunctive treatment), LEVAQUIN® for a
five-day treatment of community-acquired pneumonia, and
RISPERDAL® (risperidone) as both adjunctive and monotherapy
treatments of bipolar disorder.
Also in the fourth quarter of 2002, the Company announced
a definitive agreement to acquire OraPharma, Inc., a specialty
pharmaceutical company focused on the development and com-
mercialization of unique therapeutics in oral health care prod-
ucts. The acquisition will provide entry into the oral health
professional marketplace by providing a synergistic line of pre-
vention and treatment products to maintain periodontal health.
The transaction is valued at approximately $85 million, net of
cash, and closed in the first quarter of 2003.
Pharmaceutical segment sales in 2001 were $14.9 billion, a
total increase of 17.3% over 2000 including 21.3% growth in
domestic sales. Operationally, international sales increased
14.2% but were partially offset by a negative currency impact of
4.9%, resulting in total growth of 9.3%. Pharmaceutical segment
sales in 2000 were $12.7 billion, an increase of 12.7% over 1999
including 21.4% growth in domestic sales. Operationally, interna-
tional sales increased 7.6% but were more than offset by a nega-
tive currency impact of 8.9% resulting in a total decrease in sales
of 1.3%. Sales growth was partially offset by the restricted access
of PROPULSID® in a number of markets around the world.
Worldwide sales in 2002 of $12.6 billion in the Medical
Devices & Diagnostics segment represented an increase of
12.9% over 2001. As currency had no impact on sales growth,
the 12.9% total increase is also the operational sales increase
over prior year. Domestic sales were up 13.0% and international
sales increased 12.8% over the prior year.
Strong sales growth was achieved in each of the major fran-
chises within this segment: Cordis’ circulatory disease manage-
ment products; DePuy’s orthopaedic joint reconstruction and
spinal products; Ethicon’s wound care, surgical sports medicine
and women’s health products; LifeScan’s blood glucose monitor-
ing products; Ethicon Endo-Surgery’s minimally invasive surgical
products; Ortho-Clinical Diagnostics’ professional diagnostic
products and Vistakon’s disposable contact lenses.
Consumer segment sales in 2002 were $6.6 billion, an
increase of 3.9% over 2001. Of the 3.9% increase in Consumer
segment sales over prior year, 4.6% was operational growth
with currency negatively impacting sales growth by 0.7%.
Domestic sales increased by 4.5% while international sales gains
in local currency of 4.6% were offset by a negative currency
impact of 1.5%, resulting in total international growth of 3.1%.
Consumer sales achieved strong growth in skin care products
(NEUTROGENA®, CLEAN & CLEAR® and AVEENO®) and BAND-
AID® wound care products, as well as in McNeil Nutritionals’
SPLENDA® sweetener products and VIACTIV® calcium chews.
Consumer segment sales in 2001 were $6.3 billion, an
increase of 0.8% over 2000. Domestic sales increased by 1.4%
while international sales gains in local currency of 6.8% were
offset by a negative currency impact of 6.7%, resulting in total
growth of 0.1%. Consumer segment sales in 2000 were $6.3 bil-
lion, an increase of 0.4% over 1999. Domestic sales increased by
2.8% while international sales gains in local currency of 4.3%
were offset by a negative currency impact of 6.6%, resulting in a
total decrease of 2.3%.
Pharmaceutical segment sales in 2002 were $17.2 billion, an
increase of 15.5% over 2001 including 16.4% growth in domestic
sales and 13.5% total growth in international sales that includes
a 2.4% positive effect of currency. Of the 15.5% increase in
Pharmaceutical segment sales over prior year, 14.8% was due to
operational increases, with currency positively impacting sales
growth by 0.7%.
Sales growth reflects the strong performance of
PROCRIT®/EPREX®, for treatment of anemia; REMICADE®, a
treatment for rheumatoid arthritis and Crohn’s disease;
RISPERDAL®, an antipsychotic medication; DURAGESIC®, a
transdermal patch for chronic pain, and TOPAMAX®,an anti-
epileptic medication. Sales of PROCRIT®/EPREX® accounted
for 11.8% of total Company revenues for 2002 and 10.6% in
2001. Johnson & Johnson markets over 100 prescription drugs
around the world, with 30.5% of the sales generated outside the
United States. Thirty-three drugs sold by the Company had 2002
sales in excess of $50 million, with 24 in excess of $100 million.
The rate of growth for sales of PROCRIT® and EPREX® was
slowed in the latter half of 2002 as a result of new competition
for PROCRIT®. Sales growth may also have been affected by
rare reports of Pure Red Cell Aplasia (PRCA) in chronic renal
failure (CRF) patients administered EPREX® subcutaneously.
The Company’s on-going investigation of PRCA in CRF patients
indicates that the occurrence of PRCA continues to be rare. 
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During the third quarter of 2002, the Company announced
the final results for SIRIUS, the landmark U.S. study of the
CYPHERTM Sirolimus-eluting Stent. This drug-eluting coronary
stent is the first of its kind to be recommended for FDA
approval. Clinical results of the CYPHERTM stent indicate a sig-
nificant reduction of in-stent restenosis and revascularization
rates as compared to bare metal stents. The findings confirm
the stent’s continued excellent performance in significantly
reducing reblockage of coronary arteries in patients with
coronary artery disease. Additionally, in July 2002, the U.S.
Department of Health and Human Services (HHS) made a
decision to provide accelerated incremental reimbursement
to hospitals for this technology commencing April 1, 2003
under newly established Diagnostic Related Groups (DRGs).
In order to ensure access to this technology for patients as
rapidly as possible, HHS has taken the unprecedented step of
assigning it to new DRGs prior to FDA approval. On October 22,
2002, the Circulatory System Device Panel advisory panel voted
8-0 in favor of FDA approval with recommended conditions,
for the Company’s drug-eluting coronary stent. The Company is
continuing to work with the FDA on their on-going review for
product approval.
Also in the fourth quarter of 2002, the FDA’s Orthopaedic and
Rehabilitation Devices Panel unanimously recommended in favor
of FDA approval, with conditions, for the INDEPENDENCETM
iBOTTM Mobility System. The iBOTTM Mobility System is a
unique device that offers benefits for individuals with mobility-
related disabilities. The device can be used to navigate difficult
terrain, climb stairs and ramps and balance at standing height
on two wheels.
In December 2002, Ethicon received FDA clearance to mar-
ket VICRYL® Plus Antibacterial Suture, the first and only suture
designed with an antibacterial agent. Designed to reduce bacte-
rial colonization on the suture, VICRYL® Plus may help reduce
the risk of complications associated with surgery.
Worldwide sales in 2001 of $11.1 billion in the Medical
Devices & Diagnostics segment represented a total increase of
8.8% over 2000. Domestic sales were up 12.1%, while interna-
tional sales increased 5.1% as sales gains in local currency of
12.1% were offset by a negative currency impact of 7.0%.
Worldwide sales in 2000 of $10.2 billion in the Medical Devices
& Diagnostics segment represented a total increase of 3.7% over
1999 consisting of gains in local currency of 6.9% that were
reduced by 3.2% due to the strength of the U.S. dollar. Domestic
sales were up 3.9%, while international sales increased 3.4% as
sales gains in local currency of 10.3% were offset by a negative
currency impact of 6.9%.
Gross Profit
Gross profit margin in 2002 was 71.2%, an improvement of 0.8%
over the gross profit margin in 2001 of 70.4%. The improvement
in gross profit margin for 2001 was 1.1% over the gross profit
margin in 2000 of 69.3%, an improvement of 0.5% over 1999. The
improvement in gross profit margin over the past three years
was primarily a result of continued improvements in the mix of
businesses and successful ongoing cost control efforts.
Selling, General and Administrative Expenses
Consolidated selling, general and administrative expenses
increased 8.5%, 7.3% and 4.3% in 2002, 2001 and 2000, respec-
tively. Selling, general and administrative expenses as a percent
to sales were 33.7%, 34.8% and 36.0% in 2002, 2001 and 2000,
respectively. As a result of the implementation in 2002 of
Emerging Issues Task Force (EITF) Issue No. 01-09 “Accounting
for Consideration Given by a Vendor to a Customer or Reseller of
the Vendor’s Products,” the Company reclassified $687 million
and $674 million for 2001 and 2000, respectively, from selling,
general and administrative expenses to a reduction of sales and
reclassified $45 million and $49 million of expense for 2001 and
2000, respectively, from selling, general and administrative
expenses to cost of products sold.
Advertising expenses, which are comprised of television, radio
and print media, as well as Internet advertising, were $1.5 billion
in 2002, $1.4 billion in 2001 and $1.4 billion in 2000.
Research Expenses
Research activities represent a significant part of the
Company’s business. These expenditures relate to the develop-
ment of new products, improvement of existing products,
technical support of products and compliance with governmen-
tal regulations for the protection of the consumers and patients.
Worldwide costs of research activities, excluding in-process
research & development charges, were as follows:
(Millions of Dollars) 2002 2001 2000
Research expense $3,957 3,591 3,105
Percent increase 
over prior year 10.2% 15.7% 12.2%
Percent of sales 10.9 11.1 10.6
Research expense as a percent of sales for the Pharmaceutical
segment was 15.7% for 2002, 16.6% for 2001 and 16.4% for 2000
while averaging 6.6%, 6.5% and 6.2% in the Consumer and
Medical Devices & Diagnostics segments for 2002, 2001 and
2000, respectively.
Significant research activities continued in the Pharma-
ceutical segment, with spending increasing to $2.7 billion or
9.3% over 2001 representing a compound annual growth rate
of approximately 12.2% for the five-year period since 1997.
Johnson & Johnson Pharmaceutical Research & Development,
L.L.C., formerly known as the Janssen Research Foundation and
the R.W. Johnson Pharmaceutical Research Institute, is the pri-
mary worldwide pharmaceutical research organization and
additional research is conducted by Centocor, ALZA Corporation
(ALZA), Tibotec-Virco N.V. and through collaboration with the
James Black Foundation in London, England.
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In-Process Research & Development
In the second quarter of 2002, the Company recorded in-
process research & development (IPR&D) charges of $189 mil-
lion after-tax ($189 million before tax as IPR&D is not generally
tax deductible in the U.S.) related to acquisitions. These acquisi-
tions included Tibotec-Virco N.V., a privately-held biopharma-
ceutical company focused on developing anti-viral treatments
and Obtech Medical AG, a privately-held company that markets
an adjustable gastric band for the treatment of morbid obesity.
In the fourth quarter of 2001, the IPR&D charge of $105 mil-
lion after-tax ($105 million before tax as IPR&D is not generally
tax deductible in the U.S.) was incurred as a result of the acqui-
sition of Inverness Medical Technology, a supplier of LifeScan
electrochemical products for blood glucose monitoring follow-
ing the spin-off of its non-diabetes businesses and TERAMed, an
early stage medical device company that is developing endovas-
cular stent-graft systems for minimally invasive treatment of
abdominal aortic aneurysms and peripheral occlusive disease.
In 2000, the Company’s IPR&D charges of $66 million
after-tax ($66 million before tax as IPR&D is not generally
tax deductible in the U.S.) was related to the acquisition of
Atrionix, Inc., a development stage company whose primary
product is a pulmonary ablation catheter for the treatment of
atrial fibrillation and Crescendo, a company formed by ALZA
for the purpose of selecting, developing and commercializing
human pharmaceutical products.
Interest (Income) Expense
Interest income decreased in 2002 primarily due to the decline
in U.S. interest rates and cash expended as part of a stock
repurchase program (see page 34). In 2002, the average yield
on investments was more than 200 basis points below the aver-
age yield in 2001. Interest expense in 2002 as compared to 2001
remained relatively constant as there were no significant
changes in average debt balances.
Other (Income) Expense, Net
Other (income) expense includes gains and losses related to
the sale and write-down of certain equity securities of the
Johnson & Johnson Development Corporation, losses on the
disposal of fixed assets, currency gains & losses, minority
interests, litigation settlement expense as well as royalty
income. Additionally, in 2002, other (income) expense included
the gain on the sale of the Ortho Prefest product line and the
impact of the Amgen arbitration settlement.
On October 18, 2002, an arbitrator in Chicago denied an
effort by Amgen, Inc., to terminate the 1985 license agreement
under which Ortho Biotech obtained exclusive U.S. rights
to Amgen-developed erythropoietin (EPO which is sold as
PROCRIT®/EPREX®) for all indications outside of kidney dialysis.
Amgen had filed suit in 1995, claiming that Ortho Biotech had
breached its license rights by improperly making sales of EPO
into Amgen’s exclusive dialysis market. In his decision, the arbi-
trator found that sales had been made into markets where
Amgen had retained exclusive rights, but that they did not
warrant the extraordinary remedy of terminating the contract.
Instead, he found that Amgen could be adequately compen-
sated with monetary damages. The arbitrator awarded $150
million in damages that was recorded in the third quarter of
2002. This arbitration was the fourth between the parties
since 1989. On January 24, 2003, the arbitrator ruled that
Amgen was the “prevailing party” in this arbitration, entitling
it to an award of reasonable attorneys’ fees and costs. Amgen
has not yet submitted its application for fees and costs. The
Company expensed $85 million in the fourth quarter of 2002
in connection with this outstanding claim.
In 2001, in addition to the items indicated above, other
(income) expense included costs related to the merger
with ALZA of $147 million and the amortization expense of
approximately $141 million that is no longer required under
Financial Accounting Standards Board (FASB) Standard No.
142, “Goodwill and Other Intangible Assets” (SFAS No. 142).
In 2000, in addition to the items indicated above, other
(income) expense included a favorable adjustment to the costs
associated with the 1998 global manufacturing restructuring
charge and the gain on the sale of various product lines.
Earnings Before Provision for Taxes on Income
Consolidated earnings before provision for taxes on income
increased 17.6%, 15.0% and 16.9% in 2002, 2001 and 2000,
respectively. Excluding the IPR&D and merger charges noted
in the previous sections, the increases were 16.3%, 18.1% and
15.8% in 2002, 2001 and 2000, respectively. The increase in
2002 is due primarily to volume growth, improved gross profit
margins and efficiencies in spending in selling, marketing and
administrative expenses.
Operating profit by segment for 2002 and 2001 is as follows:
Percent
of Sales
(Millions of Dollars) 2002 2001 2002 2001
Consumer $1,229 1,004 18.7% 15.9%
Pharmaceutical 5,787 4,928 33.7 33.2
Med Devices & Diag 2,489 2,001 19.8 18.0
Segments total 9,505 7,933 26.2 24.5
Expenses not
allocated to
segments (214) (35)
Earnings before
taxes on income $9,291 7,898 25.6% 24.4%
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The increase in expenses not allocated to segments is primarily
due to the decline in interest income in 2002 as discussed in the
Interest (Income) Expense section.
Consumer segment operating profit increased 22.4% over
prior year and reflects an operating profit as a percent to sales
improvement of 2.8%. The improvement is due primarily to
leveraging of selling, promotion and administrative expenses
offset by increased expenditures in advertising. Additionally,
the Consumer segment operating profit improved 0.6% as
amortization expense is no longer required under SFAS No. 142.
Pharmaceutical segment operating profit increased 17.4% and
reflects an operating profit as a percent to sales improvement of
0.5%. The Pharmaceutical segment operating profit was nega-
tively impacted by the cost of the Amgen arbitration settlement
in 2002 of $150 million in damages and $85 million in legal fees,
IPR&D related to the Tibotec-Virco N.V. acquisition and offset by
the gain on the sale of the Ortho Prefest product line. There was
no impact of SFAS No. 142 on operating profit as a percent to
sales in the Pharmaceutical segment. The Pharmaceutical seg-
ment operating profit also included the effect of leveraging 
marketing expenses. In 2001, the Pharmaceutical operating
profit included expenses related to the merger with ALZA.
Medical Devices & Diagnostics segment operating profit
increased 24.4% and reflects an operating profit as a percent to
sales improvement of 1.8%. The non-amortization per SFAS No.
142 accounted for 0.8% of the improvement. The remaining
margin improvement over prior year was achieved despite
investment spending in support of the Cordis product line.
Operating profit includes the IPR&D associated with the acqui-
sitions of Obtech Medical AG in 2002 and Inverness Medical
Technology and TERAMed in 2001.
Provision For Taxes on Income
The worldwide effective income tax rate was 29.0% in 2002,
28.2% in 2001 and 27.9% in 2000. The increase in the effective
tax rate for the years, 2002, 2001 and 2000 was primarily due
to the increase in income subject to tax in the U.S. and the
Company’s non-deductible IPR&D charge. Refer to Footnote 8 to
the financial statements for additional information.
Net Income and Earnings Per Share
Worldwide net earnings for 2002 were $6.6 billion, reflecting a
16.4% increase over 2001. Worldwide net earnings per share for
2002 equaled $2.16 per share, an increase of 17.4% from the
$1.84 net earnings per share in 2001. Excluding the impact of
IPR&D in 2002 and the impact of IPR&D and merger costs in
2001, worldwide net earnings were $6.8 billion and net earnings
per share were $2.23, representing an increase of 15.0% and
16.8%, respectively, over 2001. The impact of the non-amortiza-
tion per SFAS No. 142 increased net earnings and earnings per
share by approximately 2.0%. Worldwide net earnings achieved
a 10-year annual growth rate of 21.0%, while earnings per share
grew at a rate of 20.3%. Excluding the impact of an accounting
change in 1992 and IPR&D in 2002, worldwide net earnings
achieved a 10-year annual growth rate of 15.7%, while earnings
per share grew at a rate of 15.0%. The 5-year annual compound
growth rates for net earnings and earnings per share are 16.3%
and 16.2%, respectively. Excluding the impact of IPR&D and
merger costs, worldwide net earnings achieved a 5-year annual
growth rate of 14.9%, while earnings per share grew at a rate
of 15.0%. 
Worldwide net earnings for 2001 were $5.7 billion, reflecting
a 14.4% increase over 2000. Worldwide net earnings per share
for 2001 equaled $1.84 per share, an increase of 14.3% from the
$1.61 net earnings per share in 2000. Excluding the impact of
IPR&D and merger costs in 2001 and IPR&D net of a favorable
adjustment to the costs associated with the 1998 global manu-
facturing restructuring charge in 2000, worldwide net earnings
were $5.9 billion and net earnings per share were $1.91, repre-
senting an increase of 18.0% and 17.2%, respectively, over 2000.
Worldwide net earnings for 2000 were $5.0 billion, reflecting a
15.9% increase over 1999. Worldwide net earnings per share for
2000 equaled $1.61 per share, an increase of 15.8% from the
$1.39 net earnings per share in 1999. Excluding the impact of
IPR&D net of a favorable adjustment to the costs associated
with the 1998 global manufacturing restructuring charge in
2000 and merger costs in 1999, worldwide net earnings were
$5.0 billion and net earnings per share were $1.63, representing
an increase of 14.9% and 14.8% respectively over 1999.
Cash Flows and Liquidity
Cash generated from operations and selected borrowings pro-
vide the major sources of funds for the growth of the business,
including working capital, capital expenditures, acquisitions,
share repurchases, dividends and debt repayments. Cash and
current marketable securities were $7.5 billion at the end of
2002 as compared with $8.0 billion at the end of 2001.
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Contractual Obligations & Commitments
The Company has long-term contractual obligations primarily
lease and debt obligations. To satisfy these obligations, the
Company intends to use cash from operations. The following
table summarizes the Company’s contractual obligations and
their aggregate maturities as of December 29, 2002 (see Notes 4
and 6 for further details):
Operating Debt
(Millions of Dollars) Leases Obligations
2003 $138 77
2004 121 270
2005 101 17
2006 86 12
2007 67 8
After 2007 $160 1,715
Financial Position & Capital Resources
Total Assets & Returns
Total assets increased $2.1 billion or 5.4% in 2002 and $4.2 bil-
lion or 12.4% in 2001. Of the consolidated assets at year-end
2002, Medical Devices & Diagnostics accounted for 37.1%, 27.4%
were Pharmaceutical segment assets, 12.5% were Consumer
segment assets and 23.0% were general corporate assets. At
year-end 2001, 35.5% and 27.5% of the consolidated assets were
identifiable to the Medical Devices & Diagnostics and Pharma-
ceutical segments, respectively while 10.9% and 26.1% were
Consumer segment and general corporate assets, respectively.
Net intangible assets in 2002 increased 1.9% over 2001 and rep-
resented 22.8% of total assets at year-end 2002. Net property,
plant and equipment increased to $8.7 billion or 12.8% and
represented 21.5% of total assets at year-end 2002.
Shareholders’ equity per share at the end of 2002 was $7.65
compared with $7.95 at year-end 2001, a decrease of 3.8%.
The decrease is primarily due to the $5 billion stock repurchase
program completed during 2002.
Financing & Market Risk
The Company uses financial instruments to manage the impact
of foreign exchange rate changes on cash flows. Accordingly,
the Company enters into forward foreign exchange contracts to
protect the value of existing foreign currency assets and liabili-
ties and to hedge future foreign currency product costs. Gains
or losses on these contracts are offset primarily by the effect of
foreign exchange rate changes on the underlying transactions.
A 10% appreciation of the U.S. Dollar from December 29, 2002
market rates would increase the unrealized value of the
Company’s forward contracts by $252 million. Conversely, a 10%
depreciation of the U.S. Dollar from December 29, 2002 market
rates would decrease the unrealized value of the Company’s for-
ward contracts by $308 million. In either scenario, the gain or
loss on the forward contract would be offset by the effect of for-
eign exchange rate changes on the underlying transaction.
Cash generated from operations amounted to $8.2 billion in
2002, which is less than the cash generated from operations in
2001 of $8.9 billion. This decrease is due primarily to the funding
of the U.S. pension plan of approximately $750 million net of the
current tax benefit during 2002. In 2001, there was a change in
the timing of salary increases and bonuses paid to employees
from December 2001 to February 2002. This change was enacted
to have 2001 results finalized in order to align compensation and
performance. The result of this change was an increase of
approximately $450 million in cash flows in 2001 from operating
activities due to the payment of the 2001 bonus in 2002.
Capital Expenditures
Capital expenditures in 2002 increased to $2.1 billion or 21.3%
over 2001 and increased 2.5% to $1.7 billion in 2001 over 2000.
The increase in 2002 is due primarily to expansion of manufac-
turing facilities to support new and existing products, invest-
ments in support of research and investments in information
systems across all business segments.
Share Repurchases & Dividends
On February 13, 2002, the Company announced a stock repur-
chase program of up to $5 billion with no time limit on this pro-
gram. This program was completed on August 1, 2002, with 83.6
million shares repurchased for an aggregate price of $5.0 bil-
lion. In addition to the 2002 stock repurchase program, the
Company has an annual program to repurchase shares for use
in employee stock and employee incentive plans.
The Company increased its cash dividend in 2002 for
the 40th consecutive year. Cash dividends paid were $0.795
per share in 2002, compared with dividends of $0.70 per share
in 2001 and $0.62 per share in 2000. The dividends were
distributed as follows:
2002 2001 2000
First quarter $ .18 .16 .14
Second quarter .205 .18 .16
Third quarter .205 .18 .16
Fourth quarter .205 .18 .16
Total $.795 .70 .62
On January 6, 2003, the Board of Directors declared a regular
cash dividend of $0.205 per share, paid on March 11, 2003 to
shareholders of record as of February 18, 2003. The Company
expects to continue the practice of paying regular cash dividends.
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The Company enters into currency swap contracts to man-
age the Company’s exposure to changes in currency exchange
rates by hedging foreign currency denominated assets and lia-
bilities. The impact of a 1% change in interest rates on the
Company’s interest rate sensitive financial instruments would
be immaterial.
The Company does not enter into financial instruments for
trading or speculative purposes. Further, the Company has a
policy of only entering into contracts with parties that have at
least an “A” (or equivalent) credit rating. The counterparties to
these contracts are major financial institutions and the
Company does not have significant exposure to any one coun-
terparty. Management believes the risk of loss is remote.
Total unused credit available to the Company approximates
$3.1 billion, including $1.5 billion of credit commitments and
$0.8 billion of uncommitted lines with various banks worldwide
that expire during 2003. The Company’s shelf registration filed
with the Securities and Exchange Commission enables the
Company to issue up to $2.6 billion of unsecured debt securities
and warrants to purchase debt securities under its medium
term note (MTN) program. No MTN’s were issued in 2002. At
December 29, 2002, the Company had $1.8 billion remaining on
its shelf registration. The Company continues to be one of few
companies with a Triple A credit rating.
Total borrowings at the end of 2002 and 2001 were $4.1 bil-
lion and $2.8 billion, respectively. In 2002, net cash (cash and
current marketable securities net of debt) was $3.3 billion. In
2001, net cash (cash and current marketable securities net of
debt) was $5.2 billion. Total debt represented 15.4% of total capi-
tal (shareholders’ equity and total debt) in 2002 and 10.3% of
total capital in 2001. For the period ended December 29, 2002,
there were no material cash commitments. A summary of bor-
rowings can be found in Note 6.
The Company believes that its operations comply in all
material respects with applicable environmental laws and regula-
tions. The Company or its subsidiaries are parties to a number of
proceedings brought under the Comprehensive Environmental
Response, Compensation and Liability Act, commonly known as
Superfund, and comparable state laws, in which the relief being
sought is the cost of past and future remediation. While it is not
feasible to predict or determine the outcome of these proceed-
ings, in the opinion of the Company, such proceedings would not
have a material adverse effect on the results of operations, cash
flows or financial position of the Company.
Other Matters
Critical Accounting Policies & Estimates
Management’s discussion and analysis of results of operations
and financial condition are based on the Company’s consolidated
financial statements that have been prepared in accordance
with accounting principles generally accepted in the U.S. The
preparation of these financial statements requires management
to make estimates and assumptions that affect the amounts
reported for revenues, expenses, assets, liabilities and other
related disclosures. Actual results may or may not differ from
these estimates. The Company’s significant accounting policies
are described in Note 1, however the Company believes that the
understanding of certain key accounting policies and estimates
is essential in achieving more insight into the Company’s operat-
ing results and financial condition. These key accounting policies
and estimates include revenue recognition, accounting for
income taxes, legal and self insurance contingencies, valuation
of long lived assets, assumptions used to determine the amounts
recorded for pensions and other employee benefit plans and
accounting for stock options.
Revenue Recognition
The Company recognizes revenue from product sales when
goods are shipped or delivered depending on when title and
risk passes to the customer. Provisions for certain rebates, sales
incentives, trade promotions, coupons, product returns and dis-
counts to customers are provided for as reductions in determin-
ing sales in the same period the related sales are recorded.
These provisions, the largest of these being the Medicaid
rebate provision, are based on estimates derived from current
program requirements and historical experience. The
Company also recognizes service revenue that is received for
co-promotion of certain products. At year-end December 29,
2002, these revenues were less than 2% of total revenues and
are included in product sales.
Income Taxes
Income taxes are recorded based on amounts refundable or
payable in the current year and include the results of any differ-
ence between U.S. GAAP accounting and U.S. tax reporting that
are recorded as deferred tax assets or liabilities. The Company
records deferred tax assets and liabilities based on current tax
regulations and rates. Changes in tax laws and rates that may
affect these deferred tax assets and liabilities are recorded in the
future. Management believes that changes in these estimates
would not have a material effect on the Company’s results of
operations, cash flows or financial position.
The Company intends to continue to reinvest its undistributed
international earnings to expand its international operations;
therefore no U.S. tax expense has been recorded to cover the
repatriation of such undistributed earnings. At December 29,
2002, and December 30, 2001, the cumulative amount of undis-
tributed international earnings was approximately $12.3 billion
and $12.1 billion, respectively.
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Legal & Self Insurance Contingencies
The Company records accruals for various contingencies
including legal proceedings and product liability cases as
they arise in the normal course of business. The accruals are
based on management’s judgment as to the probability of
losses, opinions of legal counsel and where applicable, actuari-
ally determined estimates. Additionally, the Company records
insurance receivable amounts from third party insurers based
on the probability of recovery. As appropriate, reserves against
these receivables are recorded for estimated amounts that may
not be collected from such third party insurers.
Long Lived and Intangible Assets
The Company assesses changes in economic conditions and
strategic priorities and makes assumptions regarding estimated
future cash flows in evaluating the value of the Company’s fixed
assets, goodwill and other non-current assets. As these assump-
tions and estimates may change over time, it may or may not be
necessary for the Company to record impairment charges.
Employee Benefit Plans
The Company sponsors various retirement and pension plans,
including defined benefit, defined contribution and termination
indemnity plans that cover most employees worldwide. These
plans require assumptions for the discount rate, expected
return on plan assets, expected salary increases and health
care cost trend rates. See Note 13 for further detail on these
rates and the effect of a change in these rates on the Company’s
results of operations.
Stock Options
The Company has elected the use of Accounting Principle Board
Opinion No. 25, “Accounting for Stock Issued to Employees,”
(APB 25) that does not require compensation costs related to
stock options to be recorded in net income, as all options
granted under the various stock option plans had an exercise
price equal to the market value of the underlying common stock
at grant date. Statement of Financial Accounting Standard
(SFAS) No. 148 “Accounting for Stock-Based Compensation —
Transition and Disclosure — an amendment of FASB Statement
No. 123” requires pro forma disclosure of net income and earn-
ings per share determined as if the fair value method of
accounting for stock options had been applied in measuring
compensation cost. See Notes 1 and 10 for further information
regarding stock options.
New Accounting Standards
In June 2001, the FASB issued SFAS No. 143, “Accounting for
Asset Retirement Obligations.” The Company will adopt this
standard in 2003 that is effective for fiscal years beginning after
June 15, 2002 and it is not expected to have a material impact on
the Company’s results of operations, cash flows or financial posi-
tion. In August 2001, the FASB issued SFAS No. 144, “Accounting
for the Impairment or Disposal of Long-Lived Assets,” which was
effective for the first quarter of 2002. The Company’s adoption
of SFAS No. 144 did not have a material effect on the Company’s
results of operations, cash flows or financial position. In June 
2002, the FASB issued SFAS No. 146, “Accounting for Costs
Associated with Exit or Disposal Activities” which is effective for
exit or disposal activities that are initiated after December 31,
2002. The Company will adopt SFAS No. 146 in the first quarter
of 2003 and is not expected to have a material effect on the
Company’s results of operations, cash flows or financial position.
On November 25, 2002, the FASB issued FASB Interpretation
No. 45 (FIN 45), “Guarantor’s Accounting and Disclosure
Requirements for Guarantees, Including Indirect Guarantees of
Indebtedness of Others, an interpretation of FASB Statements
No. 5, 57 and 107 and Rescission of FASB Interpretation No. 34.”
FIN 45 clarifies the requirements of FASB Statement No. 5,
“Accounting for Contingencies,” relating to the guarantor’s
accounting for, and disclosure of, the issuance of certain types
of guarantees. The disclosure requirements of FIN 45 are effec-
tive for financial statements of interim or annual periods that
end after December 15, 2002 and have been adopted by the
Company. There is no disclosure required at year-end 2002. The
provisions for initial recognition and measurement are effective
on a prospective basis for guarantees that are issued or modi-
fied after December 31, 2002, irrespective of the guarantor’s
year-end. FIN 45 requires that upon issuance of a guarantee,
the entity must recognize a liability for the fair value of the
obligation it assumes under that guarantee. The Company’s
adoption of FIN 45 in 2003 is not expected to have a material
effect on the Company’s results of operations, cash flows or
financial position.
In January 2003, the FASB issued FIN 46, “Consolidation of
Variable Interest Entities — an interpretation of ARB No. 51,”
which addresses consolidation of variable interest entities.
FIN 46 expands the criteria for consideration in determining
whether a variable interest entity should be consolidated by a
business entity, and requires existing unconsolidated variable
interest entities (which include, but are not limited to, Special
Purpose Entities, or SPEs) to be consolidated by their primary
beneficiaries if the entities do not effectively disperse risks
among parties involved. This interpretation applies immediately
to variable interest entities created after January 31, 2003, and
to variable interest entities in which an enterprise obtains an
interest after that date. It applies in the first fiscal year or inter-
im period beginning after June 15, 2003, to variable interest
entities in which an enterprise holds a variable interest that it
acquired before February 1, 2003. The adoption of FIN 46 is not
expected to have a material effect on the Company’s results of
operations, cash flows or financial position.
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Changing Prices & Inflation
Johnson & Johnson is aware that its products are used in a set-
ting where, for more than a decade, policymakers, consumers
and businesses have expressed concern about the rising cost of
health care. In response to these concerns, Johnson & Johnson
has a long-standing policy of pricing products responsibly.
For the period 1992–2002, in the United States, the weighted
average compound annual growth rate of Johnson & Johnson
price increases for health care products (prescription and
over-the-counter drugs, hospital and professional products) was
below the U.S. Consumer Price Index (CPI) for the period.
Inflation rates, even though moderate in many parts of the
world during 2002, continue to have an effect on worldwide
economies and, consequently, on the way companies operate. In
the face of increasing costs, the Company strives to maintain its
profit margins through cost reduction programs, productivity
improvements and periodic price increases.
Common Stock Market Prices
The Company’s common stock is listed on the New York Stock
Exchange under the symbol JNJ. The composite market price
ranges for Johnson & Johnson common stock during 2002 and
2001 were:
2002 2001
High Low High Low
First quarter $65.89 54.70 52.34 40.25
Second quarter 65.29 52.00 54.20 42.60
Third quarter 56.50 41.40 57.60 50.00
Fourth quarter 61.30 53.00 60.97 53.05
Year-end close $53.11 59.86
Subsequent Events
On February 10, 2003, Johnson & Johnson announced that it
signed a definitive agreement with Scios Inc., a biopharmaceuti-
cal company with a marketed product for cardiovascular dis-
ease and research projects focused on auto-immune diseases.
The Company will acquire Scios in a cash for stock exchange.
Under the terms of the agreement, Scios shareholders will
receive $45.00 for each outstanding Scios share. The value of
the transaction as of the anticipated closing date is expected
to be approximately $2.4 billion, net of cash anticipated to be
acquired, based on Scios’ approximately 59.8 million fully
diluted shares outstanding.
The boards of directors of Johnson & Johnson and Scios
have given their approval to the transaction, which is subject
to clearance under the Hart-Scott-Rodino Anti-Trust Improve-
ments Act. This transaction is also subject to the approval of the
shareholders of Scios and other customary closing conditions.
Scios is a biopharmaceutical company developing novel
treatments for cardiovascular and inflammatory disease.
The company’s disease-based technology platform integrates
expertise in protein biology with computational and medicinal
chemistry to identify novel targets and rationally design small
molecule compounds for large markets with unmet medical
needs. Scios’ product NATRECOR® is the first novel agent
approved for congestive heart failure (CHF) in more than a
decade. NATRECOR® is a recombinant form of a naturally
occurring protein secreted by the heart as part of the body’s
response to CHF. The drug has several significant advantages
over existing therapies for CHF, the single most common cause
of hospitalization in the United States for patients over 65.
The principal focus of Scios’ research and development
program is small molecule inhibitors, and includes several
potential new treatments for pain and inflammatory diseases,
including an advanced p-38 kinase inhibitor program.
The transaction is expected to close in the second quarter
of 2003, and the Company anticipates an IPR&D charge of
approximately $700 million to be incurred in connection with
this acquisition.
Cautionary Factors That May Affect Future Results
This Annual Report contains forward-looking statements.
Forward-looking statements do not relate strictly to historical
or current facts and anticipate results based on management’s
plans that are subject to uncertainty. Forward-looking state-
ments may be identified by the use of words like “plans,”
“expects,” “will,” “anticipates,” “estimates” and other words
of similar meaning in conjunction with, among other things,
discussions of future operations, financial performance, the
Company’s strategy for growth, product development, regulatory
approval, market position and expenditures.
Forward-looking statements are based on current expecta-
tions of future events. The Company cannot guarantee that any
forward-looking statement will be accurate, although the
Company believes that it has been reasonable in its expecta-
tions and assumptions. Investors should realize that if underly-
ing assumptions prove inaccurate or that unknown risks or
uncertainties materialize, actual results could vary materially
from the Company’s expectations and projections. Investors are
therefore cautioned not to place undue reliance on any for-
ward-looking statements. Furthermore, the Company assumes
no obligation to update any forward-looking statements as a
result of new information or future events or developments. The
Company’s report on Form 10-K for the year ended December
29, 2002 that will be filed in March 2003, will contain, as an
Exhibit, a discussion of various factors that could cause actual
results to differ from expectations. Prior to that filing, investors
should reference the Company’s report on Form 10-K for the fis-
cal year ended December 30, 2001. The Company notes these
factors as permitted by the Private Securities Litigation Reform
Act of 1995.
38
Consolidated Balance Sheets Johnson & Johnson and Subsidiaries
At December 29, 2002 and December 30, 2001 (Dollars in Millions Except Share and Per Share Data) (Note 1) 2002 2001
Assets
Current assets
Cash and cash equivalents (Notes 1, 14 and 15) $ 2,894 3,758
Marketable securities (Notes 1, 14 and 15) 4,581 4,214
Accounts receivable trade, less allowances for doubtful accounts $191 (2001, $197) 5,399 4,630
Inventories (Notes 1 and 2) 3,303 2,992
Deferred taxes on income (Note 8) 1,419 1,192
Prepaid expenses and other receivables 1,670 1,687
Total current assets 19,266 18,473
Marketable securities, non-current (Notes 1, 14 and 15) 121 969
Property, plant and equipment, net (Notes 1 and 3) 8,710 7,719
Intangible assets, net (Notes 1 and 7) 9,246 9,077
Deferred taxes on income (Note 8) 236 288
Other assets (Note 5) 2,977 1,962
Total assets $40,556 38,488
Liabilities and Shareholders’ Equity
Current liabilities
Loans and notes payable (Note 6) $ 2,117 565
Accounts payable 3,621 2,838
Accrued liabilities 3,820 3,135
Accrued salaries, wages and commissions 1,181 969
Taxes on income 710 537
Total current liabilities 11,449 8,044
Long-term debt (Note 6) 2,022 2,217
Deferred tax liability (Note 8) 643 493
Employee related obligations (Note 5) 1,967 1,870
Other liabilities 1,778 1,631
Shareholders’ equity
Preferred stock—without par value
(authorized and unissued 2,000,000 shares) — —
Common stock—par value $1.00 per share (Note 20)
(authorized 4,320,000,000 shares; issued 3,119,842,000 shares) 3,120 3,120
Note receivable from employee stock ownership plan (Note 16) (25) (30)
Accumulated other comprehensive income (Note 12) (842) (530)
Retained earnings 26,571 23,066
28,824 25,626
Less: common stock held in treasury, at cost (Note 20)
(151,547,000 and 72,627,000) 6,127 1,393
Total shareholders’ equity 22,697 24,233
Total liabilities and shareholders’ equity $40,556 38,488
See Notes to Consolidated Financial Statements
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Consolidated Statements of Earnings Johnson & Johnson and Subsidiaries
(Dollars in Millions Except Per Share Figures) (Note 1) 2002 2001 2000
Sales to customers $ 36,298 32,317 29,172
Cost of products sold 10,447 9,581 8,957
Gross profit 25,851 22,736 20,215
Selling, marketing and administrative expenses 12,216 11,260 10,495
Research expense 3,957 3,591 3,105
Purchased in-process research and 
development (Note 17) 189 105 66
Interest income (256) (456) (429)
Interest expense, net of portion capitalized (Note 3) 160 153 204
Other (income) expense, net 294 185 (94)
16,560 14,838 13,347
Earnings before provision for taxes on income 9,291 7,898 6,868
Provision for taxes on income (Note 8) 2,694 2,230 1,915
Net earnings $ 6,597 5,668 4,953
Basic net earnings per share (Notes 1 and 19) $ 2.20 1.87 1.65
Diluted net earnings per share (Notes 1 and 19) $ 2.16 1.84 1.61
See Notes to Consolidated Financial Statements
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Note Receivable Accumulated Common
From Employee Other Stock Treasury
Comprehensive Retained Stock Ownership Comprehensive Issued Stock
(Dollars in Millions) (Note 1) Total Income Earnings Plan (ESOP) Income Amount Amount
Balance, January 2, 2000 $16,995 14,768 (41) (399) 3,120 (453)
Net earnings 4,953 4,953 4,953
Cash dividends paid (1,724) (1,724)
Employee stock compensation
and stock option plans 619 (456) 1,075
Conversion of 
subordinated debentures 504 504
Repurchase of common stock (973) (973)
Business combinations 77 68 9
Other comprehensive income,
net of tax:
Currency translation adjustment (45) (45) (45)
Unrealized gains/(losses)
on securities (2) (2) (2)
Pension liability adjustment (15) (15) (15)
Reclassification adjustment (52)
Total comprehensive income 4,839
Note receivable from ESOP 6 6
Balance, December 31, 2000 $20,395 18,113 (35) (461) 3,120 (342)
Net earnings 5,668 5,668 5,668
Cash dividends paid (2,047) (2,047)
Employee stock compensation
and stock option plans 842 (602) 1,444
Conversion of 
subordinated debentures 815 632 183
Repurchase of common stock (2,742) (2,742)
Business combinations 1,366 1,302 64
Other comprehensive income,
net of tax:
Currency translation adjustment (175) (175) (175)
Unrealized gains/(losses)
on securities 8 8 8
Gains/(losses) on
derivatives & hedges 98 98 98
Reclassification adjustment (14)
Total comprehensive income 5,585
Note receivable from ESOP 5 5
Balance, December 30, 2001 $24,233 23,066 (30) (530) 3,120 (1,393)
Net earnings 6,597 6,597 6,597
Cash dividends paid (2,381) (2,381)
Employee stock compensation
and stock option plans 806 (489) 1,295
Conversion of 
subordinated debentures 131 (222) 353
Repurchase of common stock (6,382) (6,382)
Other comprehensive income,
net of tax:
Currency translation adjustment (10) (10) (10)
Unrealized gains/(losses)
on securities (86) (86) (86)
Pension liability adjustment (18) (18) (18)
Gains/(losses) on
derivatives & hedges (198) (198) (198)
Reclassification adjustment (26)
Total comprehensive income 6,259
Note receivable from ESOP 5 5
Balance, December 29, 2002 $22,697 26,571 (25) (842) 3,120 (6,127)
See Notes to Consolidated Financial Statements
Consolidated Statements of Equity Johnson & Johnson and Subsidiaries
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(Dollars in Millions) (Note 1) 2002 2001 2000
Cash flows from operating activities
Net earnings $ 6,597 5,668 4,953
Adjustments to reconcile net earnings to cash flows:
Depreciation and amortization of property and intangibles 1,662 1,605 1,592
Purchased in-process research and development 189 105 66
Deferred tax provision (74) (106) (128)
Accounts receivable reserves (6) 99 41
Changes in assets and liabilities, net of effects from acquisition of businesses:
Increase in accounts receivable (510) (258) (468)
(Increase) decrease in inventories (109) (167) 128
Increase in accounts payable and accrued liabilities 1,420 1,401 41
(Increase) decrease in other current and non-current assets (1,429) (270) 124
Increase in other current and non-current liabilities 436 787 554
Net cash flows from operating activities 8,176 8,864 6,903
Cash flows from investing activities
Additions to property, plant and equipment (2,099) (1,731) (1,689)
Proceeds from the disposal of assets 156 163 166
Acquisition of businesses, net of cash acquired (Note 17) (478) (225) (151)
Purchases of investments (6,923) (8,188) (5,676)
Sales of investments 7,353 5,967 4,827
Other (206) (79) (142)
Net cash used by investing activities (2,197) (4,093) (2,665)
Cash flows from financing activities
Dividends to shareholders (2,381) (2,047) (1,724)
Repurchase of common stock (6,538) (2,570) (973)
Proceeds from short-term debt 2,359 338 814
Retirement of short-term debt (560) (1,109) (1,485)
Proceeds from long-term debt 22 14 591
Retirement of long-term debt (245) (391) (35)
Proceeds from the exercise of stock options 390 514 387
Net cash used by financing activities (6,953) (5,251) (2,425)
Effect of exchange rate changes on cash and cash equivalents 110 (40) (47)
(Decrease) increase in cash and cash equivalents (864) (520) 1,766
Cash and cash equivalents, beginning of year (Note 1) 3,758 4,278 2,512
Cash and cash equivalents, end of year (Note 1) $ 2,894 3,758 4,278
Supplemental cash flow data
Cash paid during the year for:
Interest $ 141 185 215
Income taxes 2,006 2,090 1,651
Supplemental schedule of noncash investing 
and financing activities
Treasury stock issued for employee compensation and stock
option plans, net of cash proceeds $ 946 971 754
Conversion of debt 131 815 504
Acquisition of businesses
Fair value of assets acquired $ 550 1,925 241
Fair value of liabilities assumed (72) (434) (5)
478 1,491 236
Treasury stock issued at fair value — (1,266) (85)
Net cash paid for acquisitions $ 478 225 151
See Notes to Consolidated Financial Statements
Consolidated Statements of Cash Flows Johnson & Johnson and Subsidiaries
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1 Summary of Significant Accounting Principles
Principles of Consolidation
The financial statements include the accounts of Johnson &
Johnson and subsidiaries. Intercompany accounts and
transactions are eliminated.
New Accounting Pronouncements
In June 2001, the Financial Accounting Standards Board
(FASB) issued Statement of Financial Accounting Standard
(SFAS) No. 143, “Accounting for Asset Retirement Obligations.”
The Company will adopt this standard in 2003 that is effective
for fiscal years beginning after June 15, 2002 and it is not
expected to have a material impact on the Company’s results
of operations, cash flows or financial position. In August 2001,
the FASB issued SFAS No. 144, “Accounting for the Impairment
or Disposal of Long-Lived Assets,” which was effective for the
first quarter of 2002. The Company’s adoption of SFAS No. 144
did not have a material effect on the Company’s results of
operations, cash flows or financial position. In June 2002, the
FASB issued SFAS No. 146, “Accounting for Costs Associated
with Exit or Disposal Activities” which is effective for exit or
disposal activities that are initiated after December 31, 2002.
The Company’s adoption of SFAS No. 146 in the first quarter
of 2003 is not expected to have a material effect on the Com-
pany’s results of operations, cash flows or financial position.
On November 25, 2002, the FASB issued FASB Interpretation
No. 45 (FIN 45), “Guarantor’s Accounting and Disclosure
Requirements for Guarantees, Including Indirect Guarantees of
Indebtedness of Others, an interpretation of FASB Statements
No. 5, 57 and 107 and Rescission of FASB Interpretation No. 34.”
FIN 45 clarifies the requirements of FASB Statement No. 5,
“Accounting for Contingencies,” relating to the guarantor’s
accounting for, and disclosure of, the issuance of certain types
of guarantees. The disclosure requirements of FIN 45 are effec-
tive for financial statements of interim or annual periods that
end after December 15, 2002. The disclosure provisions have
been implemented and no disclosures were required at year-
end 2002. The provisions for initial recognition and measure-
ment are effective on a prospective basis for guarantees that are
issued or modified after December 31, 2002, irrespective of the
guarantor’s year-end. FIN 45 requires that upon issuance of a
guarantee, the entity must recognize a liability for the fair value
of the obligation it assumes under that guarantee. The Com-
pany’s adoption of FIN 45 in 2003 has not and is not expected to
have a material effect on the Company’s results of operations,
cash flows or financial position.
In January 2003, the FASB issued FIN 46, “Consolidation of
Variable Interest Entities — an interpretation of ARB No. 51,”
which addresses consolidation of variable interest entities. FIN
46 expands the criteria for consideration in determining
whether a variable interest entity should be consolidated by a
business entity, and requires existing unconsolidated variable
interest entities (which include, but are not limited to, Special
Purpose Entities, or SPEs) to be consolidated by their primary
beneficiaries if the entities do not effectively disperse risks
among parties involved. This interpretation applies immediately
to variable interest entities created after January 31, 2003, and
to variable interest entities in which an enterprise obtains an
interest after that date. It applies in the first fiscal year or
interim period beginning after June 15, 2003, to variable interest
entities in which an enterprise holds a variable interest that it
acquired before February 1, 2003. The adoption of FIN 46 is not
expected to have a material effect on the Company’s results of
operations, cash flows or financial position.
Cash Equivalents
The Company considers securities with maturities of three
months or less, when purchased, to be cash equivalents.
Investments
Short-term marketable securities are carried at cost, which
approximates fair value. Long-term debt securities that the
Company has the ability and intent to hold until maturity are
carried at amortized cost, which also approximates fair value.
Investments classified as available-for-sale are carried at
estimated fair value with unrealized gains and losses recorded
as a component of accumulated other comprehensive income.
Management determines the appropriate classification of its
investment in debt and equity securities at the time of purchase
and re-evaluates such determination at each balance sheet
date. The Company periodically reviews its investments in non-
marketable equity securities for impairment and adjusts these
investments to their fair value when a decline in market value
is deemed to be other than temporary.
Property, Plant and Equipment and Depreciation
Property, plant and equipment are stated at cost. The
Company utilizes the straight-line method of depreciation
over the estimated useful lives of the assets:
Building and building equipment 20-40 years
Land and leasehold improvements 10-20 years
Machinery and equipment 2-13 years
The Company capitalizes certain computer software and
development costs incurred in connection with developing
or obtaining computer software for internal use. Capitalized
software costs are amortized over the estimated useful lives
of the software, which generally ranges from 3 to 5 years.
The Company reviews long-lived assets to assess recoverabil-
ity using undiscounted cash flows. When necessary, charges for
impairments of long-lived assets are recorded for the amount
by which the present value of future cash flows is less than the
carrying value of these assets.
Revenue Recognition
The Company recognizes revenue from product sales when the
goods are shipped or delivered depending on when title and
risk passes to the customer. Provisions for certain rebates, sales
incentives, trade promotions, product returns and discounts to
customers are provided for as reductions in determining sales
in the same period the related sales are recorded.
Sales Incentives and Trade Promotional Allowances
The Company has adopted Emerging Issues Task Force (EITF)
Issue No. 01-09 “Accounting for Consideration Given by a Vendor to
a Customer or Reseller of the Vendor’s Products” effective Decem-
ber 31, 2001. All prior periods have been restated to reclassify
Notes to Consolidated Financial Statements
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values of these derivatives are recognized in earnings, thereby
offsetting the current earnings effect of the related foreign
currency assets and liabilities.
The designation as a cash flow hedge is made at the date
of entering into the derivative contract. At inception, all deriva-
tives are expected to be highly effective. Changes in the fair
value of a derivative that is designated as a cash flow hedge
and that is highly effective, are recorded in accumulated other
comprehensive income, until the underlying transaction affects
earnings and are then reclassified to earnings in the same
account as the hedged transaction. Fair value of a forward
exchange contract represents the present value of the change
in forward exchange rates times the notional amount of the
derivative. The fair value of a currency swap contract is deter-
mined by discounting to the present all future cash flows of
the currencies to be exchanged at interest rates prevailing in
the market for the periods the currency exchanges are due,
and expressing the result in U.S. dollars at the current spot
foreign currency exchange rate.
On an ongoing basis, the Company assesses whether each
derivative continues to be highly effective in offsetting changes
in the cash flows of hedged items. If and when a derivative
is no longer expected to be highly effective, hedge accounting
is discontinued. Hedge ineffectiveness, if any, is included in
current period earnings.
The Company documents all relationships between hedged
items and derivatives. The overall risk management strategy
includes reasons for undertaking hedge transactions and
entering into derivatives. The objectives of this strategy are:
(1) minimize foreign currency exposure’s impact on the
Company’s financial performance; (2) protect the Company’s
cash flow from adverse movements in foreign exchange
rates; (3) ensure the appropriateness of financial instruments;
and (4) manage the enterprise risk associated with finan-
cial institutions.
Product Liability
Accruals for product liability claims are recorded, on an
undiscounted basis, when it is probable that a liability has
been incurred and the amount of the liability can be reason-
ably estimated, based on existing information. The accruals
are adjusted periodically as additional information becomes
available. Receivables for insurance recoveries related to prod-
uct liability related claims are recorded, on an undiscounted
for the time value of money basis, when it is probable that a
recovery will be realized.
Research and Development
Research and development expenses are expensed as
incurred. Upfront and milestone payments made to third
parties in connection with research and development col-
laborations are expensed as incurred up to the point of
regulatory approval. Payments made to third parties subse-
quent to regulatory approval are capitalized and amortized
over the remaining useful life of the related product. Amounts
capitalized for such payments are included in other intangi-
bles, net of accumulated amortization.
Advertising
Costs associated with advertising are expensed in the year
incurred. Advertising expenses worldwide, which are
sales incentives and trade promotional allowances from selling,
general and administrative expenses to either a reduction of
sales or cost of sales. As such, sales were reduced by $687 mil-
lion and $674 million for 2001 and 2000, respectively, and cost of
products sold increased by $45 million and $49 million for 2001
and 2000, respectively.
Shipping and Handling
Shipping and handling costs incurred were $518 million, $473
million and $492 million in 2002, 2001 and 2000, respectively,
and are included in selling, marketing and administrative
expense. The amount of revenue received for shipping and
handling is immaterial for all periods presented.
Inventories
Inventories are stated at the lower of cost or market
determined by the first-in, first-out method.
Intangible Assets
In accordance with SFAS No. 142, no amortization was
recorded for goodwill and/or intangible assets deemed to have
indefinite lives for acquisitions completed after June 30, 2001.
Further, effective the beginning of fiscal year 2002 in accor-
dance with SFAS No. 142, the Company discontinued the amor-
tization relating to all existing goodwill and indefinite lived
intangible assets. The effect of non-amortization of this good-
will and these intangible assets was approximately $141 mil-
lion before tax for 2002. Intangible assets that have finite
useful lives continue to be amortized over their useful lives.
SFAS No. 142 requires that goodwill and non-amortizable
intangible assets be assessed annually for impairment. The
required initial assessment was completed at June 30, 2002
and no impairment was determined. This initial impairment
assessment was updated in the fourth quarter of 2002 and no
impairment was determined. Future impairment tests will be
performed in the fourth quarter, annually. 
Financial Instruments
Effective January 1, 2001, the Company adopted SFAS No. 133
“Accounting for Derivative Instruments and Hedging Activi-
ties,” as amended by SFAS No. 138 “Accounting for Certain
Derivative Instruments and Certain Hedging Activities, an
amendment of FASB Statement No. 133,” collectively referred
to as SFAS No. 133. SFAS No. 133 requires that all derivative
instruments be recorded on the balance sheet at fair value.
Changes in the fair value of derivatives are recorded each
period in current earnings or other comprehensive income,
depending on whether the derivative is designated as part 
of a hedge transaction, and if it is, depending on the type of
hedge transaction.
The Company uses forward exchange contracts to manage
its exposure to the variability of cash flows, primarily related
to the foreign exchange rate changes of future intercompany
product and third party purchases of raw materials denomi-
nated in foreign currency. The Company also uses currency
swaps to manage currency risk primarily related to borrow-
ings. Both of these types of derivatives are designated as cash
flow hedges. Additionally, the Company uses forward exchange
contracts to offset its exposure to certain foreign currency
assets and liabilities. These forward exchange contracts are
not designated as hedges and, therefore, changes in the fair
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the U.S. requires management to make estimates and assump-
tions that affect the amounts reported. Actual results may or
may not differ from those estimates.
Annual Closing Date
The Company follows the concept of a fiscal year which ends
on the Sunday nearest to the end of the month of December.
Normally each fiscal year consists of 52 weeks, but every five
or six years, as will be the case in 2004, the fiscal year consists
of 53 weeks.
Reclassification
Certain prior year amounts have been reclassified to conform
with current year presentation.
Stock Split
On April 26, 2001, the Board of Directors declared a 2-for-1
stock split. Shareholders of record at the close of business on
May 22, 2001 were issued one additional share of Johnson &
Johnson common stock on June 12, 2001 for each share held
as of the record date. All shares and per share data for all
periods presented in these financial statements have been
adjusted to reflect the stock split.
2 Inventories
At the end of 2002 and 2001, inventories were comprised of:
(Dollars in Millions) 2002 2001
Raw materials and supplies $ 835 842
Goods in process 803 605
Finished goods 1,665 1,545
$3,303 2,992
3 Property, Plant and Equipment
At the end of 2002 and 2001, property, plant and equipment at
cost and accumulated depreciation were:
(Dollars in Millions) 2002 2001
Land and land improvements $ 472 459
Buildings and building equipment 4,364 3,911
Machinery and equipment 7,869 6,805
Construction in progress 1,609 1,283
14,314 12,458
Less accumulated depreciation 5,604 4,739
$ 8,710 7,719
The Company capitalizes interest expense as part of the cost
of construction of facilities and equipment. Interest expense
capitalized in 2002, 2001 and 2000 was $98 million, $95 million
and $97 million, respectively.
Depreciation expense, including the amortization of capital-
ized interest in 2002, 2001 and 2000 was $1.3 billion, $1.1 billion
and $1.1 billion, respectively.
Upon retirement or other disposal of fixed assets, the cost
and related amount of accumulated depreciation or amortization
are eliminated from the asset and accumulated depreciation
accounts, respectively. The difference, if any, between the net
asset value and the proceeds is adjusted to earnings.
4 Rental Expense and Lease Commitments
Rentals of space, vehicles, manufacturing equipment and office
and data processing equipment under operating leases
comprised of television, radio, print media as well as Internet
advertising, were $1.5 billion in 2002, $1.4 billion in 2001 and
$1.4 billion in 2000.
Income Taxes
The Company intends to continue to reinvest its undistributed
international earnings to expand its international operations;
therefore, no U.S. tax expense has been recorded to cover the
repatriation of such undistributed earnings. At December 29,
2002, and December 30, 2001, the cumulative amount of
undistributed international earnings was approximately
$12.3 billion and $12.1 billion, respectively.
Deferred income taxes are recognized for tax consequences
of temporary differences by applying enacted statutory tax rates,
applicable to future years, to differences between the financial
reporting and the tax basis of existing assets and liabilities.
Net Earnings Per Share
Basic earnings per share is computed by dividing net income
available to common shareholders by the weighted average
number of common shares outstanding for the period. Diluted
earnings per share reflects the potential dilution that could
occur if securities or other contracts to issue common stock
were exercised or converted into common stock.
Stock Options
At December 29, 2002, the Company has 24 stock-based
employee compensation plans that are described in Note 10.
The Company accounts for those plans under the recognition
and measurement principles of Accounting Principle Board
Opinion No. 25 “Accounting for Stock Issued to Employees”
and its related Interpretations. Compensation costs are not
recorded in net income for stock options, as all options granted
under those plans had an exercise price equal to the market
value of the underlying common stock on the date of grant.
As required by SFAS No. 148, “Accounting for Stock-Based
Compensation — Transition and Disclosure — an amendment
of FASB Statement No. 123,” the following table shows the
estimated effect on net income and earnings per share if the
Company had applied the fair value recognition provision of
SFAS No. 123, “Accounting for Stock-Based Compensation,”
to stock-based employee compensation.
(Dollars in Millions
Except Per Share Data) 2002 2001 2000
Net income, 
as reported $ 6,597 5,668 4,953
Less:
Compensation
expense(1) 320 263 189
Pro forma $ 6,277 5,405 4,764
Earnings per share:
Basic—as reported $ 2.20 1.87 1.65
—pro forma 2.09 1.78 1.59
Diluted—as reported 2.16 1.84 1.61
—pro forma 2.06 1.75 1.55
(1) Determined under fair value based method for all awards, net of tax.
Risks and Uncertainties
The preparation of consolidated financial statements in
conformity with accounting principles generally accepted in
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amounted to approximately $298 million in 2002, $275 million
in 2001 and $264 million in 2000.
The approximate minimum rental payments required under
operating leases that have initial or remaining noncancelable
lease terms in excess of one year at December 29, 2002 are:
(Dollars
After
in Millions) 2003 2004 2005 2006 2007 2007 Total
$138 121 101 86 67 160 673
Commitments under capital leases are not significant.
5 Employee Related Obligations
At the end of 2002 and 2001, employee related obligations were:
(Dollars in Millions) 2002 2001
Pension benefits $ 643 605
Post retirement benefits 907 878
Post employment benefits 193 168
Deferred compensation 335 311
$2,078 1,962
Current benefits payable 111 92
Employee related obligations $1,967 1,870
Prepaid employee related obligations of $959 million for 2002
are included in other assets on the consolidated balance sheet.
6 Borrowings
The components of long-term debt are as follows:
Eff. Eff.
(Dollars in Millions) 2002 Rate% 2001 Rate%
3% Zero Coupon 
Convertible
Subordinated Debentures
due 2020 $ 621 3.00 626 3.00
5.25% Zero Coupon
Convertible
Subordinated Debentures
due 2014 11 5.25 117 5.25
8.72% Debentures
due 2024 300 8.72 300 8.72
6.95% Notes due 2029 293 7.14 293 7.14
6.73% Debentures 
due 2023 250 6.73 250 6.73
7.375% Notes due 2002 — — 200 7.49
8.25% Eurodollar Notes
due 2004 200 8.37 199 8.37
6.625% Notes due 2009 198 6.80 198 6.80
5.12% Notes due 2003(2) 60 0.82 60 0.82
Industrial Revenue Bonds 39 3.85 39 5.30
Other, principally
international 127 — 163 —
2,099 5.85(1) 2,445 5.98(1)
Less current portion 77 228
$2,022 2,217
(1) Weighted average effective rate.
(2) Represents 5.12% U.S. Dollar notes due 2003 issued by a Japanese
subsidiary and converted to a 0.82% fixed rate yen note via a currency swap.
The Company has access to substantial sources of funds at
numerous banks worldwide. Total unused credit available to
the Company approximates $3.1 billion, including $1.5 billion of
credit commitments and $0.8 billion of uncommitted lines with
various banks worldwide that expire during 2003. Interest
charged on borrowings under the credit line agreements is
based on either bids provided by the banks, the prime rate or
London Interbank Offered Rates (LIBOR), plus applicable mar-
gins. Commitment fees under the agreements are not material. 
The Company’s shelf registration filed with the Securities and
Exchange Commission enables the Company to issue up to $2.6
billion of unsecured debt securities and warrants to purchase
debt securities under its medium term note (MTN) program. No
MTN’s were issued in 2002. At December 29, 2002, the Company
had $1.8 billion remaining on its shelf registration. 
Long term debt includes two convertible subordinated
debentures issued by ALZA prior to its merger with 
Johnson & Johnson.
On July 28, 2000, ALZA completed a private offering of the
3% Zero Coupon Convertible Subordinated Debentures which
were issued at a price of $551.26 per $1,000 principal amount
at maturity. At December 29, 2002, the outstanding 3% Deben-
tures had a total principal amount at maturity of $1.0 billion
with a yield to maturity of 3% per annum, computed on a
semiannual bond equivalent basis. There are no periodic inter-
est payments. Under the terms of the 3% debentures, holders
are entitled to convert their debentures into approximately
15.0 million shares of Johnson & Johnson stock at a price of
$40.102 per share. Approximately 579,000 shares have been
issued as of December 29, 2002 due to voluntary conversions
by note holders. At the option of the holder, the 3% Debentures
may be repurchased by the Company on July 28, 2003, 2008 or
2013, at a purchase price equal to the issue price plus accreted
original issue discount to such purchase date. The Company, at
its option, may elect to deliver either Johnson & Johnson com-
mon stock or cash, or a combination of stock and cash, in the
event of repurchase of the 3% Debentures. The Company, at its
option, may also redeem any or all of the 3% Debentures after
July 28, 2003 at the issue price plus accreted original issue
discount. At December 29, 2002 and December 30, 2001, the
fair value based on quoted market value of the 3% Debentures
was $813 million and $910 million, respectively.
In 1994, ALZA issued the 5.25% Zero Coupon Convertible
Subordinated Debentures at a price of $354.71 per $1,000 prin-
cipal amount at maturity. At December 29, 2002, the outstand-
ing 5.25% Debentures had a total principal amount at maturity
of $20 million, with a yield to maturity of 5.25% per annum,
computed on a semiannual bond equivalent basis. There are
no periodic interest payments. Under the terms of the deben-
tures, note holders are entitled to convert their debentures
into approximately 24.0 million shares of Johnson & Johnson
stock at a price of $13.939 per share. Approximately 23.5 mil-
lion shares of Johnson & Johnson stock have been issued as at
December 29, 2002 due to voluntary conversions by note hold-
ers. At the option of the holder, the 5.25% Debentures may be
purchased by the Company on July 14, 2004 or July 14, 2009,
at a purchase price equal to the issue price plus accreted
original issue discount to such purchase date. At December 29,
2002 and December 30, 2001, the fair value based on quoted
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market value of the 5.25% Debentures was $27 million and
$339 million, respectively.
Short-term borrowings and current portion of long-term
debt amounted to $2.1 billion at the end of 2002. These
borrowings are comprised of $1.6 billion of commercial paper
and $468 million of local borrowings, principally by interna-
tional subsidiaries.
Aggregate maturities of long-term obligations commencing
in 2003 are:
After
(Dollars in Millions) 2003 2004 2005 2006 2007 2007
$77 270 17 12 8 1,715
7 Intangible Assets
At the end of 2002 and 2001, the gross and net amounts of
intangible assets were:
(Dollars in Millions) 2002 2001
Goodwill—gross $ 5,320 5,245
Less accumulated amortization 667 674
Goodwill—net $ 4,653 4,571
Trademarks (non-amortizable)—gross $ 1,021 935
Less accumulated amortization 138 132
Trademarks (non-amortizable)—net $ 883 803
Patents and trademarks—gross $ 2,016 1,881
Less accumulated amortization 534 376
Patents and trademarks—net $ 1,482 1,505
Other intangibles—gross $ 2,998 2,849
Less accumulated amortization 770 651
Other intangibles—net $ 2,228 2,198
Total intangible assets—gross $11,355 10,910
Less accumulated amortization 2,109 1,833
Total intangible assets—net $ 9,246 9,077
Goodwill as of December 29, 2002 as allocated by segments of
business is as follows:
Med Dev
(Dollars in Millions) Consumer Pharm & Diag Total
Goodwill, net of 
accumulated 
amortization at
December 30, 2001 $ 806 232 3,533 4,571
Reclassification of 
intangibles, net of 
accumulated 
amortization — (109) — (109)
Acquisitions — 150 60 210
Translation & other 15 (29) (5) (19)
Goodwill at 
December 29, 2002 $ 821 244 3,588 4,653
The weighted average amortization periods for patents and
trademarks and other intangible assets are 16 years and 18
years, respectively. The amortization expense of amortizable
intangible assets for the fiscal year ended December 29, 2002
was $405 million pre-tax and the estimated amortization
expense for the five succeeding years approximates $425
million pre-tax, per year, respectively.
8 Income Taxes
The provision for taxes on income consists of:
(Dollars in Millions) 2002 2001 2000
Currently payable:
U.S. taxes $ 2,042 1,726 1,375
International taxes 726 610 668
2,768 2,336 2,043
Deferred:
U.S. taxes 20 (22) (36)
International taxes (94) (84) (92)
(74) (106) (128)
$ 2,694 2,230 1,915
A comparison of income tax expense at the federal statutory
rate of 35% in 2002, 2001 and 2000, to the Company’s effective
tax rate is as follows:
(Dollars in Millions) 2002 2001 2000
U.S. $ 6,189 4,744 3,892
International 3,102 3,154 2,976
Earnings before taxes
on income: $ 9,291 7,898 6,868
Statutory taxes $ 3,252 2,764 2,404
Tax rates:
Statutory 35.0% 35.0% 35.0%
Puerto Rico and
Ireland operations (4.5) (5.4) (5.0)
Research tax credits (0.7) (0.4) (0.8)
Domestic state and local 1.2 0.9 0.8
International
subsidiaries
excluding Ireland (2.2) (2.6) (2.9)
IPR&D 0.7 0.5 0.3
All other (0.5) 0.2 0.5
Effective tax rate 29.0% 28.2% 27.9%
During 2002, the Company had subsidiaries operating in
Puerto Rico under a tax incentive grant expiring in 2014. In
addition, the Company has subsidiaries manufacturing in Ireland
under an incentive tax rate effective through the year 2010.
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Temporary differences and carry forwards for 2002 and
2001 are as follows:
2002 2001
Deferred Tax Deferred Tax
(Dollars in Millions) Asset Liability Asset Liability
Employee related 
obligations $ 443 625
Depreciation (318) (294)
Non-deductible 
intangibles (931) (959)
International R&D 
capitalized for tax 340 237
Reserves & liabilities 479 636
Income reported 
for tax purposes 343 313
Miscellaneous 
international 359 (278) 275 (260)
Capitalized intangible 139 156
Miscellaneous U.S. 354 183
Total deferred 
income taxes $2,457 (1,527) 2,425 (1,513)
The difference between the net deferred tax on income per
the balance sheet and the net deferred tax above is included
in Taxes on Income on the balance sheet.
9 International Currency Translation
For translation of its subsidiaries operating in non-U.S. dollar
currencies, the Company has determined that the local curren-
cies of its international subsidiaries are the functional curren-
cies except those in highly inflationary economies, which are
defined as those which have had compound cumulative rates of
inflation of 100% or more during the past three years.
In consolidating international subsidiaries, balance sheet cur-
rency effects are recorded as a component of accumulated other
comprehensive income. This equity account includes the results of
translating all balance sheet assets and liabilities at current
exchange rates, except for those located in highly inflationary
economies which are reflected in operating results.
An analysis of the changes during 2002 and 2001 for foreign
currency translation adjustments is included in Note 12.
Net currency transaction and translation gains and
losses included in other expense were after-tax losses of
$25 million, $3 million and $65 million, in 2002, 2001
and 2000, respectively.
10 Common Stock, Stock Option Plans and Stock
Compensation Agreements
At December 29, 2002 the Company had 24 stock-based com-
pensation plans. Under the 2000 Stock Option Plan, the Com-
pany may grant options to its employees for up to 1.6% of the
issued shares of the Company’s Common Stock, plus the num-
ber of shares available from the previous year that were not
issued, as well as shares issued under the Plan that expired
or terminated without being exercised. The shares outstanding
are for contracts under the Company’s 1991, 1995 and 2000
Employee Stock Option Plans, the 1997 Non-Employee Direc-
tor’s Plan and the Mitek, Cordis, Biosense, Gynecare, Centocor,
Innovasive Devices, ALZA and Inverness Stock Option Plans.
Stock options generally expire 10 years from the date they
are granted and vest over service periods that range from one
to six years. All options are granted at current market price
on the date of grant. Shares available, under the 2000 Stock
Option Plan, for future grants are based on 1.6% of the issued
shares each year, and 49.9 million shares could be granted
each year during the years 2002 through 2005, in addition to
any other available shares as described above. Shares avail-
able for future grants under the 2000 plan were 62.1 million
at the end of 2002. 
A summary of the status of the Company’s stock option
plans as of December 29, 2002, December 30, 2001 and
December 31, 2000 and changes during the years ending on
those dates, is presented below:
Weighted 
Options Average
(Shares in Thousands) Outstanding Exercise Price
Balance at January 2, 2000 181,486 $25.65
Options granted 46,456 48.29
Options exercised (27,130) 15.22
Options canceled/forfeited (6,824) 33.03
Balance at December 31, 2000 193,988 32.27
Options granted 8,975(1) 36.31
Options exercised (30,622) 19.00
Options canceled/forfeited (5,117) 49.38
Balance at December 30, 2001 167,224 34.37
Options granted 48,072 57.30
Options exercised (21,012) 19.64
Options canceled/forfeited (4,543) 50.86
Balance at December 29, 2002 189,741 $41.42
(1) Includes 3,108 options issued to replace Inverness options outstanding at or
granted prior to the acquisition.
For the year ended December 30, 2001, there was a change
in the timing of granting stock compensation and options to
employees from December 2001 to February 2002. This
change was enacted to have 2001 results finalized in order to
align compensation with performance. The same timing of
grants will be followed for fiscal 2002.
The average fair value of options granted was $15.49 in
2002, $13.72 in 2001 and $14.79 in 2000. The fair value was
estimated using the Black-Scholes option pricing model based
on the weighted average assumptions of:
2002 2001 2000
Risk-free rate 4.39% 4.87% 5.45%
Volatility 26.0% 27.0% 27.0%
Expected life 5.0 yrs 5.0 yrs 5.0 yrs
Dividend yield 1.33% 1.33% 1.40%
The following table summarizes stock options outstanding and
exercisable at December 29, 2002:
(Shares in Thousands) Outstanding Exercisable
Average Average
Exercise Average Exercise Exercise
Price Range Options Life(a) Price Options Price
$.79-$11.15 5,572 1.2 $10.29 5,572 $10.29
$11.16-$21.24 16,550 1.8 12.93 16,550 12.93
$21.57-$39.86 43,541 4.0 27.05 42,403 26.85
$40.08-$50.66 40,916 6.7 45.94 35,829 45.76
$50.69-$55.91 36,337 7.8 50.74 306 51.82
$57.30-$61.68 46,655 9.1 57.34 1 57.36
$63.30-$66.50 170 8.0 64.37 41 64.74
189,741 6.3 $41.42 100,702 $30.47
(a) Average contractual life remaining in years.
Stock options exercisable at December 30, 2001 and
December 31, 2000 were 99,176 options at an average exercise
price of $24.34 and 90,384 options at an average exercise price
of $19.46, respectively.
11 Segments of Business and Geographic Areas
See page 57 for information on segments of business and
geographic areas.
12 Accumulated Other Comprehensive Income 
Components of other comprehensive income/(loss) consist of
the following:
Total
Unrealized Gains/ Accumulated
Foreign Gains/ Pension (Losses) on Other
Currency (Losses) Liability Derivatives Comprehensive
(Dollars in Millions) Translation on Securities Adjustments & Hedges Income/(Loss)
Jan. 2, 2000 $(477) 78 (399)
2000 changes (45) (2) (15) (62)
Dec. 31, 2000 $(522) 76 (15) (461)
2001 changes
Transition
Adjustment — — — 17
Net change due
to hedging
transactions — — — 228
Net amount 
reclassed to
net earnings — — — (147)
Net 2001 
changes (175) 8 — 98 (69)
Dec. 30, 2001 $(697) 84 (15) 98 (530)
2002 changes
Net change due
to hedging 
transactions — — — (394)
Net amount 
reclassed to 
net earnings — — — 196
Net 2002 
changes (10) (86) (18) (198) (312)
Dec. 29, 2002 $(707) (2) (33) (100) (842)
Total other comprehensive income for 2002 includes
reclassification adjustment gains of $45 million realized from
the sale of equity securities and the associated tax expense
of $19 million. In 2001, total other comprehensive income
included reclassification adjustment gains of $21 million real-
ized from the sale of equity securities and the associated tax
expense of $7 million. In 2000, total other comprehensive
income included reclassification adjustment gains of $80 mil-
lion and the associated tax expense of $28 million. 
The tax effect on these unrealized gains/(losses) on equity
securities is a benefit of $1 million in 2002, an expense of $64
million in 2001 and an expense of $53 million in 2000. The tax
effect on the gains/(losses) on derivatives and hedges is a benefit
of $56 million in 2002 and an expense of $53 million in 2001.
See Note 15 for additional information relating to derivatives
and hedging.
The currency translation adjustments are not currently
adjusted for income taxes as they relate to permanent
investments in non-U.S. subsidiaries.
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13 Retirement and Pension Plans
The Company sponsors various retirement and pension
plans, including defined benefit, defined contribution and
termination indemnity plans, which cover most employees
worldwide. The Company also provides postretirement
benefits, primarily health care to all domestic retired
employees and their dependents.
Most international employees are covered by government
sponsored programs and the cost to the Company is not
significant.
Retirement plan benefits are primarily based on the
employee’s compensation during the last three to five years
before retirement and the number of years of service. The Com-
pany’s objective in funding its domestic plans is to accumulate
funds sufficient to provide for all accrued benefits. International
subsidiaries have plans under which funds are deposited with
trustees, annuities are purchased under group contracts or
reserves are provided.
In certain countries other than the United States, the funding of
pension plans is not a common practice as funding provides no
economic benefit. Consequently, the Company has several pension
plans which are not funded. 
The Company does not fund retiree health care benefits in
advance and has the right to modify these plans in the future.
Net periodic benefit costs for the Company’s defined benefit
retirement plans and other benefit plans for 2002, 2001 and
2000 include the following components:
Retirement Plans Other Benefit Plans
(Dollars in Millions) 2002 2001 2000 2002 2001 2000
Service cost $ 249 219 201 23 23 20
Interest cost 354 325 295 59 52 51
Expected return on plan assets (447) (413) (377) (4) (5) (5)
Amortization of prior service cost 15 18 21 (3) (3) (1)
Amortization of net transition asset (7) (6) (7) — — —
Recognized actuarial gains (41) (68) (81) — (7) (10)
Curtailments and settlements (1) (1) — — — —
Net periodic benefit cost $ 122 74 52 75 60 55
Retirement Plans Other Benefit Plans
Domestic Benefit Plans 2002 2001 2000 2002 2001 2000
Weighted average discount rate 6.75% 7.50% 7.50% 6.75% 7.50% 7.50%
Expected long-term rate of return on plan assets 9.00 9.00 9.00 9.00 9.00 9.00
Rate of increase in compensation levels 4.50 4.50 5.00 4.50 4.50 5.00
International Benefit Plans
Weighted average discount rate 5.75% 5.75% 6.00% 6.75% 6.75% 6.75%
Expected long-term rate of return on plan assets 7.50 7.50 7.50 — — —
Rate of increase in compensation levels 3.50 3.50 3.50 4.25 4.25 4.25
Health care cost trends in the United States are projected at
annual rates, for all individuals, grading from 9.0% to 4.5% by
the year 2009 and beyond. The effect of a 1% change in these
assumed cost trends on the accumulated postretirement
benefit obligation at the end of 2002 would be a $125 million
increase or a $106 million decrease and the effect on the
service and interest cost components of the net periodic
postretirement benefit cost for 2002 would be a $13 million
increase or a $10 million decrease.
Plan assets consist primarily of listed common stocks, U.S.
and non-U.S. equities and fixed income investments. The fair
value of Johnson & Johnson common stock in the plan assets
was $384 million at December 29, 2002.
The net periodic (income) cost attributable to domestic retire-
ment plans was $61 million in 2002, $28 million in 2001 and
($14) million in 2000.
The following tables provide the weighted-average assump-
tions used to develop net periodic benefit cost and the actuar-
ial present value of projected benefit obligations:
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The following tables set forth the change in benefit obliga-
tions and change in plan assets at year-end 2002 and 2001
for the Company’s defined benefit retirement plans and other
benefit plans:
(Dollars in Millions) Retirement Plans Other Benefit Plans
Change in Benefit Obligation 2002 2001 2002 2001
Benefit obligation—beginning of year $ 5,026 4,555 782 722
Service cost 249 219 23 23
Interest cost 354 325 59 52
Plan participant contributions 18 15 — —
Amendments 17 8 — —
Actuarial loss 478 210 190 22
Divestitures & acquisitions (4) 1 8 —
Curtailments & settlements (6) (1) — —
Total benefits paid (246) (223) (50) (34)
Effect of exchange rates 165 (83) 3 (3)
Benefit obligation—end of year $ 6,051 5,026 1,015 782
Change in Plan Assets
Plan assets at fair value—beginning of year $ 4,355 4,847 48 58
Actual return on plan assets (611) (276) (12) (8)
Company contributions 1,074 56 47 31
Plan participant contributions 18 15 — —
Divestitures (2) — (49) —
Benefits paid from plan assets (232) (212) — (33)
Effect of exchange rates 103 (75) — —
Plan assets at fair value—end of year $ 4,705 4,355 34 48
Amounts recognized in the Company’s balance sheet consist of
the following:
Retirement Plans Other Benefit Plans
(Dollars in Millions) 2002 2001 2002 2001
Plan assets less than projected benefit obligation $(1,346) (671) (981) (734)
Unrecognized actuarial losses/(gains) 1,588 (14) 92 (123)
Unrecognized prior service cost 124 118 (18) (21)
Unrecognized net transition asset (4) (9) — —
Total recognized in the consolidated balance sheet $ 362 (576) (907) (878)
Book reserves $ (643) (770) (907) (878)
Prepaid benefits 959 165 — —
Intangible assets 13 14 — —
Accumulated comprehensive income 33 15 — —
Total recognized in consolidated balance sheet $ 362 (576) (907) (878)
A minimum pension liability adjustment is required when the
actuarial present value of accumulated benefits (ABO) exceeds
the fair value of plan assets and accrued pension liabilities.
The minimum pension liability adjustments in 2002 and 2001
of $46 million and $29 million, respectively relate primarily to
plans outside the U.S.
Plans with accumulated benefit obligations in excess of plan
assets consist of the following:
Retirement Plans Other Benefit Plans
(Dollars in Millions) 2002 2001 2002 2001
Accumulated benefit obligation $ (953) (544) (941) (782)
Projected benefit obligation $(1,024) (645) — —
Plan assets at fair value $ 305 111 34 48
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15 Financial Instruments
Effective January 1, 2001, the Company adopted SFAS 133
requiring that all derivative instruments be recorded on
the balance sheet at fair value.
As of December 29, 2002 the balance of deferred net losses
on derivatives included in accumulated other comprehensive
income was $100 million after-tax. For additional information,
see Note 12. Of this amount, the Company expects that
$100 million will be reclassified into earnings over the next
12 months as a result of transactions that are expected to
occur over that period. The amount ultimately realized in
earnings will differ as foreign exchange rates change. Realized
gains and losses are ultimately determined by actual exchange
rates at maturity of the derivative. Transactions with third
parties will cause the amount in accumulated other compre-
hensive income to affect net earnings. The maximum length
of time over which the Company is hedging is 15 months.
For the year ended December 29, 2002 the net impact of the
hedges’ ineffectiveness to the Company’s financial statements
was insignificant. For the year ended December 29, 2002 the
Company has recorded a net gain of $10 million (after tax) in
the “other (income) expense, net” category of the consolidated
statement of earnings, representing the impact of discontinu-
ance of cash flow hedges because it is probable that the origi-
nally forecasted transactions will not occur by the end of the
originally specified time period.
Refer to Note 12 for disclosures of movements in
Accumulated Other Comprehensive Income.
Concentration of Credit Risk
The Company invests its excess cash in both deposits
with major banks throughout the world and other high quality
money market instruments. Refer to Note 14 for additional
information. The Company has a policy of making investments
only with commercial institutions that have at least an “A”
(or equivalent) credit rating. These investments generally
mature within six months and the Company has not incurred
any related losses.
16 Savings Plan
The Company has voluntary 401(k) savings plans designed to
enhance the existing retirement programs covering eligible
employees. The Company matches a percentage of each
employee’s contributions consistent with the provisions of the
plan for which he/she is eligible.
In the U.S. salaried plan, one-third of the Company match is
paid in Company stock under an employee stock ownership
plan (ESOP). In 1990, to establish the ESOP, the Company
loaned $100 million to the ESOP Trust to purchase shares of
the Company stock on the open market. In exchange, the Com-
pany received a note, the balance of which is recorded as a
reduction of shareholders’ equity.
Total contributions to the plans were $111 million in 2002,
$96 million in 2001 and $81 million in 2000.
14 Marketable Securities
December 29, 2002 December 30, 2001
(Dollars in Millions) Net Unrealized Unrealized Estimated Net Unrealized Unrealized Estimated
Cost Gains Losses Fair Value Cost Gains Losses Fair Value
Money market funds $ 701 — — 701 1,276 — — 1,276
Commercial paper 35 — — 35 54 — — 54
Time deposits 754 — — 754 1,162 — — 1,162
Government securities 
and obligations 1,976 3 — 1,979 1,046 2 — 1,048
Asset backed securities — — — — 7 — — 7
Bank notes 18 — — 18 118 — — 118
Corporate debt securities 2,791 6 — 2,797 3,221 16 — 3,237
Total current 
marketable securities $ 6,275 9 — 6,284 6,884 18 — 6,902
Government securities 14 — — 14 314 6 — 320
Asset backed securities — — — — 122 — — 122
Bank notes 27 — — 27 131 2 — 133
Corporate debt securities — — — — 311 7 — 318
Investments held in trust 80 — — 80 91 4 — 95
Total non-current 
marketable securities $ 121 — — 121 969 19 — 988
Current marketable securities include $1.7 billion and $2.7 billion that are classified as cash equivalents on the balance sheet at
December 29, 2002 and December 30, 2001, respectively.
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17 Mergers & Acquisitions
Certain businesses were acquired for $478 million in cash and
liabilities assumed of $72 million assumed during 2002. These
acquisitions were accounted for by the purchase method and,
accordingly, results of operations have been included in the
accompanying consolidated financial statements from their
respective dates of acquisition.
The 2002 acquisitions included Tibotec-Virco N.V., a
privately-held biopharmaceutical company focused on devel-
oping anti-viral treatments; Micro Typing Systems, Inc., a
manufacturer of reagents and supplier of distributed instru-
ments known as the ID-Micro Typing SystemTM and Obtech
Medical AG, a privately-held company that markets an
adjustable gastric band for the treatment of morbid obesity.
The excess of purchase price over the estimated fair value
of tangible assets of the acquired entities amounted to
$325 million and has been allocated to identifiable intangibles
and goodwill. In addition, approximately $189 million has been
identified as the value of in-process research and development
(IPR&D) associated with the Tibotec-Virco N.V. and Obtech
Medical AG acquisitions.
The IPR&D charge related to Tibotec-Virco N.V. was $150
million and is associated with two early stage HIV compounds.
The value of the IPR&D was calculated with the assistance of a
third party appraiser using cash flow projections discounted
for the risk inherent in such projects using probability of suc-
cess factors ranging from 30–33%. The discount rate was 9%.
The IPR&D charge related to Obtech Medical AG was $39
million and is associated with the development of the current
Swedish Adjustable Gastric Band (SAGB) for use in the United
States as well as development of a next generation technology
platform. The value of the IPR&D was calculated with the
assistance of a third party appraiser using cash flow projec-
tions discounted for the risk inherent in such projects using a
70% probability of success factor and a 20% discount rate.
Pro forma information is not provided since the impact of
the acquisitions does not have a material effect on the Com-
pany’s results of operations, cash flows or financial position.
On June 22, 2001, Johnson & Johnson and ALZA Cor-
poration (ALZA) completed the merger between the two
companies. This transaction was accounted for as a pooling-
of-interests. ALZA had approximately 239 million shares out-
standing (286 million on a fully diluted basis) that were
exchanged for approximately 234 million shares of Johnson
& Johnson common stock. On a diluted basis when adjusted
for stock options and convertible debt, the number of Johnson
& Johnson shares issued total approximately 280 million.
Holders of ALZA common stock received 0.98 of a share of
Johnson & Johnson common stock, valued at $52.39 per share.
ALZA is a research-based pharmaceutical company with
leading drug delivery technologies. The company applies its
delivery technologies to develop pharmaceutical products
with enhanced therapeutic value for Johnson & Johnson
affiliate portfolios and for many of the world’s leading
pharmaceutical companies.
Certain businesses were acquired for $1.9 billion during
2001 ($0.6 billion in cash and liabilities assumed and 24.5
million shares of the Company’s common stock issued from
Treasury valued at $1.3 billion). These acquisitions were
accounted for by the purchase method and, accordingly,
results of operations have been included in the accompanying
consolidated financial statements from their respective dates
of acquisition.
The 2001 acquisitions included Inverness Medical Technol-
ogy, the supplier of LifeScan’s electrochemical products for
blood glucose monitoring following the spin-off of its non-
diabetes businesses; Heartport, a company that develops and
manufactures products for less invasive open chest and mini-
mally invasive heart operations, including stopped heart and
beating heart procedures; TERAMed Inc., an early-stage
medical device company that is developing endovascular
stent-graft systems for the minimally invasive treatment of
abdominal aortic aneurysms and peripheral occlusive disease;
BabyCenter, L.L.C., an Internet content and commerce com-
pany devoted to supporting a community of expectant and
new mothers; and the VIACTIV® product line, a chewable cal-
cium supplement, from the Mead Johnson Nutritionals Divi-
sion of Bristol-Myers Squibb.
Inverness Medical Technology was acquired to enhance
control of the primary supplier of LifeScan blood glucose mon-
itoring products and will allow for the achievement of opera-
tional synergies. The acquisition also provides key technology
for the development of future products.
Approximately $105 million has been identified as the value
of IPR&D associated with the Inverness Medical Technology
and TERAMed Inc. acquisitions. The IPR&D charge is primar-
ily related to Inverness projects for minimally invasive testing,
continuous monitoring and insulin delivery. The value of the
IPR&D was calculated with the assistance of a third party
appraiser using cash flow projections discounted for the risk
inherent in such projects using probability of success factors
ranging from 25–40%. The discount rate used was 12%.
Certain businesses were acquired for $241 million during
2000. These acquisitions were accounted for by the purchase
method and, accordingly, results of operations have been
included in the accompanying consolidated financial state-
ments from their respective dates of acquisitions.
The 2000 acquisitions included Crescendo, a company
formed by ALZA for the purpose of selecting, developing and
commercializing human pharmaceutical products; Innovasive
Devices, a company that manufactures and sells devices for
sports medicine surgery for soft tissue injuries; Atrionix, Inc.,
a development stage company whose primary product is a
pulmonary ablation catheter for the treatment of atrial fibril-
lation; Medtrex, a company that develops and manufactures
electrosurgical generators and disposable products, and the
ST. JOSEPH® aspirin business. The IPR&D writeoff associated
with Atrionix, Inc. and ALZA’s Crescendo acquisition was $66
million. The IPR&D charge is primarily related to an Atrionix
project for the design of a catheter system to be used in a
procedure which blocks electrical impulses originating in pul-
monary veins, which can cause atrial fibrillation. The value of
IPR&D was calculated with the assistance of a third party
appraiser using a cash flow projection discounted for the risk
inherent in such a project. The discount rate used was 26%.
Divestitures in 2002, 2001 and 2000 did not have a material
effect on the Company’s results of operations, cash flows or
financial position.
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18 Legal Proceedings
The Company is involved in numerous product liability cases in
the United States, many of which concern adverse reactions to
drugs and medical devices. The damages claimed are substan-
tial, and while the Company is confident of the adequacy of the
warnings and instructions for use which accompany such prod-
ucts, it is not feasible to predict the ultimate outcome of litiga-
tion. However, the Company believes that if any liability results
from such cases, it will be substantially covered by reserves
established under its self-insurance program and by commer-
cially available excess liability insurance.
One group of cases against the Company concerns the
Janssen Pharmaceutica product PROPULSID®, which was with-
drawn from general sale and restricted to limited use in 2000.
In the wake of publicity about those events, numerous lawsuits
have been filed against Janssen, which is a wholly owned
subsidiary of the Company, and the Company regarding
PROPULSID® in state and federal courts across the country.
There are approximately 753 such cases currently pending,
including the claims of approximately 5,556 plaintiffs, 1,961 of
whom recently filed in Mississippi to avoid application of tort
reform legislation effective January 1, 2003. More cases were
likely filed in Mississippi but have not yet been served. In the
active cases, 429 individuals are alleged to have died from the
use of PROPULSID®. These actions seek substantial compen-
satory and punitive damages and accuse Janssen and the
Company of inadequately testing for and warning about the
drug’s side effects, of promoting it for off-label use and of over-
promotion. In addition, Janssen and the Company have entered
into agreements with various plaintiffs’ counsel halting the run-
ning of the statutes of limitations with respect to the potential
claims of a significant number of individuals while those attor-
neys evaluate whether or not to sue Janssen and the Company
on their behalf.
In September 2001, the first 10 plaintiffs in the Rankin case,
which comprises the claims of 155 PROPULSID® plaintiffs, went
to trial in state court in Claiborne County, Mississippi. The jury
returned compensatory damage verdicts for each plaintiff in
the amount of $10 million, for a total of $100 million. The trial
judge thereafter dismissed the claims of punitive damages. On
March 4, 2002, the trial judge reduced these verdicts to a total
of $48 million, and denied the motions of Janssen and the Com-
pany for a new trial. Janssen and the Company believe these
verdicts, even as reduced, are insupportable and have
appealed. In the view of Janssen and the Company, the proof at
trial demonstrated that none of these plaintiffs was injured by
PROPULSID® and that no basis for liability existed.
In April 2002, a state court judge in New Jersey denied
plaintiffs’ motion to certify a national class of PROPULSID®
users for purposes of medical monitoring and refund of the
costs of purchasing PROPULSID®. An effort to appeal that ruling
has been denied. In June 2002 the federal judge presiding over
the PROPULSID® Multi-District Litigation in New Orleans,
Louisiana similarly denied plaintiffs’ motion there to certify a
national class of PROPULSID® users. Plaintiffs in the Multi-
District Litigation have said they are preserving their right to
appeal that ruling and other complaints filed against Janssen
and the Company include class action allegations which could
be the basis for future attempts to have classes certified.
With respect to all the various PROPULSID® actions against
them, Janssen and the Company dispute the claims in those
lawsuits and are vigorously defending against them except
where, in their judgment, settlement is appropriate. Janssen
and the Company believe they have adequate self-insurance
reserves and commercially available excess insurance with
respect to these cases. In communications to the Company, the
excess insurance carriers have raised certain defenses to their
liability under the policies. However, in the opinion of the Com-
pany, those defenses are pro forma and lack substance and the
carriers will honor their obligations under the policies.
The Company’s Ortho Biotech subsidiary was party to an
arbitration proceeding filed against it in 1995 by Amgen, Ortho
Biotech’s licensor of U.S. non-dialysis rights to PROCRIT®, in
which Amgen sought to terminate Ortho Biotech’s U.S. license
rights and collect substantial damages based on alleged delib-
erate PROCRIT® sales by Ortho Biotech during the early 1990s
into Amgen’s reserved dialysis market. On October 18, 2002,
the arbitrator issued his decision rejecting Amgen’s request
to terminate the license and finding no material breach of the
license. However, the arbitrator found that conduct by Ortho
Biotech in the early 1990s, which was subsequently halted
by Ortho Biotech, amounted to a non-material breach of the
license and awarded Amgen $150 million in damages which
the Company expensed in the third quarter of 2002. Amgen
had sought $1.2 billion in damages. On January 24, 2003, the
arbitrator ruled that Amgen was the “prevailing party” in this
arbitration, entitling it to an award of reasonable attorneys’ fees
and costs. Amgen has not yet submitted its application for fees
and costs. The Company expensed $85 million in the fourth
quarter of 2002 in connection with this outstanding claim.
In patent infringement actions tried in Delaware Federal
Court in late 2000, Cordis Corporation, a subsidiary of Johnson
& Johnson, obtained verdicts of infringement and patent valid-
ity, and damage awards, against Boston Scientific Corporation
and Medtronic AVE, Inc., based on a number of Cordis coro-
nary stent patents. On December 15, 2000, the jury in the dam-
age action against Boston Scientific returned a verdict of $324
million and on December 21, 2000 the jury in the Medtronic
AVE action returned a verdict of $271 million. These sums rep-
resent lost profit and reasonable royalty damages to compen-
sate Cordis for infringement but do not include pre or post
judgment interest. In February 2001 a hearing was held on the
claims of Boston Scientific and Medtronic AVE that the patents
at issue were unenforceable owing to alleged inequitable con-
duct before the patent office. In March and May 2002, the
district judge issued post trial rulings which confirmed the
validity and enforceability of the main Cordis stent patent
claims but found certain other Cordis patents unenforceable.
Further, the district judge granted Boston Scientific a new
trial on liability and damages and vacated the verdict against
Medtronic AVE on legal grounds. Appeals to the Federal Circuit
Court of Appeals are underway.
The products of various Johnson & Johnson operating com-
panies are the subject of various patent lawsuits which could
potentially affect the ability of those operating companies to sell
those products, require the payment of past damages and future
royalties or, with respect to patent challenges by generic phar-
maceutical firms, result in the introduction of generic versions of
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the products in question and the ensuing loss of market share.
The following patent lawsuits concern important products of
Johnson & Johnson operating companies. Medtronic/
AVE v. Cordis Corporation: This action, filed in April 2002
in federal court in Texas, asserts certain patents owned by
Medtronic/AVE against the Cordis BX VELOCITYTM stent, which
is also the stent structure used in the CYPHERTM drug eluting
product. No trial date has been set for this action. Ortho Phar-
maceutical v. Barr Laboratories, Inc.: Pending in federal court
in New Jersey, this action, filed in June 2000, involves Barr’s
effort to invalidate Ortho’s patents covering its ORTHO TRI-
CYCLEN® oral contraceptive product. Trial has not yet been
scheduled in this case. Ortho-McNeil and Daiichi, Inc. v. Mylan
Laboratories and Ortho-McNeil and Daiichi, Inc. v. Teva Phar-
maceutical: These matters, the first of which was filed in Febru-
ary 2002 in federal court in West Virginia and the second in
June 2002 in federal court in New Jersey, concern the efforts of
Mylan and Teva to invalidate and establish non-infringement of
the patent covering LEVAQUIN® levofloxacin tablets. The patent
is owned by Daiichi and exclusively licensed to Ortho-McNeil. In
the Mylan case trial has been set for late 2003. No trial date has
been set in the Teva matter. Janssen and ALZA v. Mylan Labo-
ratories: This action, filed in federal district court in Vermont in
February 2002, concerns Mylan’s effort to invalidate and assert
non-infringement of ALZA’s patent covering the DURAGESIC®
product. Trial is likely in the spring of 2003. With respect to all
of the above matters, the Johnson & Johnson operating com-
pany involved is vigorously defending the validity and asserting
the infringement of its own or its licensors’ patents or, where its
product is accused of infringing patents held by others, defend-
ing against those claims.
The Company is also involved in a number of other patent,
trademark and other lawsuits incidental to its business.
The ultimate legal and financial liability of the Company in
respect to all claims, lawsuits and proceedings referred to
above cannot be estimated with any certainty. However, in the
opinion of management, based on its examination of these
matters, its experience to date and discussions with counsel,
the ultimate outcome of these legal proceedings, net of liabili-
ties already accrued in the Company’s consolidated balance
sheet, is not expected to have a material adverse effect on the
Company’s consolidated financial position, although the reso-
lution in any reporting period of one or more of these matters
could have a significant impact on the Company’s results of
operations for that period.
19 Earnings Per Share
The following is a reconciliation of basic net earnings per share
to diluted net earnings per share for the years ended Decem-
ber 29, 2002, December 30, 2001 and December 31, 2000:
(Shares in Millions) 2002 2001 2000
Basic earnings per share $ 2.20 1.87 1.65
Average shares
outstanding—basic 2,998.3 3,033.8 2,993.5
Potential shares
exercisable under
stock option plans 188.3 166.6 119.0
Less: shares repurchased
under treasury stock method (146.9) (121.8) (71.7)
Convertible debt shares 14.4 20.7 58.4
Adjusted average shares
outstanding—diluted 3,054.1 3,099.3 3,099.2
Diluted earnings per share $ 2.16 1.84 1.61
Diluted earnings per share calculation includes the dilution
effect of convertible debt: a decrease in interest expense
of $12 million, $25 million and $47 million after tax for years
2002, 2001 and 2000, respectively. 
Diluted earnings per share excludes 1 million shares of
options for each of the years 2002 and 2001, and 62 million
shares of options for the year 2000, as the exercise price
of these options was greater than their average market
value, resulting in an anti-dilutive effect on diluted earnings
per share.
20 Capital and Treasury Stock
Changes in treasury stock were:
(Dollars in Millions Except
Treasury Stock
Number of Shares in Thousands) Shares Amount
Balance at January 2, 2000 140,154 $ 453
Employee compensation and stock
option plans (28,886) (1,075)
Conversion of Subordinated Debentures (25,676) —
Repurchase of common stock 21,402 973
Business combinations (1,776) (9)
Balance at December 31, 2000 105,218 342
Employee compensation and stock
option plans (30,581) (1,444)
Conversion of Subordinated Debentures (30,061) (183)
Repurchase of common stock 51,244 2,742
Business combinations (23,193) (64)
Balance at December 30, 2001 72,627 1,393
Employee compensation and stock
option plans (22,720) (1,295)
Conversion of Subordinated Debentures (5,742) (353)
Repurchase of common stock 107,382 6,382
Balance at December 29, 2002 151,547 $6,127
Shares of common stock authorized and issued were
3,119,842,000 shares at the end of 2002, 2001 and 2000.
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21 Selected Quarterly Financial Data (Unaudited)
Selected unaudited quarterly financial data for the years 2002 and 2001 are summarized below:
2002 2001
(Dollars in Millions First Second Third Fourth First Second Third Fourth
Except Per Share Amounts) Quarter Quarter(1) Quarter(2) Quarter(3) Quarter Quarter(4) Quarter(5) Quarter(6)
Segment sales to customers
Consumer $1,604 1,649 1,661 1,650 1,631 1,530 1,609 1,551
Pharmaceutical 4,181 4,258 4,277 4,435 3,489 3,864 3,677 3,820
Med Devices & Diagnostics 2,958 3,166 3,141 3,318 2,735 2,785 2,772 2,854
Total sales $8,743 9,073 9,079 9,403 7,855 8,179 8,058 8,225
Gross profit 6,286 6,491 6,468 6,606 5,544 5,807 5,662 5,723
Earnings before provision
for taxes on income 2,621 2,428 2,393 1,849 2,217 2,129 2,108 1,444
Net earnings 1,834 1,654 1,725 1,384 1,552 1,482 1,529 1,105
Basic net earnings per share $ .60 .55 .58 .47 .51 .49 .50 .36
Diluted net earnings per share $ .59 .54 .57 .46 .50 .48 .49 .36
(1) The second quarter of 2002 includes an after tax charge of $189 million relating to In-Process Research and Development (IPR&D) costs.
(2) The third quarter of 2002 includes an after tax charge of $92 million relating to the Amgen arbitration settlement.
(3) The fourth quarter of 2002 includes an after tax charge of $54 million relating to Amgen legal fees.
(4) The second quarter of 2001 includes an after tax charge of $102 million relating to ALZA merger costs.
(5) The third quarter of 2001 includes an after tax charge of $24 million relating to ALZA merger costs.
(6) The fourth quarter of 2001 includes an after tax charge of $105 million relating to IPR&D costs. The fourth quarter also includes an after tax charge of 
$29 million relating to a LifeScan class action settlement.
22 Subsequent Event
On February 10, 2003, Johnson & Johnson announced that it
signed a definitive agreement with Scios Inc., a biopharmaceu-
tical company with a marketed product for cardiovascular dis-
ease and research projects focused on auto-immune diseases.
The Company will acquire Scios in a cash for stock exchange.
Under the terms of the agreement, Scios shareholders will
receive $45.00 for each outstanding Scios share. The value of
the transaction as of the anticipated closing date is expected
to be approximately $2.4 billion, net of cash anticipated to be
acquired, based on Scios’ approximately 59.8 million fully
diluted shares outstanding.
The boards of directors of Johnson & Johnson and Scios
have given their approval to the transaction, which is subject
to clearance under the Hart-Scott-Rodino Anti-Trust Improve-
ments Act. This transaction is also subject to the approval of the
shareholders of Scios and other customary closing conditions.
Scios is a biopharmaceutical company developing novel
treatments for cardiovascular and inflammatory disease.
The company’s disease-based technology platform integrates
expertise in protein biology with computational and medicinal
chemistry to identify novel targets and rationally design small
molecule compounds for large markets with unmet medical
needs. Scios’ product NATRECOR® is a recombinant form of
a naturally occurring protein secreted by the heart as part of
the body’s response to congestive heart failure (CHF). The drug
has several significant advantages over existing therapies for
CHF, the single most common cause of hospitalization in the
United States for patients over 65.
The principal focus of Scios’ research and development
program is small molecule inhibitors, and includes several
potential new treatments for pain and inflammatory diseases,
including an advanced p-38 kinase inhibitor program.
The transaction is expected to close in the second quarter
of 2003.
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To the Shareholders and Board of Directors of
Johnson & Johnson:
In our opinion, the accompanying consolidated balance sheets
and the related consolidated statements of earnings, consoli-
dated statements of equity and consolidated statements of
cash flows present fairly, in all material respects, the financial
position of Johnson & Johnson and subsidiaries at December
29, 2002 and December 30, 2001, and the results of their
operations and their cash flows for each of the three years
in the period ended December 29, 2002, in conformity with
accounting principles generally accepted in the United States
of America. These financial statements are the responsibility
of the Company’s management; our responsibility is to express
an opinion on these financial statements based on our audits.
We conducted our audits of these statements in accordance
with auditing standards generally accepted in the United
States of America, which require that we plan and perform
the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An
audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements,
assessing the accounting principles used and significant esti-
mates made by management, and evaluating the overall finan-
cial statement presentation. We believe that our audits provide
a reasonable basis for our opinion.
As discussed in Notes 1 and 7 to the financial statements,
the Company has adopted Statement of Financial Accounting
Standards No. 142, “Goodwill and Other Intangible Assets,”
effective December 31, 2001.
New York, New York
January 20, 2003, except for Note 22 for which the date
is February 10, 2003
Independent Auditor’s Report
Sales to Customers (2)
(Dollars in Millions) 2002 2001 2000
Consumer—Domestic $ 3,605 3,449 3,403
International 2,959 2,871 2,868
Total 6,564 6,320 6,271
Pharmaceutical—Domestic 11,919 10,240 8,441
International 5,232 4,611 4,220
Total 17,151 14,851 12,661
Medical Devices & Diagnostics—Domestic 6,931 6,136 5,472
International 5,652 5,010 4,768
Total 12,583 11,146 10,240
Worldwide total $36,298 32,317 29,172
Operating Profit Identifiable Assets
(Dollars in Millions) 2002(5) 2001(6) 2000(7) 2002 2001 2000
Consumer $ 1,229 1,004 867 5,056 4,209 4,761
Pharmaceutical 5,787 4,928 4,394 11,112 10,591 9,209
Medical Devices & Diagnostics 2,489 2,001 1,696 15,052 13,645 12,745
Segments total 9,505 7,933 6,957 31,220 28,445 26,715
Expenses not allocated to segments(3) (214) (35) (89)
General corporate(4) 9,336 10,043 7,530
Worldwide total $ 9,291 7,898 6,868 40,556 38,488 34,245
Additions to Property, Depreciation and
Plant & Equipment Amortization
(Dollars in Millions) 2002 2001 2000 2002 2001 2000
Consumer $ 222 230 336 244 263 275
Pharmaceutical 1,012 749 627 557 492 474
Medical Devices & Diagnostics 713 621 665 776 801 801
Segments total 1,947 1,600 1,628 1,577 1,556 1,550
General corporate 152 131 61 85 49 42
Worldwide total $ 2,099 1,731 1,689 1,662 1,605 1,592
Geographic Areas
Sales to Customers(2) Long-Lived Assets
(Dollars in Millions) 2002 2001 2000 2002 2001 2000
United States $22,455 19,825 17,316 12,854 11,922 10,043
Europe 7,636 6,687 6,210 4,712 3,632 3,551
Western Hemisphere excluding U.S. 2,018 2,070 2,020 622 640 653
Asia-Pacific, Africa 4,189 3,735 3,626 603 433 427
Segments total 36,298 32,317 29,172 18,791 16,627 14,674
General corporate 383 319 255
Other non long-lived assets 21,382 21,542 19,316
Worldwide total $36,298 32,317 29,172 40,556 38,488 34,245
(1) See Management’s Discussion and Analysis, pages 28 to 29, for a description of the segments in which the Company does business.
(2) Export sales and intersegment sales are not significant. Sales to three distributors accounted for 10.3%, 9.8% and 9.2% of total revenues in 2002. These
sales were concentrated in the pharmaceutical segment. Sales of PROCRIT®/EPREX® accounted for 11.8% and 10.6%, of total Company revenues, for 2002 and
2001, respectively.
(3) Amounts not allocated to segments include interest income/expense, minority interest and general corporate income and expense.
(4) General corporate includes cash and marketable securities.
(5) Includes $150 million of In-Process Research & Development (IPR&D), $150 million and $85 million of Amgen costs in the Pharmaceutical segment and 
$39 million of IPR&D in the Medical Devices and Diagnostics segment.
(6) Includes $147 million of ALZA merger costs in the Pharmaceutical segment and $105 million of IPR&D and $45 million of class action settlement in the Medical
Devices and Diagnostics segment.
(7) Includes restructuring gains of $24 million in the Consumer segment and $8 million and $49 million of IPR&D charges net of restructuring gains in the
Pharmaceutical and Medical Devices and Diagnostics segments, respectively.
Segments of Business(1) Johnson & Johnson and Subsidiaries
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Summary of Operations and Statistical Data 1992-2002(3) Johnson & Johnson and Subsidiaries
(Dollars in Millions Except Per Share Figures) 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992
Sales to customers–Domestic $ 22,455 19,825 17,316 15,532 12,901 11,814 10,851 9,065 7,731 7,121 6,899
Sales to customers–International 13,843 12,492 11,856 11,825 10,910 10,708 10,536 9,472 7,723 6,756 6,701
Total sales 36,298 32,317 29,172 27,357 23,811 22,522 21,387 18,537 15,454 13,877 13,600
Cost of products sold 10,447 9,581 8,957 8,539 7,700 7,350 7,185 6,352 5,393 4,908 4,783
Selling, marketing and administrative expenses 12,216 11,260 10,495 10,065 8,525 8,185 7,848 6,950 5,901 5,364 5,356
Research expense 3,957 3,591 3,105 2,768 2,506 2,373 2,109 1,788 1,416 1,296 1,282
Purchased in-process research and development 189 105 66 — 298 108 — — 37 — —
Interest income (256) (456) (429) (266) (302) (263) (196) (151) (85) (104) (122)
Interest expense, net of portion capitalized 160 153 204 255 186 179 176 184 182 165 162
Other (income) expense, net 294 185 (94) 119 565 248 122 70 (5) (71) 20
27,007 24,419 22,304 21,480 19,478 18,180 17,244 15,193 12,839 11,558 11,481
Earnings before provision for taxes on income 9,291 7,898 6,868 5,877 4,333 4,342 4,143 3,344 2,615 2,319 2,119
Provision for taxes on income 2,694 2,230 1,915 1,604 1,232 1,237 1,185 926 654 533 547
Earnings before cumulative effect of accounting changes 6,597 5,668 4,953 4,273 3,101 3,105 2,958 2,418 1,961 1,786 1,572
Cumulative effect of accounting changes (net of tax) — — — — — — — — — — (595)
Net earnings $ 6,597 5,668 4,953 4,273 3,101 3,105 2,958 2,418 1,961 1,786 977
Percent of sales to customers 18.2 17.5 17.0 15.6 13.0(2) 13.8 13.8 13.0 12.7 12.9 7.2
Diluted net earnings per share of common stock* $ 2.16(2) 1.84(2) 1.61(2) 1.39(2) 1.02(2) 1.02(2) .98 .84 .69 .63 .34(1)
Percent return on average shareholders’ equity 28.1 25.4 26.5 27.0 22.2(2) 24.6 27.2 27.6 28.4 30.1 16.4(1)
Percent increase (decrease) over previous year:
Sales to customers 12.3 10.8 6.6 14.9 5.7 5.3 15.4 19.9 11.4 2.0 11.4
Diluted net earnings per share 17.4(2) 14.3(2) 15.8(2) 36.3(2) —(2) 4.1(2) 16.7 21.7 9.5 85.3(1) (22.7)(1)
Supplementary expense data:
Cost of materials and services(4) $ 16,540 15,333 14,113 13,922 11,779 11,702 11,341 9,984 8,104 7,168 7,736
Total employment costs 8,450 7,749 7,085 6,537 5,908 5,586 5,447 4,849 4,401 4,181 4,166
Depreciation and amortization 1,662 1,605 1,592 1,510 1,335 1,117 1,047 886 754 649 576
Maintenance and repairs(5) 360 372 327 322 286 270 285 257 222 205 213
Total tax expense(6) 3,497 2,995 2,619 2,271 1,881 1,824 1,753 1,458 1,132 957 975
Supplementary balance sheet data:
Property, plant and equipment, net $ 8,710 7,719 7,409 7,155 6,767 6,204 6,025 5,544 5,230 4,717 4,443
Additions to property, plant and equipment 2,099 1,731 1,689 1,822 1,610 1,454 1,427 1,307 979 1,001 1,162
Total assets 40,556 38,488 34,245 31,064 28,966 23,615 22,248 19,355 17,027 13,372 13,087
Long-term debt 2,022 2,217 3,163 3,429 2,652 2,084 2,347 2,702 2,776 1,761 1,832
Operating cash flow 8,176 8,864 6,903 5,920 5,106 4,210 4,001 3,436 2,984 2,202 2,136
Common stock information*
Dividends paid per share $ .795 .70 .62 .55 .49 .425 .368 .32 .283 .253 .223
Shareholders’ equity per share $ 7.65 7.95 6.77 5.70 4.93 4.51 4.07 3.46 2.76 2.16 2.03
Market price per share (year-end close) $ 53.11 59.86 52.53 46.63 41.94 32.44 25.25 21.38 13.69 11.19 12.63
Average shares outstanding (millions)–basic 2,998.3 3,033.8 2,993.5 2,978.2 2,973.6 2,951.9 2,938.0 2,820.1 2,796.9 2,816.6 2,845.8
–diluted 3,054.1 3,099.3 3,099.2 3,100.4 3,082.7 3,073.0 3,046.2 2,890.0 2,843.2 2,840.8 2,876.4
Employees (thousands) 108.3 101.8 100.9 99.8 96.1 92.6 91.5 84.2 83.4 83.2 86.9
* Adjusted to reflect the 2001 two-for-one stock split.
(1) Excluding the cumulative effect of accounting changes of $595 million. –1992 earnings percent of sales to customers before accounting changes is 11.6%. –1992 earnings per
share before accounting change is $.55. –1992 earnings percent return on average shareholders’ equity before accounting changes is 25.1%. –1993 diluted net earnings per
share percent increase over prior year before accounting changes is 14.5%; 1992 diluted net earnings per share increase over prior year is 25.0%.
(2) Excluding In-Process Research and Development (IPR&D), merger and restructuring costs: –2002 diluted net earnings per share is $2.23 and the increase over prior year is
16.8%. –2001 diluted net earnings per share is $1.91 and the increase over prior year is 17.2%. –2000 diluted net earnings per share is $1.63 and the increase over prior year
is 14.8%. –1999 diluted net earnings per share is $1.42 and the increase over prior year is 14.5%. –1998 diluted net earnings per share is $1.24 and the increase over prior
year is 11.7%. –1998 cost of products sold includes $60 million of inventory write-offs for restructuring, the percent return on average shareholders’ equity is 26.5% and the
earnings percent of sales to customers is 16.0%. –1997 diluted net earnings per share is $1.11 and the increase over prior year is 13.3%.
(3) All periods have been adjusted to include the effects of the ALZA merger.
(4) Net of interest and other income.
(5) Also included in cost of materials and services category.
(6) Includes taxes on income, payroll, property and other business taxes.
Principal Global Affiliates
Advanced Sterilization Products, a division of Ethicon, Inc., develops, manufactures and markets a
range of sterilization systems based on a patented low temperature hydrogen peroxide gas plasma
process, as well as sterilizing/disinfecting solutions. The STERRAD® Sterilization System is safe,
fast, environmentally friendly and effective, and can be used on a broad range of medical products
in health care facilities. CIDEX® OPA Solution is a fast and effective method to disinfect a wide
range of instruments and endoscopes.
ALZA Corporation has pioneered and continues to lead in the development of drug delivery-based
pharmaceuticals for Johnson & Johnson companies that enhance health care for millions of
patients worldwide. ALZA also partners with other leading pharmaceutical and biotechnology
companies to develop products that address unmet patient needs by precisely controlling the
targeting, timing and dosing of therapeutic compounds.
BabyCenter, L.L.C. is the leading online pregnancy and parenting resource, reaching millions of
new moms each month. Through its Web sites, BabyCenter.com and ParentCenter.com, the compa-
ny provides award-winning health, child development and parenting information customized for a
woman’s stage of pregnancy or her child’s age. BabyCenter also offers an online baby store and a
thriving online community. 
Centocor, Inc. is a leading, fully integrated biopharmaceutical and biotechnology company special-
izing in the development and commercialization of therapeutic products to meet critical human
health care needs. A world leader in monoclonal antibody technology and manufacturing, Centocor
manufactures products including REMICADE® (infliximab) for the treatment of rheumatoid arthri-
tis and Crohn’s disease; REOPRO® (abciximab) for use in percutaneous coronary intervention, and
RETAVASE® (reteplase), a clot buster that is administered during heart attack.
Cordis Corporation is a global leader in developing and marketing devices for circulatory disease
management, including stents, balloons and catheters used in treating cardiovascular disease and
related conditions. Products are marketed by clinical application through four main divisions:
Cordis Cardiology for coronary applications; Cordis Endovascular for all peripheral applications;
Cordis Neurovascular for neurological applications; and Biosense Webster for electrophysiology
and medical sensor technology in endocardial procedures.
DePuy, Inc. develops and markets products under the DEPUY®, ACE®, ACROMED®, CODMAN® and
MITEK® brands. DePuy and DePuy Ace provide products for reconstructing damaged or diseased
joints, and for repairing and reconstructing traumatic skeletal injuries. AcroMed facilitates fusion
of elements of the spine and correction of spinal deformities, and repairing bone fractures.
Codman provides for the surgical treatment of central nervous system disorders through a wide
range of products such as hydrocephalic shunt valve systems, implantable drug pumps and micro-
surgical instrumentation. The Mitek Products sports medicine line offers innovative devices for the
treatment of soft tissue injuries.
eJNJ, L.L.C. is a catalyst for accelerating the adoption of e-business through the identification,
incubation and development of new Web-enabled health care business models that increase long-
term growth potential.
Ethicon, Inc. is a global leader in developing and marketing products for surgery in the areas of
wound care and wound management, women’s health, cardiovascular surgery and advanced
wound care treatment. Products are marketed through four divisions: ETHICON® Products offers
devices that facilitate precise wound closure and tissue repair; CARDIOVATIONS® pioneers mini-
mally-invasive surgical devices that help restore and improve cardiac health; GYNECARE® offers
minimally-invasive solutions for gynecological health problems; and Johnson & Johnson Wound
Management offers a complete line of innovative products for hemostasis, tissue regeneration and
advanced wound care.
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Ethicon Endo-Surgery, Inc. develops and markets a broad portfolio of advanced surgical instru-
ments for less invasive and traditional surgery, as well as a line of safety catheters for vascular
access. Its mission is to help physicians around the world transform patient care through innova-
tion. The company’s focus is on designing innovative, procedure-enabling devices for interventional
diagnosis and treatment of various diseases and conditions in the areas of general, thoracic and
bariatric surgery, breast disease, gynecology and urology.
Greiter AG develops and produces a line of elegant sunscreen and after-sun products that
combine sun protection with special moisturizers. Its products are sold throughout Europe and
other markets.
Independence Technology, L.L.C. markets products and services that increase the independence of
people with disabilities. Products include the INDEPENDENCE™ iGLIDE™ Manual Assist Wheelchair,
the INDEPENDENCE™ maxPRO™ Seat Cushion and the INDEPENDENCE™ iBOT™ Mobility System,
which is expected to be approved in the U.S. in 2003.
The Janssen-Cilag companies produce and market a broad range of pharmaceutical products,
mainly discovered and/or developed by Johnson & Johnson Pharmaceutical Research &
Development, L.L.C. Leading products include EPREX®/ERYPO® (hematology), RISPERDAL® (psychia-
try), SPORANOX® (dermatology/fungal infections), DURAGESIC®/DUROGESIC® (pain management),
TOPAMAX® (epilepsy), PARIET®/ACIPHEX® (gastroenterology), and REMINYL® (Alzheimer’s disease).
Janssen Pharmaceutica Products, L.P. produces and markets prescription medications in four thera-
peutic areas: central nervous system disorders, gastrointestinal health, pain management and the
treatment of fungal infections. Leading products include RISPERDAL® (risperidone), an antipsychot-
ic; ACIPHEX® (rabeprazole sodium), a proton pump inhibitor; DURAGESIC® (fentanyl transdermal
system), a skin patch for the treatment of moderate to severe pain; SPORANOX® (itraconazole), an
antifungal; and REMINYL® (galantamine hydrobromide), for Alzheimer’s disease.
The primary businesses of Johnson & Johnson Consumer Products Company are baby care, wound
care and skin care. The company’s wide range of products includes the familiar line of baby and
child care products, a complete line of family first aid and home health care products, skin care
products such as cleansers, astringents, moisturizers and acne treatments, and body powders.
The Johnson & Johnson Development Corporation makes equity investments in early-stage
venture and young publicly-traded health care companies, where promising new technologies
are under development. Portfolio companies include those in the fields of pharmaceuticals,
biotechnology, medical and surgical devices, health care information technology, diagnostics
and consumer products.
Johnson & Johnson Gateway, L.L.C. develops and manages the Web-based resource of information
created for health care professionals by Johnson & Johnson medical devices and diagnostics
companies. Accessed in a global Internet destination are product information, clinical content,
professional education, patient materials, and in many countries, e-commerce transaction and
inquiry capabilities.
Johnson & Johnson Health Care Systems, Inc. provides national, managed care, government and
large hospital customers with a single point of contact for products from Johnson & Johnson
domestic companies. In addition to customer account management, the company offers business
support services, including contract management, supply chain, electronic business resources, and
health and fitness services for employers.
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Johnson & Johnson • Merck Consumer Pharmaceuticals Co. is a 50/50 joint venture formed to
develop and market a broad range of nonprescription products derived primarily from Merck
& Co., Inc. prescription medicines, as well as products licensed and acquired from outside
sources. Current products include PEPCID® AC Acid Controller, for both the prevention and relief
of heartburn and acid indigestion; PEPCID® Complete, a combination acid controller and antacid,
and MYLANTA® Antacid, a leading line of antacid/antigas products in liquid and solid forms.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. conducts research and
development and achieves regulatory approval for products in psychiatry, gastroenterology,
oncology, anti-infective, central nervous system, diabetes, hematology, immunology/inflammation,
women’s health and wound healing.
Johnson & Johnson Sales and Logistics Company, a division of Johnson & Johnson Consumer
Companies, Inc., provides sales, marketing and logistical services to U.S. retail customers on behalf
of the domestic consumer operating companies. It represents a single point of contact with our
customers for customer-focused selling teams, customer service, distribution, retail merchandis-
ing and professional detailing. Additionally, the SLC provides leadership for an emerging global
customer base in the areas of transportation, enterprise-wide systems, business processes and
global customer development.
LifeScan, Inc. is dedicated to improving the quality of life for people with diabetes by developing,
manufacturing and marketing a wide range of blood glucose monitoring systems and software
for use by individuals with diabetes and health care institutions. LifeScan brands include the
ONETOUCH® Brand of consumer products, consisting of portable, electronic meters and disposable
reagent test strips to provide accurate, less painful blood glucose readings, and the SURESTEP®
Brand of institutional systems.
McNeil Consumer & Specialty Pharmaceuticals, a division of McNeil-PPC, Inc., markets a range of
over-the-counter and prescription pharmaceuticals including complete lines of TYLENOL®
Acetaminophen and MOTRIN® IB Ibuprofen products for adults and children. Other McNeil OTC
brands include IMODIUM® A-D Anti-diarrheal, ST. JOSEPH® Adult Regimen Aspirin and NIZORAL®
A-D Shampoo. Its prescription products include CONCERTA® (methylphenidate HCl) for attention
deficit hyperactivity disorder, and FLOXIN® Otic (ofloxacin otic solution) for ear infections, which
McNeil co-markets with Daiichi Pharmaceutical Corp.
McNeil Nutritionals, a division of McNeil-PPC, Inc., markets innovative nutritional products and
dietary alternatives. Its major franchises include BENECOL® cholesterol-lowering foods and
supplements, LACTAID® products that enable lactose-intolerant consumers to enjoy dairy foods,
SPLENDA® (sucralose) no calorie sweetener with broad-based applications, and VIACTIV®, for
calcium supplementation.
Johnson & Johnson Networking & Computing Services provides a broad range of networking
and computing technology products, services and solutions to Johnson & Johnson operating com-
panies throughout the world. The group also provides leadership for the optimization of the
enterprise information management infrastructure and in the development of emerging infra-
structure technologies that can create new business opportunities for its internal customers.
Neutrogena Corporation develops, manufactures and markets premium, high quality skin and
hair care products that are sold worldwide and recommended by medical professionals. The prod-
uct line includes bar and liquid cleansers, shampoo, hand cream, body lotion, facial moisturizers,
bath preparations and cosmetics, as well as other hair and skin care products. Through the
Ortho-Neutrogena group, the company markets skin and hair care products recommended, used
and prescribed by dermatologists.
Noramco, Inc. produces a variety of active pharmaceutical ingredients besides being a major world-
wide producer of medicinal analgesics, pharmaceutical intermediates and synthetic fine organic
chemicals. It also produces monomers and polymers for pharmaceutical and medical devices.
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Ortho Biotech Products, L.P. and its worldwide affiliates market PROCRIT® (Epoetin alfa), also
known as EPREX® and ERYPO® outside the U.S., used to treat anemia associated with specific
diseases. The company also markets ORTHOCLONE® OKT3® (muromonab-CD3), a monoclonal
antibody used to reverse rejection of transplanted organs; SPORANOX® (itraconazole) for difficult-
to-treat and life-threatening fungal infections; LEUSTATIN® (cladribine) for hairy cell leukemia,
and DURAGESIC® (fentanyl transdermal system) for moderate to severe chronic pain in cancer
patients. In the U.S., Ortho Biotech markets DOXIL® (doxorubicin HCl liposome injection) for
ovarian cancer and Kaposi’s sarcoma.
Ortho-Clinical Diagnostics, Inc. provides professional diagnostic products to hospital laboratories,
commercial clinical laboratories and blood donor centers. Its products include reagents used in
blood transfusions and blood screening; reagents and instrument systems for clinical chemistry;
and RhoGAM®, an injectable drug used to prevent hemolytic disease of the newborn.
Ortho-McNeil Pharmaceutical, Inc. provides prescription drugs in the following categories:
women’s health, analgesics, anti-infectives, anti-epileptics and urology. The company is a pioneer
and leader in the area of reproductive health, where leading contraceptive products include
ORTHO TRI-CYCLEN® LO (norgestimate/ethinyl estradiol) and ORTHO EVRA®
(norelgestromin/ethinyl estradiol), the first weekly contraceptive patch. Other leading products
include ULTRACET ™ (tramadol HCI), a pain medication; LEVAQUIN® (levofloxacin), an antibiotic;
DITROPAN XL® (oxybutynin chloride) for overactive bladder; ELMIRON™ (pentosan polysulfate
sodium) for interstitial cystitis; and TOPAMAX® (topiramate), the anti-epilepsy medication.
Personal Products Company, a division of McNeil-PPC, Inc., develops, produces and markets
innovative oral health, women’s health and sanitary protection products. It is a leader in the oral
health market with a full line of REACH® floss, ACT® rinse and REACH® toothbrush products.
Personal Products is also a leader in women’s health products with MONISTAT® vaginal yeast
cures, K-Y® personal lubricant, URISTAT® urinary pain relief tablets and vaginal contraceptives.
The company’s comprehensive line of sanitary products includes CAREFREE® pantiliners, o.b.®
tampons and STAYFREE® maxi pads.
The Pharmaceutical Sourcing Group – Americas, a division of Ortho-McNeil Pharmaceutical, Inc.,
integrates the Johnson & Johnson pharmaceutical operations and quality assurance organizations
within the Americas, thereby enhancing supply chain performance.
RoC® is a line of products for the care of sensitive skin that includes lotions, cosmetics and creams
for the face and body, and a sun protection line.
The Spectacle Lens Group, a division of Johnson & Johnson Vision Care, Inc., designs, develops,
manufactures and markets innovative spectacle lenses. The first line of products is a newly
patented innovation in the Progressive Addition Lens market designed to meet the needs of
today’s presbyopes.
Therakos, Inc. specializes in extracorporeal cell-based therapies for the prevention and treatment
of serious immune-mediated and neoplastic diseases that have substantial unmet medical needs.
Therakos’ proprietary procedures in photopheresis are currently approved and successfully used
by physicians for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma.
Additional research is under way for the treatment of autoimmune disease, complications of
transplantation and improved delivery of the therapy.
Vistakon, a division of Johnson & Johnson Vision Care, Inc., is the world’s leading disposable
contact lens brand. ACUVUE®, ACUVUE® 2, and SUREVUE® Brands are market-leading spherical
brands. 1-DAY ACUVUE® Brand is the top-selling daily disposable product worldwide. The ACUVUE®
Brand Bifocal Contact Lens is the leading disposable product for presbyopes. ACUVUE® Brand Toric
is our unique lens for people with astigmatism. New ACUVUE® 2 COLOURS™ Brand Contact Lenses,
launched around the world, offer exceptional comfort and handling in seven natural-looking colors.
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Worldwide Family of Companies
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Global Franchise and Americas
64
Canada
Janssen-Ortho Inc.
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Johnson & Johnson Inc.
Montreal, Quebec
Johnson & Johnson Medical Products
Markham, Ontario
LifeScan Canada Ltd.
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McNeil Consumer Healthcare, Canada
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Latin America
Argentina
Janssen-Cilag Farmaceutica
Buenos Aires
Johnson & Johnson de 
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Caracas
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England
Cordis U.K. Limited
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DePuy International Limited
Leeds
Ethicon Endo-Surgery U.K.
Bracknell
Janssen-Cilag Limited
High Wycombe
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Maidenhead
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High Wycombe
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High Wycombe
Ortho-Clinical Diagnostics
Amersham
Vistakon Europe
Bracknell
Finland
Janssen-Cilag OY
Espoo
France
Cordis S.A.
Issy-Les-Moulineaux
DePuy France S.A.
Lyon
Ethicon S.A.
Issy-Les-Moulineaux
Ethicon Endo-Surgery S.A.
Issy-Les-Moulineaux
Janssen-Cilag S.A.
Issy-Les-Moulineaux
Johnson & Johnson
Consumer France S.A.S.
Issy-Les-Moulineaux
LifeScan 
Issy-Les-Moulineaux 
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Ortho Biotech
Issy-Les-Moulineaux
Ortho-Clinical Diagnostics S.A.
Issy-Les-Moulineaux
Germany
Cordis G.m.b.H.
Langenfeld
DePuy Orthopädie G.m.b.H.
Sulzbach
Ethicon G.m.b.H.
Norderstedt
Ethicon Endo-Surgery 
(Europe) G.m.b.H.
Norderstedt
Janssen-Cilag G.m.b.H.
Rosellen
Johnson & Johnson G.m.b.H.
Düsseldorf
LifeScan G.m.b.H.
Neckargemund
Ortho Biotech
Rosellen 
Ortho-Clinical Diagnostics G.m.b.H.
Neckargemund
Vistakon
Norderstedt
Greece
Janssen-Cilag Pharmaceutical S.A.C.I.
Athens
Johnson & Johnson Hellas S.A.
Athens
Johnson & Johnson
Medical Products S.A.
Athens
Hungary
Janssen-Cilag Kft.
Budapest
Johnson & Johnson Kft.
Budapest
Ireland
Janssen-Cilag Pharmaceutical Limited
Cork
Johnson & Johnson (Ireland) Limited
Tallaght
Italy
Cordis S.p.A.
Milan
DePuy Italy SRL
Milan
Ethicon S.p.A.
Rome
Ethicon Endo-Surgery
Rome
Janssen-Cilag S.p.A.
Milan
Johnson & Johnson S.p.A.
Rome
LifeScan
Milan
Ortho Biotech
Milan 
Ortho-Clinical 
Diagnostics S.p.A.
Milan
Vistakon
Rome
The Netherlands
Cordis Benelux
Amersfoort
Janssen-Cilag B.V.
Tilburg
Johnson & Johnson/Gaba B.V.
Almere
Johnson & Johnson Medical B.V. 
Zaventem
Norway
Janssen-Cilag AS
Oslo
Poland
Janssen-Cilag
Warsaw
Johnson & Johnson Poland, Sp. z.o.o.
Warsaw
Portugal
Janssen-Cilag Farmaceutica, Ltda.
Queluz
Johnson & Johnson Limitada
Queluz
Johnson & Johnson Professional 
Products, Limitada
Queluz
Russia
Johnson & Johnson L.L.C.
Moscow
Scotland
Ethicon Limited
Edinburgh
Slovenia
Johnson & Johnson S.E.
Ljubljana
Spain
Janssen-Cilag S.A.
Madrid
Johnson & Johnson S.A.
Madrid
Johnson & Johnson Medical
Madrid
Johnson & Johnson•Merck Europe
Madrid
LifeScan
Madrid
Ortho-Clinical Diagnostics 
Madrid
Sweden
Janssen-Cilag AB
Sollentuna
Johnson & Johnson AB
Sollentuna
Johnson & Johnson Consumer
Products
Sollentuna
Switzerland
Cilag AG 
Schaffhausen
Greiter AG
Baar
Janssen-Cilag 
Zug
Janssen-Cilag AG
Baar
Johnson & Johnson AG
Spreitenbach
McNeil Consumer Nutritionals Europe
Zug
Ortho Biotech
Baar
Turkey
Johnson & Johnson Limited
Istanbul
Janssen-Cilag
Istanbul
66
Asia-Pacific, Africa
Australia
DePuy Australia Pty. Ltd.
Nottinghill, Victoria
Janssen-Cilag Pty. Ltd.
North Ryde
Johnson & Johnson Medical Pty. Ltd.
North Ryde
Johnson & Johnson Pacific Pty. Limited
Sydney
Tasmanian Alkaloids Pty. Limited
Westbury, Tasmania
China
Johnson & Johnson China Ltd.
Shanghai
Johnson & Johnson Medical Ltd.
Shanghai
Shanghai Johnson & Johnson Ltd.
Shanghai
Shanghai Johnson & Johnson 
Pharmaceuticals Ltd.
Shanghai
Xian-Janssen Pharmaceutical Ltd.
Beijing
Egypt
Johnson & Johnson (Egypt) S.A.E.
Cairo
Hong Kong
Janssen-Cilag
Hong Kong
Johnson & Johnson (Hong Kong) Limited
Hong Kong
Johnson & Johnson Medical Hong Kong
Hong Kong
Vistakon
Hong Kong
India
Janssen-Cilag 
Mumbai
Johnson & Johnson Limited
Mumbai
Johnson & Johnson Professional
Mumbai
Indonesia
Janssen-Cilag Pharmaceutica
Jakarta 
Saudi Arabia
Johnson & Johnson Saudi Arabia
Riyadh
Singapore
Janssen-Cilag Singapore/Malaysia
Singapore
Johnson & Johnson Medical Singapore
Singapore
Johnson & Johnson Pte. Ltd.
Singapore
Ortho-Clinical Diagnostics
Singapore
South Africa
Janssen-Cilag (Pty.) Ltd.
Sandton
Johnson & Johnson (Pty.) Limited
East London
Johnson & Johnson Medical (Pty.) Ltd.
Halfway House
Taiwan
Janssen-Cilag Taiwan
Taipei
Johnson & Johnson Medical Taiwan
Taipei
Johnson & Johnson Taiwan, Ltd.
Taipei
Thailand
Janssen-Cilag Pharmaceutica Limited
Bangkok
Johnson & Johnson Asean Limited
Bangkok
Johnson & Johnson Medical Thailand
Bangkok
United Arab Emirates
Johnson & Johnson (Middle East) Inc.
Dubai
P.T. Johnson & Johnson Indonesia
Jakarta
Israel
Biosense Europe
Haifa
Janssen-Cilag
Kibbutz Shefayim
Johnson & Johnson Consumer
Kibbutz Shefayim
Johnson & Johnson Medical
Kibbutz Shefayim
Japan
DePuy Japan, Inc.
Tokyo 
Janssen Pharmaceutical K.K.
Tokyo
Johnson & Johnson K.K.
Tokyo
Johnson & Johnson Medical
Tokyo
Ortho-Clinical Diagnostics K.K.
Tokyo
Vistakon Japan
Tokyo
Korea
Janssen-Cilag Korea, Ltd.
Seoul
Johnson & Johnson Korea, Ltd.
Seoul
Johnson & Johnson Medical Korea Ltd.
Seoul
Malaysia
Johnson & Johnson Sdn. Bhd.
Selangor Darul Ehsan
Morocco
Johnson & Johnson Morocco S.A.
Casablanca
Pakistan
Johnson & Johnson Pakistan
(Private) Limited
Karachi
Philippines
Janssen-Cilag Philippines
Metro Manila
Johnson & Johnson (Philippines), Inc. 
Metro Manila
Corporate and Shareholder/Investor Information
Principal Office
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933
(732) 524-0400
Annual Meeting
The Annual Meeting of Shareholders will
take place April 24, 2003, at the Hyatt
Regency New Brunswick, 2 Albany
Street, New Brunswick, New Jersey.
The meeting will convene at 10 A.M.
All shareholders are cordially invited
to attend. A formal Notice of Meeting,
Proxy Statement and Proxy have been
sent to shareholders.
Reports Available
Copies of the Company’s 2002 Annual
Report on Form 10-K and Quarterly
Reports on Form 10-Q to the Securities
and Exchange Commission, and the
Annual Report are available online at
www.jnj.com, or to shareholders without
charge upon written request to the
Secretary at the Company’s principal
office or by calling (800) 328-9033 or
(781) 575-2718 (outside the U.S.).
Common Stock
Listed on New York Stock Exchange
Stock Symbol JNJ
Shareholder Relations Contact
Michael H. Ullmann
Corporate Secretary
(732) 524-2455
Investor Relations Contact
Helen E. Short
Vice President, Investor Relations
(800) 950-5089
(732) 524-6492
Transfer Agent and Registrar
Questions regarding stock holdings,
certificate replacement/transfer,
dividends and address changes should
be directed to:
EquiServe Trust Company, N.A.
P. O. Box 43069
Providence, Rhode Island 02940-3069
(800) 328-9033 or (781) 575-2718
(outside the U.S.)
Internet: (EquiServe Home Page)
http://www.EquiServe.com
This Annual Report is printed in its entirety on recycled paper.
© Johnson & Johnson 2003
The following trademarks, service marks and trade names of Johnson & Johnson and its affiliated companies appear in this report:
ACE, ACROMED, ACT, ACUVUE, ACUVUE 2, ACUVUE 2 COLOURS, 1-DAY ACUVUE, AQUA T3, AVEENO, BABYCENTER.COM, BAND-AID,
BENECOL, Bx VELOCITY, CARDIOVATIONS, CAREFREE, CIDEX, CLEAN & CLEAR, CODMAN, COMPEED, CONCERTA, CORDIS, CYPHER,
DAKTARIN, DEFINITY 2, DEPUY, DERMABOND, DITROPAN, DOXIL, DURAGESIC, DUROGESIC, DUROTEP, eJNJ, ELMIRON, EPREX, ERGAMISOL,
ERYPO, ETHICON, ETHICON ENDO-SURGERY, EUROFLASH, FLOXIN, GLOBAL, GYNECARE, GYNECARE INTERGEL, GYNECARE TVT,
HAKIM, HALDOL, ID-MICRO TYPING SYSTEM, IMODIUM, INDEPENDENCE iBOT,  INDEPENDENCE iGLIDE, INDEPENDENCE TECHNOLOGY,
INDUO, K-Y, JANSSEN, JANSSEN-CILAG, JOHNSON & JOHNSON, JOHNSON’S, JOHNSON’S pH5.5, LACTAID, LAP DISC, LEUSTATIN,
LIFESCAN, MAMMOTOME, MAX, MaxPRO, MCNEIL, MITEK,  MONARCH, MONISTAT, MOTILIUM, MOTRIN, MYLANTA, NATUSAN,
NEUTROGENA, NIZORAL, o.b., ONETOUCH, OROS, ORTHO, ORTHO BIOTECH, ORTHO-CLINICAL DIAGNOSTICS, ORTHOCLONE OKT3, ORTHO
EVRA, ORTHO-MCNEIL, ORTHO-NOVUM, ORTHO TRI-CYCLEN, PARENTCENTER.COM, PENATEN, PERSONAL PRODUCTS COMPANY, PINNACLE,
PIZ BUIN, POSITIVELY RADIANT, PRESERVATION, PROCRIT, PROLENE, PROMOGRAN, PROPULSID, PURPOSE, RAZOR DEFENSE, REACH,
REMICADE, REMINYL, REOPRO, RETAVASE, RETIN-A MICRO, RhoGAM, RISPERDAL,  RISPERDAL CONSTA, RoC, ST. JOSEPH, SHOWER TO
SHOWER, SIMPLY COUGH, SIMPLY STUFFY, SMARTSCAN, SPLENDA, SPORANOX, STAYFREE, STERRAD, STUGERON, SUNDOWN, SUMMIT,
SURESTEP, SUREVUE, SURGIFOAM, The Campaign for Nursing’s Future, TOPAMAX, TRICILEST, TYLENOL, ULTRA, ULTRACET, ULTRASMART,
URISTAT, VIACTIV, VICRYL, WATCHBAND INCISION, VISTAKON.
The following trademarks of other companies also appear in this report: ACIPHEX and PARIET (Eisai Co., Ltd.), LEVAQUIN (Daiichi
Pharmaceutical Co.), NATRECOR (Scios Inc.), PEPCID (Merck & Co., Inc.), Together Rx (Together Rx, LLC).
Dividend Reinvestment Plan
The Plan allows for full or partial
dividend reinvestment, and additional
monthly cash investments up to $50,000
per year, in Johnson & Johnson stock
without brokerage commissions or
service charges on stock purchases. If
you are interested in joining the Plan
and need an authorization form and/or
more background information, please
call EquiServe Trust Company, N.A. at
(800) 328-9033 or (781) 575-2718
(outside the U.S.).
Hearing Impaired
Shareholders who have inquiries regard-
ing stock-related matters can communi-
cate directly with EquiServe Trust
Company, N.A. via a telecommunications
device (TDD). The telephone number
for this service is (800) 952-9245,
(800) 490-1493 or (781) 575-2692
(outside the U.S.).
World Wide Web Site
http://www.jnj.com
We believe our first responsibility is to the doctors, nurses and patients, to mothers
and fathers and all others who use our products and services. In meeting their
needs everything we do must be of high quality. We must constantly strive to
reduce our costs in order to maintain reasonable prices. Customers’ orders must
be serviced promptly and accurately. Our suppliers and distributors must have an
opportunity to make a fair profit.
We are responsible to our employees, the men and women who work with us
throughout the world. Everyone must be considered as an individual. We must
respect their dignity and recognize their merit. They must have a sense of security
in their jobs. Compensation must be fair and adequate, and working conditions
clean, orderly and safe. We must be mindful of ways to help our employees fulfill
their family responsibilities. Employees must feel free to make suggestions and
complaints. There must be equal opportunity for employment, development 
and advancement for those qualified. We must provide competent management,
and their actions must be just and ethical.
We are responsible to the communities in which we live and work and to the world
community as well. We must be good citizens – support good works and charities
and bear our fair share of taxes. We must encourage civic improvements and 
better health and education. We must maintain in good order the property we are
privileged to use, protecting the environment and natural resources.
Our final responsibility is to our stockholders. Business must make a sound 
profit. We must experiment with new ideas. Research must be carried on, innovative
programs developed and mistakes paid for. New equipment must be purchased,
new facilities provided and new products launched. Reserves must be created 
to provide for adverse times. When we operate according to these principles, 
the stockholders should realize a fair return.
Our Credo
One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933
